[{"drug": "Magnesium Sulfate", "disease": "COPD", "orig_sen": "Although the improvement in peak expiratory flow rate and arterial blood gas favored nebulized IB over magnesium sulfate, there was a nonsignificant difference between both drugs with regard to hospital admission, intubation, and hospital death rates in patients with COPD treated in the emergency department for acute exacerbation. ", "polarity": 1}, {"drug": "Magnesium Sulfate", "disease": "COPD", "orig_sen": "Twenty-two male COPD patients (64+/-6 years old, FEV1: 49+/-20%) received an IV infusion of 2 g of magnesium sulfate or placebo on two distinct occasions. ", "polarity": 1}, {"drug": "Magnesium Sulfate", "disease": "COPD", "orig_sen": " OBJECTIVE: Magnesium sulfate has been shown to have a bronchodilating effect in asthma, but this effect has not been clearly established in the context of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Magnesium Sulfate", "disease": "COPD", "orig_sen": "For this reason we investigated the possible bronchodilating effect of magnesium sulfate in COPD exacerbations. ", "polarity": 1}, {"drug": "Magnesium Sulfate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Intravenous administration of magnesium sulfate has no bronchodilating effect in patients with COPD exacerbations. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "RESULTS AND CONCLUSION: The data show that the ICS-containing treatment arms (containing fluticasone propionate) had a small effect on peripheral blood eosinophils in steroid-na\u00efve patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVE: The objective of this study was to compare persistence to salmeterol/fluticasone propionate combination treatment as AirFluSal Forspiro with persistence to Seretide Diskus in patients with asthma or COPD aged 12 years and above. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The WISDOM study (NCT00975195) reported a change in lung function following withdrawal of fluticasone propionate in patients with severe to very severe COPD treated with tiotropium and salmeterol. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: From the GlaxoSmithKline trial registry, we selected randomised, double-blind, clinical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in duration. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) and guide treatment.The ISOLDE study randomised 751 patients (mean post-bronchodilator forced expiratory volume in 1\u2009s (FEV1) 1.4\u2005L: 50% predicted normal) to fluticasone propionate 500\u2005\u03bcg twice daily or placebo for 3\u2005years, finding no difference in FEV1 rate of decline between treatments (p=0.16) and a significant reduction in median exacerbation rate with fluticasone propionate versus placebo (p=0.026). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Exacerbation rate reduction on ICS for fluticasone propionate versus placebo was higher in the eosinophil <2% group compared with the \u22652% group; time-to-first moderate/severe exacerbation was not different between treatments in either group.A baseline blood eosinophil count of \u22652% identifies a group of COPD patients with slower rates of decline in FEV1 when treated with ICS: prospective testing of this hypothesis is now warranted. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVE: The study aimed to assess the effect on lung function of once-daily tiotropium + olodaterol versus twice-daily salmeterol + fluticasone propionate in all participants with Global initiative for chronic Obstructive Lung Disease 2 or 3 (moderate to severe) COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSION: Once-daily tiotropium + olodaterol in participants with moderate-to-severe COPD provided superior lung function improvements to twice-daily salmeterol + fluticasone propionate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Biopsy samples were taken from patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 wk). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-blind study to evaluate the efficacy and safety of two doses of fluticasone propionate/formoterol compared to formoterol monotherapy in COPD patients with FEV1 \u226550% predicted and a history of exacerbations. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Triple therapy using salmeterol/fluticasone propionate (FP) and tiotropium bromide is commonly used to treat chronic obstructive pulmonary disease (COPD), but sparse efficacy data exist in COPD patients with fewer symptoms and with a lower dose of inhaled corticosteroid in Japanese patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: We performed a review of studies of fluticasone propionate (FP)/salmeterol (SAL) (combination inhaled corticosteroid (ICS)/long-acting \u03b22-agonist (LABA)) in patients with COPD, which measured baseline (pretreatment) blood eosinophil levels, to test whether blood eosinophil levels \u22652% were associated with a greater reduction in exacerbation rates with ICS therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA) are approved maintenance therapies for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50 mcg and fluticasone propionate 250 mcg (SFC 250) in Japanese patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50\u2005\u00b5g, once-daily tiotropium (TIO) 18\u2005\u00b5g or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500\u2005\u00b5g twice daily. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "She was diagnosed with COPD 2 months prior to her presentation and started on treatment with fluticasone propionate and albuterol. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "AIM: To assess the adherence of patients diagnosed with asthma and COPD treated with polytherapy with fluticasone propionate and formoterol fumarate using the Fantasmino inhaler in relation to primary diagnosis and illness perception as well as patients' and doctors' opinion about this form of therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: The illness perception, younger age, disease duration and severity are predictors of adherence to treatment with fluticasone propionate and formoterol fumarate using the Fantasmino inhaler among patients with asthma and COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "This study compared the rate of COPD exacerbations over the 26 weeks after an initial exacerbation in patients receiving the combination of fluticasone propionate and salmeterol (FP/SAL) or SAL alone. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 \u03bcg once daily), salmeterol (50 \u03bcg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 \u03bcg twice daily) during a 6-week run-in period. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In this study, we applied IOS and spirometry to evaluate the effectiveness of fluticasone propionate and salmeterol (SFC) combined with tiotropium (TIO) in COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "COPD subjects were randomized to twice daily MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, MF 400\u00a0\u03bcg, F 10\u00a0\u03bcg, and placebo; asthma subjects were randomized to MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, fluticasone propionate/salmeterol (FP/S) 250/50\u00a0\u03bcg, and FP/S 500/50\u00a0\u03bcg. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Assessment of the effects of inhaled fluticasone propionate (FP; 500 \u03bcg twice daily for 6 months) versus placebo in 34 COPD patients (23 on fluticasone propionate and eleven on placebo). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of adding fluticasone propionate/salmeterol (FSC) to tiotropium (Tio) in COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Minimal data are available on the use of the fluticasone propionate/salmeterol xinafoate combination (FSC) in the real-life COPD setting and prescription compliance with the licensed specifications. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "All patients older than 40 years with a diagnosis of COPD between 2001 and 2010 were entered in the study cohort at the time of their first prescription for tiotropium (TIO) alone or co-administered with fluticasone propionate/salmeterol (TIO\u2009+\u2009FSC). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination in COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: 14 subjects with COPD were commenced on combination fluticasone propionate/salmeterol therapy for 3 months. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 \u03bcg, FP 500 \u03bcg, salmeterol xinafoate (SLM) 50 \u03bcg, and combination FP 100 \u03bcg + SLM 50 \u03bcg. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Thirty-three COPD patients on stable bronchial therapy (salmeterol/fluticasone propionate 50/500 mg b.i.d. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: Our aim was to obtain descriptive data on exacerbation rates in patients with severe or very severe COPD (GOLD Stages III and IV as per GOLD 2009 classification) receiving salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC) or via separate inhalers (Sal/FP) in addition to individual existing therapy in order to investigate the potential benefit of a fixed combination device as compared with two separate devices due to potentially improved patients' compliance. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "COPD-related outcomes were compared between patients initiating fluticasone propionate-salmeterol 250/50\u2009mcg (FSC) vs anticholinergics (ACs) following a moderate COPD exacerbation. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Bronchodilators (such as ipratropium bromide), steroids (such as fluticasone propionate), and newly developed anti-inflammatory drugs (such as roflumilast) are used for patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: In this retrospective, observational study using administrative claims data, we identified COPD patients age \u226540 years who received maintenance therapy within 30 days of an initial COPD-related hospitalization or ED visit with: (1) fluticasone propionate/salmeterol combination (FSC 250 mcg/50 mcg) as new therapy, or (2) an anticholinergic (AC; tiotropium or ipratropium with or without albuterol). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "EXPERIMENTAL APPROACH: Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-\u03b1-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Although the addition of salmeterol/fluticasone propionate to tiotropium bromide did not reduce the COPD exacerbation rate, it did improve lung function and HR-QOL. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 \u00b5g/500 \u00b5g combination (SFC), or placebo in a 12-week, randomized, double-blind, double-dummy study (MKI102428/NCT00642148). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of tiotropium and fluticasone propionate/salmeterol (FSC) is commonly used to treat chronic obstructive pulmonary disease (COPD), but no study had evaluated the effectiveness of tiotropium plus FSC with 250\u00a0\u03bcg of fluticasone propionate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: This was a randomized, double-blind, placebo-controlled, crossover study (NCT00387036) to compare the effects of inhaled fluticasone propionate 500 \u03bcg (FP500) twice-daily and placebo (PLA) on airway function during rest and exercise, measured during constant work rate cycle exercise at 75% of maximum incremental cycle work rate, in 17 patients with COPD (FEV(1) \u2264 70% predicted). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To compare, in commercially-insured individuals 240 years old, the risk of chronic obstructive pulmonary disease (COPD) exacerbations and COPD-related health care utilization and costs in patients initiating maintenance treatment with fluticasone propionate/salmeterol xinafoate 250 microg/50 microg (FSC) with those in patients initiating treatment with tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Prior studies suggest that fluticasone propionate/salmeterol (FSC) may improve cardiovascular outcomes in COPD and we hypothesized that FSC would reduce arterial stiffness in these patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVES: To quantify healthcare use and costs associated with chronic obstructive pulmonary disease (COPD) among patients discharged from a COPD-related hospitalization or emergency department (ED) visit on a regimen of fluticasone propionate-salmeterol combination versus other inhaled maintenance therapies. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The adjusted rate of COPD-related hospitalizations or ED visits was 35% lower in the fluticasone propionate-salmeterol cohort (P <.05). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Adjusted COPD-related total (medical plus pharmacy) costs were lower in the fluticasone propionate-salmeterol cohort ($240 vs $279 per patient per month, P <.05), mostly because of lower medical costs ($113 vs $160 per patient per month, P <.05). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Initiation of fluticasone propionate-salmeterol after discharge from a COPD-related hospitalization or ED visit significantly reduced the risk of a recurrent event during the ensuing months and decreased COPD-related medical costs, without an increase in COPD-related pharmacy costs, in a real-world setting. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: A total of 60 exsmokers with severe COPD (mean forced expiratory volume in one second [FEV(1)] 1.07 L, 36% of predicted) spent 4 weeks free of any ICS, followed by 4 weeks of ICS use (fluticasone propionate 500 \u03bcg twice daily). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Relative costs and utilization-related outcomes of a fluticasone propionate 250 \u03bcg + salmeterol 50 \u03bcg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "COPD patients \u2265 35 years with at least one LABD claim between July 1, 2004 and June 30, 2006 were classified into five cohorts based on index LABD: monotherapy with tiotropium, salmeterol/fluticasone propionate, formoterol fumarate, or salmeterol or combination therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Patients treated with salmeterol/fluticasone propionate (p < 0.001), formoterol fumarate (p = 0.032), salmeterol (p = 0.004), or with combination therapy (p < 0.001) had higher COPD-related costs and a greater risk of inpatient admission (p < 0.01 for all) versus tiotropium. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In a large population-based study in the United Kingdom, we estimated the association between fluticasone propionate/salmeterol fixed-dose combination (FSC) and other ICS use and nonvertebral fracture incidence among patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: Although salmeterol/fluticasone propionate combination (SFC) therapy has been widely used for the treatment of COPD, the relationship between airway dimensions and improvement in pulmonary function remains unknown. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We examined the effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on the management of patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: A total of 1,481 women and 4,631 men with COPD were enrolled in TORCH, a trial comparing salmeterol, 50 \u03bcg, plus fluticasone propionate, 500 \u03bcg, twice a day and each component individually. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To estimate the cost-effectiveness of fluticasone propionate-salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We investigated predictive factors for response to fluticasone propionate/salmeterol (FSC) in severe COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 microg) and the long-acting beta(2)-agonist salmeterol (50 microg) in a single inhaler (250/50 microg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: To test the hypothesis that ICS and theophylline have a greater therapeutic effect than theophylline alone, 30 patients with COPD were treated with placebo theophylline capsules and either inhaled fluticasone propionate (FP) (500 microg bid) or inhaled placebo for 4 weeks in a double-dummy, randomized, double-blind, parallel study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " AIM: To assess the risk of pneumonia among COPD patients using salmeterol/fluticasone propionate combination inhalers (SFC), inhaled corticosteroids (ICS), or long-acting beta-agonists (LABA), alone or in combination, compared to those using only short-acting bronchodilators (SABD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Subsequently, 19 patients with COPD (Group A) were randomized and continued on S50, and 20 (Group B) were randomized to fluticasone propionate 250 microg (F250)/S50 bid for 86 +/- 16 days. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In 20 patients with COPD initially randomized to F250/S50 (Group B), after 57 +/- 22 days of S50 in 16 of 20 patients there was a significant (P = .04) increase only in (FENO) at 50 mL/s and large airway NO flux, which was not reduced after 60 +/- 23 days of fluticasone propionate 100 microg (F100)/S50(P = .07). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The effect of the long acting beta(2)-agonist/corticosteroid combination salmeterol-fluticasone propionate (SFC) on respiratory muscles and ventilation in severe COPD is unknown. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We examined directly the effect on the parasternal intercostal respiratory chest wall muscle and ventilation of four puffs of salmeterol 25 microg and fluticasone propionate 125 microg via the metered dose combination inhaler in 12 patients with severe Global Initiative on Obstructive Lung Disease stage III-IV COPD, mean FEV(1) = 0.91 L (32% predicted). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: The study aims to compare healthcare resource utilization associated with hospitalization or emergency department (ED) visits between FDA-approved inhaled corticosteroid/long-acting beta-agonist combinations [fluticasone propionate 250 microg/salmeterol 50 microg combination (FSC)] and anticholinergic treatments (ATC) in managed-care Medicare beneficiaries with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The TOwards a Revolution in COPD Health (TORCH) study was a 3-yr multicentre trial of 6,112 patients randomised to salmeterol (Salm), fluticasone propionate (FP), a Salm/FP combination (SFC) or placebo (P). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol (SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe COPD in the TOwards a Revolution in COPD Health (TORCH) study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 microg, fluticasone propionate (FP) 500 microg, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "STUDY DESIGN: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "An anti-inflammatory effect of salmeterol (S)/fluticasone propionate (FP) combination (SFC), as demonstrated in a number of biopsy studies, may be the mechanism by which it provides a potential survival benefit in COPD patients in the TORCH study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSION: No beneficial treatment effects for either high-dosed inhaled fluticasone propionate or oral N-acetylcysteine were observed in our study population of patients with COPD or chronic bronchitis. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: We examine the lifetime cost-effectiveness of treatment with fluticasone propionate/salmeterol (500/50 microg) compared with no maintenance treatment in COPD in the US. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: A decision-analytic model was developed to estimate lifetime costs and outcomes associated with fluticasone propionate/salmeterol 500/50 microg treatment, salmeterol 50 microg, and fluticasone propionate 500 microg compared to no maintenance treatment in treating COPD from a third-party US payer perspective. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Treatment of COPD with fluticasone propionate/salmeterol 500/50 microg appears to be cost-effective (<or=$50,000/QALY) compared to no maintenance treatment. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: A double-blind, placebo-controlled, randomized 2:1 study of fluticasone propionate (FP), 500 microg twice daily versus placebo over 6 months was performed in subjects with mild to moderate COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: The objectives of this retrospective study were to compare the effects of fluticasone propionate 500 microg/salmeterol 50 microg (FSC 500/50) with those of ipratropium (IPR) in older adult patients with COPD on the following factors: (1) the risk of all-cause and COPD-related hospitalization and emergency department (ED) visits; and (2) all-cause and COPD-related treatment costs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Fluticasone propionate reduces the frequency and severity of the episodes of exacerbation of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study was a trial that randomised 752 patients with moderate to severe COPD to fluticasone propionate 1000 mcg/day or placebo for three years. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "RESULTS: In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with fluticasone propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "This study supports the use of fluticasone propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " This retrospective analysis of data from two multi-center, randomized, double-blind, parallel group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50 mcg twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in albuterol-reversible (n=320 [44%]) and non-reversible (n=399 [56%]) patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but there are few data on their effectiveness when used together. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: In a pragmatic randomised, double-blind, placebo-controlled trial in 31 practices, 260 COPD patients stopped their usual ICS (median duration of use 8 years) and were allocated to 500 mcg fluticasone propionate twice daily (n = 128), or placebo (n = 132). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Results of the INSPIRE trial suggest that salmeterol/fluticasone propionate is associated with a significantly lower mortality rate than tiotropium bromide monotherapy in patients with COPD; the two treatments had similar effects in terms of exacerbation rates and lung function. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Few studies of the efficacy and safety of therapy with combinations of salmeterol/fluticasone propionate (SFCs) have been conducted in Chinese patients with COPD, and the benefits of combination therapy in nonsmoking patients with COPD are, to our knowledge, not known. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: We compared the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 microg twice daily and the long-acting bronchodilator (tiotropium) 18 microg once daily in preventing exacerbations and related outcomes in severe and very severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: The study population was a historical cohort of Texas Medicaid beneficiaries aged 40 to 64 years with COPD-related medical costs (International Classification of Diseases, Ninth Revision, Clinical Modification codes 491.xx, 492.xx, 496.xx), 24 months of continuous Medicaid enrollment (12 months before and after the index prescription), and at least 1 prescription claim (index) for a combination product containing fluticasone propionate + salmeterol, an inhaled corticosteroid, salmeterol, or ipratropium between April 1, 2001, and March 31, 2003. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The TORCH (Towards a Revolution in COPD Health) study confirmed that the effects of combined therapy with salmeterol/fluticasone propionate are greater than the monocomponents. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "This review critically appraises the pharmacology of salmeterol/fluticasone propionate, the evidence for efficacy in COPD and its potential use in combination with other drugs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The TORCH study (Towards a Revolution in COPD Health) was a double-blind, randomised, placebo-controlled clinical trial, investigating the combination of salmeterol/fluticasone propionate for 3 years in COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "A study was therefore undertaken to evaluate combined salmeterol/fluticasone propionate (SFC) and fluticasone propionate (FP) alone on inflammatory cells in the airways of patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The only major pharmacological advancement for the treatment of these diseases has been to increase the duration of action of bronchodilators (asthma: salmeterol; COPD: tiotropium bromide) and glucocorticosteroids (asthma: fluticasone propionate) and, increasingly, to formulate these agents in the same delivery device. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "A large multicenter prospective randomized trial (Towards a Revolution in COPD Health [TORCH]) is now ongoing and will examine the effect of fluticasone propionate in combination with salmeterol on all-cause mortality. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the impact of combination therapy with salmeterol/fluticasone propionate compared with salmeterol alone on moderate and severe exacerbations in patients with severe COPD and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In an open-label study at 38 outpatient centres, patients > or =12 years old with asthma or chronic obstructive pulmonary disease (COPD) received two actuations of fluticasone propionate/salmeterol 125/25 microg (115/21 microg ex-actuator) hydrofluoroalkane (ADVAIR) HFA) via MDI with counter twice a day until all 120 actuations were completed. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " STUDY OBJECTIVE: To examine the effect of fluticasone propionate, 250 microg/salmeterol, 50 microg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of exercise performance in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Several short-term follow-up trials have also suggested a reduction in mortality with a combination of long-acting beta(2)-agonist and inhaled corticosteroids, and a large, long-term study that is currently ongoing (the Toward a Revolution in COPD Health [TORCH] study) will provide data on the effects of fluticasone propionate and salmeterol in combination on all-cause mortality. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "A study was undertaken to examine the effects of theophylline and fluticasone propionate (FP) on RNS production in subjects with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVE: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The aim of this pilot study was to explore the relative efficacy in terms of improvement in symptoms and lung function of combining fluticasone propionate/salmeterol combination (FSC) and tiotropium in patients with severe-to-very severe stable COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVES: To explore the cost-effectiveness of fluticasone propionate (FP) for the treatment of chronic obstructive pulmonary disease (COPD), we estimated costs and quality-adjusted life-years (QALYs) over 3 years, based on an economic appraisal of a previously reported clinical trial (Inhaled Steroids in Obstructive Lung Disease in Europe [ISOLDE]). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Thus, the aim of this study was to investigate the effects of the low molecular weight heparin, enoxaparin (ENX), as an add-on therapy for a period of 12 weeks, to inhaled salmeterol/fluticasone propionate (SLM/FP) combination in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "This study determined the cost effectiveness of withdrawing fluticasone propionate (FP) in outpatients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To develop a Markov model that allows the cost effectiveness of interventions in patients with chronic obstructive pulmonary disease (COPD) to be estimated, and to apply the model to investigate the cost effectiveness of an inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist (beta(2)-agonist) combination (salmeterol/fluticasone propionate) versus usual care. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Efficacy data for the combination of inhaled salmeterol/fluticasone propionate 50/500microg twice daily in poorly reversible COPD patients with a history of exacerbations were obtained from the 1-year TRISTAN (TRial of Inhaled STeroids ANd long-acting beta-agonists) study and applied to the model, based on patient profiles representative of COPD clinical trials. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Initial evidence suggests that for patients with poorly reversible COPD and a documented history of frequent COPD exacerbations, the addition of salmeterol (a long-acting beta(2)-agonist) to fluticasone propionate (an inhaled corticosteroid) is potentially cost effective from the Canadian healthcare payer's perspective. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 microg FP + 50 microg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "budesonide 800 microg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20-30% and improve the health status of COPD patients by a similar amount compared with placebo. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "MATERIAL & METHODS: We studied blood and sputum samples from stable COPD patients (mean FEV1 60.5+/-7.5% predicted) at baseline (no treatment) and after 10 weeks treatment with either inhaled steroid, fluticasone propionate (FP) (1000 microg/d) or 10 weeks treatment with N-acetylcysteine (600mg/d) (NAC). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The \"TOwards a Revolution in COPD Health\" (TORCH) survival study is aiming to determine the impact of salmeterol/fluticasone propionate (SFC) combination and the individual components on the survival of COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In the US, twice-daily salmeterol/fluticasone propionate 50/250 microg is approved for use in adults with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and in the EU, the twice-daily 50/500 microg dosage is approved for use in patients with severe COPD, repeat exacerbations and significant symptoms despite bronchodilator therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In patients with moderate-to-severe COPD, twice-daily inhaled salmeterol/fluticasone propionate 50/250 or 50/500 microg for 24-52 weeks improves predose forced expiratory volume in 1 second (FEV1) significantly more than salmeterol monotherapy, improves postdose or postbronchodilator FEV1 significantly more than fluticasone propionate monotherapy and results in clinically significant improvements in health-related quality of life. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Salmeterol/fluticasone propionate 50/500 microg significantly reduced annual COPD exacerbations, especially in severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Some corticosteroid-related adverse events were increased in recipients of fluticasone propionate with or without salmeterol versus salmeterol monotherapy or placebo; withdrawal from fluticasone propionate, including combination therapy, needs careful management to minimise COPD exacerbations. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: The aim of this study was to compare the relative efficacy in terms of improvement in symptoms and lung function of salmeterol/fluticasone propionate (SLM/FP) combination administered through the Diskus inhaler versus theophylline (THEO) added to FP Diskus in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled long-acting beta(2)-agonist salmeterol (SM), when administered together in a single device (Diskus; GlaxoSmithKline, Inc; Research Triangle Park, NC), with that of placebo and the individual agents alone in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Forty-one stable patients with moderate COPD (FEV(1) approximately 60% predicted) were randomized to sequence 1; first HFA-134a beclomethasone dipropionate (HFA-BDP, an ICS with more peripheral deposition) 400 microg b.i.d., then fluticasone propionate (FP, an ICS with more central deposition) 375 microg b.i.d. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Oral prednisolone 0.6 mg/kg was given for 14 days to 524 patients with COPD before randomised treatment for 3 years with fluticasone propionate or placebo. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: We conclude that the altered pharmacokinetics of inhaled fluticasone propionate in COPD caused less hypothalamic-pituitary-adrenal suppression than in healthy controls. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We prospectively evaluated the cost-effectiveness offluticasone propionate (FP) treatment in patients with moderate-to-severe COPD, who were symptomatic on regular bronchodilator therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) study in COPD showed a 26% reduction in the yearly rate of exacerbations in patients treated with fluticasone propionate (FP) compared to placebo, but did not indicate which patients showed greatest benefit. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Observational data may provide an insight into the expected survival in clinical trials of fluticasone propionate (FP) and salmeterol in COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Patients had mild to moderately severe COPD (FEV(1) 25-80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 micro g twice daily, n=14) or placebo (n=10). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSION: Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "A study was undertaken to examine whether inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a subgroup of COPD patients with bronchial hyperresponsiveness (BHR). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We have performed a double-blind, placebo-controlled, randomized study to compare fluticasone propionate (FP) 500 microg twice daily via a dry powder inhaler and placebo (P) over a 3-month period in subjects with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The data indicate that inhaled fluticasone does affect selected aspects of airway inflammation in COPD, and this may explain, in part, the decrease in exacerbations seen in long-term studies with fluticasone propionate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "STUDY OBJECTIVES: We evaluated the short-term effects of an inhaled corticosteroid, fluticasone propionate (FP), on FEV(1) and on the mechanical properties of patients in stable condition with severe COPD and chronic hypercapnic respiratory failure who were receiving long-term ventilatory support. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " In a prospective study, we investigated the long-term compliance to fluticasone propionate (FP) by dry powder inhalation (Rotadisk) in subjects with early signs of asthma and chronic obstructive pulmonary disease (COPD) without an established diagnosis. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Because COPD involves airway inflammation and probable protease-antiprotease imbalance, we examined the effect of high dose fluticasone propionate on markers of activity of both pathogenetic mechanisms. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Thirteen patients with COPD were treated with fluticasone propionate (500 microg twice a day) for 4 wk, delivered via MDI and spacer, in a double-blind crossover study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We compared the effect of inhaled fluticasone propionate with placebo in the treatment of patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "INTERPRETATION: Fluticasone propionate may be of clinical benefit in patients with COPD over at least 6 months. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVE: The objective of this study was to compare persistence to salmeterol/fluticasone propionate combination treatment as AirFluSal Forspiro with persistence to Seretide Diskus in patients with asthma or COPD aged 12 years and above. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The WISDOM study (NCT00975195) reported a change in lung function following withdrawal of fluticasone propionate in patients with severe to very severe COPD treated with tiotropium and salmeterol. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: From the GlaxoSmithKline trial registry, we selected randomised, double-blind, clinical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in duration. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Biopsy samples were taken from patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 wk). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Triple therapy using salmeterol/fluticasone propionate (FP) and tiotropium bromide is commonly used to treat chronic obstructive pulmonary disease (COPD), but sparse efficacy data exist in COPD patients with fewer symptoms and with a lower dose of inhaled corticosteroid in Japanese patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA) are approved maintenance therapies for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50 mcg and fluticasone propionate 250 mcg (SFC 250) in Japanese patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50\u2005\u00b5g, once-daily tiotropium (TIO) 18\u2005\u00b5g or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500\u2005\u00b5g twice daily. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "This study compared the rate of COPD exacerbations over the 26 weeks after an initial exacerbation in patients receiving the combination of fluticasone propionate and salmeterol (FP/SAL) or SAL alone. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 \u03bcg once daily), salmeterol (50 \u03bcg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 \u03bcg twice daily) during a 6-week run-in period. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In this study, we applied IOS and spirometry to evaluate the effectiveness of fluticasone propionate and salmeterol (SFC) combined with tiotropium (TIO) in COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "COPD subjects were randomized to twice daily MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, MF 400\u00a0\u03bcg, F 10\u00a0\u03bcg, and placebo; asthma subjects were randomized to MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, fluticasone propionate/salmeterol (FP/S) 250/50\u00a0\u03bcg, and FP/S 500/50\u00a0\u03bcg. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Minimal data are available on the use of the fluticasone propionate/salmeterol xinafoate combination (FSC) in the real-life COPD setting and prescription compliance with the licensed specifications. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 \u03bcg, FP 500 \u03bcg, salmeterol xinafoate (SLM) 50 \u03bcg, and combination FP 100 \u03bcg + SLM 50 \u03bcg. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Thirty-three COPD patients on stable bronchial therapy (salmeterol/fluticasone propionate 50/500 mg b.i.d. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: Our aim was to obtain descriptive data on exacerbation rates in patients with severe or very severe COPD (GOLD Stages III and IV as per GOLD 2009 classification) receiving salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC) or via separate inhalers (Sal/FP) in addition to individual existing therapy in order to investigate the potential benefit of a fixed combination device as compared with two separate devices due to potentially improved patients' compliance. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "EXPERIMENTAL APPROACH: Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-\u03b1-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Although the addition of salmeterol/fluticasone propionate to tiotropium bromide did not reduce the COPD exacerbation rate, it did improve lung function and HR-QOL. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 \u00b5g/500 \u00b5g combination (SFC), or placebo in a 12-week, randomized, double-blind, double-dummy study (MKI102428/NCT00642148). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of tiotropium and fluticasone propionate/salmeterol (FSC) is commonly used to treat chronic obstructive pulmonary disease (COPD), but no study had evaluated the effectiveness of tiotropium plus FSC with 250\u00a0\u03bcg of fluticasone propionate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To compare, in commercially-insured individuals 240 years old, the risk of chronic obstructive pulmonary disease (COPD) exacerbations and COPD-related health care utilization and costs in patients initiating maintenance treatment with fluticasone propionate/salmeterol xinafoate 250 microg/50 microg (FSC) with those in patients initiating treatment with tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVES: To quantify healthcare use and costs associated with chronic obstructive pulmonary disease (COPD) among patients discharged from a COPD-related hospitalization or emergency department (ED) visit on a regimen of fluticasone propionate-salmeterol combination versus other inhaled maintenance therapies. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The adjusted rate of COPD-related hospitalizations or ED visits was 35% lower in the fluticasone propionate-salmeterol cohort (P <.05). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Adjusted COPD-related total (medical plus pharmacy) costs were lower in the fluticasone propionate-salmeterol cohort ($240 vs $279 per patient per month, P <.05), mostly because of lower medical costs ($113 vs $160 per patient per month, P <.05). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Initiation of fluticasone propionate-salmeterol after discharge from a COPD-related hospitalization or ED visit significantly reduced the risk of a recurrent event during the ensuing months and decreased COPD-related medical costs, without an increase in COPD-related pharmacy costs, in a real-world setting. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Relative costs and utilization-related outcomes of a fluticasone propionate 250 \u03bcg + salmeterol 50 \u03bcg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "COPD patients \u2265 35 years with at least one LABD claim between July 1, 2004 and June 30, 2006 were classified into five cohorts based on index LABD: monotherapy with tiotropium, salmeterol/fluticasone propionate, formoterol fumarate, or salmeterol or combination therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Patients treated with salmeterol/fluticasone propionate (p < 0.001), formoterol fumarate (p = 0.032), salmeterol (p = 0.004), or with combination therapy (p < 0.001) had higher COPD-related costs and a greater risk of inpatient admission (p < 0.01 for all) versus tiotropium. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In a large population-based study in the United Kingdom, we estimated the association between fluticasone propionate/salmeterol fixed-dose combination (FSC) and other ICS use and nonvertebral fracture incidence among patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: Although salmeterol/fluticasone propionate combination (SFC) therapy has been widely used for the treatment of COPD, the relationship between airway dimensions and improvement in pulmonary function remains unknown. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We examined the effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on the management of patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: A total of 1,481 women and 4,631 men with COPD were enrolled in TORCH, a trial comparing salmeterol, 50 \u03bcg, plus fluticasone propionate, 500 \u03bcg, twice a day and each component individually. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To estimate the cost-effectiveness of fluticasone propionate-salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "We investigated predictive factors for response to fluticasone propionate/salmeterol (FSC) in severe COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: The study aims to compare healthcare resource utilization associated with hospitalization or emergency department (ED) visits between FDA-approved inhaled corticosteroid/long-acting beta-agonist combinations [fluticasone propionate 250 microg/salmeterol 50 microg combination (FSC)] and anticholinergic treatments (ATC) in managed-care Medicare beneficiaries with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 microg, fluticasone propionate (FP) 500 microg, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "STUDY DESIGN: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: The objectives of this retrospective study were to compare the effects of fluticasone propionate 500 microg/salmeterol 50 microg (FSC 500/50) with those of ipratropium (IPR) in older adult patients with COPD on the following factors: (1) the risk of all-cause and COPD-related hospitalization and emergency department (ED) visits; and (2) all-cause and COPD-related treatment costs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "CONCLUSIONS: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but there are few data on their effectiveness when used together. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Results of the INSPIRE trial suggest that salmeterol/fluticasone propionate is associated with a significantly lower mortality rate than tiotropium bromide monotherapy in patients with COPD; the two treatments had similar effects in terms of exacerbation rates and lung function. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: We compared the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 microg twice daily and the long-acting bronchodilator (tiotropium) 18 microg once daily in preventing exacerbations and related outcomes in severe and very severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: The study population was a historical cohort of Texas Medicaid beneficiaries aged 40 to 64 years with COPD-related medical costs (International Classification of Diseases, Ninth Revision, Clinical Modification codes 491.xx, 492.xx, 496.xx), 24 months of continuous Medicaid enrollment (12 months before and after the index prescription), and at least 1 prescription claim (index) for a combination product containing fluticasone propionate + salmeterol, an inhaled corticosteroid, salmeterol, or ipratropium between April 1, 2001, and March 31, 2003. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The TORCH (Towards a Revolution in COPD Health) study confirmed that the effects of combined therapy with salmeterol/fluticasone propionate are greater than the monocomponents. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "This review critically appraises the pharmacology of salmeterol/fluticasone propionate, the evidence for efficacy in COPD and its potential use in combination with other drugs. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "A study was therefore undertaken to evaluate combined salmeterol/fluticasone propionate (SFC) and fluticasone propionate (FP) alone on inflammatory cells in the airways of patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The only major pharmacological advancement for the treatment of these diseases has been to increase the duration of action of bronchodilators (asthma: salmeterol; COPD: tiotropium bromide) and glucocorticosteroids (asthma: fluticasone propionate) and, increasingly, to formulate these agents in the same delivery device. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "A large multicenter prospective randomized trial (Towards a Revolution in COPD Health [TORCH]) is now ongoing and will examine the effect of fluticasone propionate in combination with salmeterol on all-cause mortality. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " BACKGROUND: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the impact of combination therapy with salmeterol/fluticasone propionate compared with salmeterol alone on moderate and severe exacerbations in patients with severe COPD and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In an open-label study at 38 outpatient centres, patients > or =12 years old with asthma or chronic obstructive pulmonary disease (COPD) received two actuations of fluticasone propionate/salmeterol 125/25 microg (115/21 microg ex-actuator) hydrofluoroalkane (ADVAIR) HFA) via MDI with counter twice a day until all 120 actuations were completed. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Several short-term follow-up trials have also suggested a reduction in mortality with a combination of long-acting beta(2)-agonist and inhaled corticosteroids, and a large, long-term study that is currently ongoing (the Toward a Revolution in COPD Health [TORCH] study) will provide data on the effects of fluticasone propionate and salmeterol in combination on all-cause mortality. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVE: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVES: To explore the cost-effectiveness of fluticasone propionate (FP) for the treatment of chronic obstructive pulmonary disease (COPD), we estimated costs and quality-adjusted life-years (QALYs) over 3 years, based on an economic appraisal of a previously reported clinical trial (Inhaled Steroids in Obstructive Lung Disease in Europe [ISOLDE]). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Thus, the aim of this study was to investigate the effects of the low molecular weight heparin, enoxaparin (ENX), as an add-on therapy for a period of 12 weeks, to inhaled salmeterol/fluticasone propionate (SLM/FP) combination in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To develop a Markov model that allows the cost effectiveness of interventions in patients with chronic obstructive pulmonary disease (COPD) to be estimated, and to apply the model to investigate the cost effectiveness of an inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist (beta(2)-agonist) combination (salmeterol/fluticasone propionate) versus usual care. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Efficacy data for the combination of inhaled salmeterol/fluticasone propionate 50/500microg twice daily in poorly reversible COPD patients with a history of exacerbations were obtained from the 1-year TRISTAN (TRial of Inhaled STeroids ANd long-acting beta-agonists) study and applied to the model, based on patient profiles representative of COPD clinical trials. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Initial evidence suggests that for patients with poorly reversible COPD and a documented history of frequent COPD exacerbations, the addition of salmeterol (a long-acting beta(2)-agonist) to fluticasone propionate (an inhaled corticosteroid) is potentially cost effective from the Canadian healthcare payer's perspective. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 microg FP + 50 microg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "The \"TOwards a Revolution in COPD Health\" (TORCH) survival study is aiming to determine the impact of salmeterol/fluticasone propionate (SFC) combination and the individual components on the survival of COPD patients. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In the US, twice-daily salmeterol/fluticasone propionate 50/250 microg is approved for use in adults with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and in the EU, the twice-daily 50/500 microg dosage is approved for use in patients with severe COPD, repeat exacerbations and significant symptoms despite bronchodilator therapy. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In patients with moderate-to-severe COPD, twice-daily inhaled salmeterol/fluticasone propionate 50/250 or 50/500 microg for 24-52 weeks improves predose forced expiratory volume in 1 second (FEV1) significantly more than salmeterol monotherapy, improves postdose or postbronchodilator FEV1 significantly more than fluticasone propionate monotherapy and results in clinically significant improvements in health-related quality of life. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Salmeterol/fluticasone propionate 50/500 microg significantly reduced annual COPD exacerbations, especially in severe COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Some corticosteroid-related adverse events were increased in recipients of fluticasone propionate with or without salmeterol versus salmeterol monotherapy or placebo; withdrawal from fluticasone propionate, including combination therapy, needs careful management to minimise COPD exacerbations. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: The aim of this study was to compare the relative efficacy in terms of improvement in symptoms and lung function of salmeterol/fluticasone propionate (SLM/FP) combination administered through the Diskus inhaler versus theophylline (THEO) added to FP Diskus in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Observational data may provide an insight into the expected survival in clinical trials of fluticasone propionate (FP) and salmeterol in COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "EXPERIMENTAL APPROACH: Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-\u03b1-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Although the addition of salmeterol/fluticasone propionate to tiotropium bromide did not reduce the COPD exacerbation rate, it did improve lung function and HR-QOL. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "budesonide 800 microg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20-30% and improve the health status of COPD patients by a similar amount compared with placebo. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: Relative costs and utilization-related outcomes of a fluticasone propionate 250 \u03bcg + salmeterol 50 \u03bcg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "OBJECTIVE: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS). ", "polarity": 1}, {"drug": "Fluticasone propionate", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "Taken together, procaterol and Compound T are potentially good drugs to treat asthma and COPD complicated with ozone exposure. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "METHODS: A double-blind crossover trial was performed to compare the treatment of COPD patients with an SABA (20 \u00b5g of inhaled procaterol) versus a placebo. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "METHODS: Patients with moderate to severe stable COPD were randomly divided into 2 groups those who inhaled procaterol before exercise (n=10) and those who did not (control group) (n=11). ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "CONCLUSION: Our data suggest that a pulmonary rehabilitation program combined with inhaled procaterol can improve both HRQOL and exercise tolerance in COPD patients. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "The aim of this study was to investigate the clinical effect of supplementary inhaled procaterol hydrochloride in patients with COPD. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "CONCLUSION: Use of supplementary inhaled procaterol before performing daily activities improved dyspnea symptoms in subjects with Stage III COPD. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": " The purpose of this study was to evaluate the inhibitory effect of procaterol (procaterol hydrochloride, CAS 62929-91-3) on exercise dynamic lung hyperinflation during the 6-min walk test (6MWT) in stable chronic obstructive disease (COPD) patients. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "In the present study, there was a significant attenuation in exercise dynamic lung hyperinflation, suggesting the important role of the beta2-receptor agonist procaterol in the treatment of COPD. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "It is therefore likely that most patients with COPD may derive considerable benefit from bronchodilator therapy with procaterol. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": " AIM: To examine the effects of inhaled procaterol (Meptin Air : MA), a short-acting beta2-agonist, for proactive use rather than rescue use in dyspnea and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD), who complained of dyspnea in daily activities despite treatment with long-acting bronchodilators. ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": " The present study was undertaken to evaluate the long-term effect of procaterol hydrochloride (CAS 62929-91-3, Meptin), a third generation beta2-receptor agonist on lung function, exercise capacity, health-related quality of life (HRQOL) and activities of daily living (ALDs) in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Procaterol", "disease": "COPD", "orig_sen": "These results suggest the effectiveness of long-term regular bronchodilator therapy with the beta2-receptor agonist procaterol in patients with stable COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "She was diagnosed with COPD 2 months prior to her presentation and started on treatment with fluticasone propionate and albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: In this retrospective, observational study using administrative claims data, we identified COPD patients age \u226540 years who received maintenance therapy within 30 days of an initial COPD-related hospitalization or ED visit with: (1) fluticasone propionate/salmeterol combination (FSC 250 mcg/50 mcg) as new therapy, or (2) an anticholinergic (AC; tiotropium or ipratropium with or without albuterol). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Time-to-first COPD-related health care event beginning 30 days following therapy initiation with FSC (n = 16,684), ipratropium alone or in fixed dose combination with albuterol (n = 14,449), or tiotropium (n = 12,659) was estimated using Cox proportional hazard models that controlled for differences in patient demographic characteristics, health care utilization, and comorbidities at baseline. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "RESULTS: In 39 (18 women), clinically stable ex-smokers with COPD aged 73 +/- 9 years (mean +/- SD) on salmeterol 50 microg (S50) bid, after 180 microg aerosolized albuterol, FEV(1) (L) was 52% +/- 12% predicted and FEV(1)/FVC was 55% +/- 6%. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Patients age 40 years or older with a primary diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification code 490, 491, 492, or 496), at least 18 months of continuous eligibility, and an index prescription for fluticasone/salmeterol combination, salmeterol alone, inhaled corticosteroid alone, ipratropium/albuterol combination, or ipratropium alone (reference) were identified. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " This retrospective analysis of data from two multi-center, randomized, double-blind, parallel group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50 mcg twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in albuterol-reversible (n=320 [44%]) and non-reversible (n=399 [56%]) patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "PATIENTS: Eligible patients were > or = 40 years old with a diagnosis of COPD, prealbuterol FEV(1) < 70% of predicted, FEV1/FVC ratio > or = 0.70, and functional residual capacity (FRC) > or = 120% of predicted normal. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS AND PATIENTS: Airway blood flow (Qaw) responses to therapy with inhaled albuterol, which causes endothelium-dependent vasodilation, were measured with a noninvasive soluble-gas-uptake technique in age-matched healthy current smokers (n = 10), healthy ex-smokers (n = 10), ex-smokers with COPD (n = 10), and healthy lifetime nonsmokers. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In the ex-smokers with COPD, the albuterol responsiveness measurement was repeated after 4 weeks of treatment with fluticasone/salmeterol and after a drug washout period of 4 or 8 weeks. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Albuterol inhalation increased mean Qaw significantly in lifetime nonsmokers (50.1 +/- 8.3% predicted; p < 0.05) and healthy ex-smokers (37.2 +/- 3.4% predicted; p < 0.05), but not in healthy current smokers (13.9 +/- 3.2% predicted; difference was not significant) and ex-smokers with COPD (9.7 +/- 4.5% predicted; difference was not significant). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "While fluticasone/salmeterol did not change Qaw significantly, it restored albuterol responsiveness (67.6 +/- 11.1% predicted; p < 0.05) in the ex-smokers with COPD; this effect was no longer seen after the drug washout period. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Cigarette smoking is associated with a blunted vasodilator response to inhaled albuterol in the airway as an expression of endothelial dysfunction, with a partial recovery of albuterol responsiveness after smoking cessation in healthy ex-smokers but not in ex-smokers with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Airway blood flow (Q(aw)) responses to inhaled albuterol as an index of endothelial function were measured in age-matched healthy current smokers, healthy ex-smokers, ex-smokers with COPD and healthy lifetime non-smokers; in the ex-smokers with COPD, the albuterol responsiveness was repeated after a 4-week treatment with an inhaled glucocorticoid/beta(2)-adrenergic agonist combination drug. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Albuterol inhalation increased mean Q(aw) in lifetime non-smokers (50.1+/-8.3%; p<0.05) and in healthy ex-smokers (37.2+/-3.4%; p<0.05) but not in healthy current smokers (13.9+/-3.2%; p=NS) and ex-smokers with COPD (9.7+/-4.5%; p=NS). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "While drug treatment per se did not change Q(aw) significantly, it restored albuterol responsiveness (+67.6+/-11.1%; p<0.05) in the ex-smokers with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "PARTICIPANTS: Seven hundred fifty-one patients with stable COPD defined clinically and as baseline postbronchodilator FEV(1) > or = 0.8 L and < 85% predicted, FEV(1)/FVC ratio < 70%, and FEV(1) change after albuterol < 10% of predicted. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Time-to-first COPD-related health care event beginning 30 days following therapy initiation with FSC (n = 16,684), ipratropium alone or in fixed dose combination with albuterol (n = 14,449), or tiotropium (n = 12,659) was estimated using Cox proportional hazard models that controlled for differences in patient demographic characteristics, health care utilization, and comorbidities at baseline. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Patients age 40 years or older with a primary diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification code 490, 491, 492, or 496), at least 18 months of continuous eligibility, and an index prescription for fluticasone/salmeterol combination, salmeterol alone, inhaled corticosteroid alone, ipratropium/albuterol combination, or ipratropium alone (reference) were identified. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those \"unresponsive\" to albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "He was originally diagnosed with healthcare associated pneumonia (HCAP) and an acute on chronic COPD exacerbation and treated with prednisone, inhalers, ipratropium/albuterol, and broad-spectrum antibiotics. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "placebo, umeclidinium and vilanterol, umeclidinium plus vilanterol improves lung function and quality of life in patients with COPD, reduces the use of albuterol, and does not increase the incidence of adverse events and serious adverse events. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "OBJECTIVES: This study aimed to investigate whether airway obstruction could interfere with real FENO levels and if different FeNO changes after albuterol inhalation could assist in distinguishing asthma from chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: FeNO and spirometry measurements were performed before and after albuterol inhalation in the following three patient groups: 30 steroid-naive asthmatics, 25 asthmatics inhaling corticosteroids/long-acting \u03b2(2)-adrenergic agonists for at least 1 month and 20 COPD patients. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "RESULTS: FeNO increased significantly after albuterol inhalation in steroid-naive asthmatics but not in ICS-treated asthmatics or COPD patients. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Both the levels of FeNO and changes in FENO after albuterol inhalation in steroid-naive asthma patients were higher than those in ICS-treated asthmatics and COPD patients (P\u2009<\u20090.001). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " PURPOSE: Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: In a single-center open-label study, selected adults hospitalized for asthma or COPD exacerbations over a 21-month period were randomly assigned to receive levalbuterol 1.25 mg three times daily (n = 55) or albuterol 2.5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSION: Clinical outcomes were similar with the use of levalbuterol versus albuterol for exacerbations of COPD or asthma. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The objective of this study was to compare daily variation in bronchodilator response to the combined use of albuterol and ipratropium with monotherapies in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " INTRODUCTION: In severe asthma attacks or in severe chronic obstructive pulmonary disease (COPD) exacerbations, inhaled short-acting bronchodilators, such as salbutamol (albuterol), terbutaline or ipratropium, often have a limited effectiveness due to significantly impaired ventilation. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Subjects required inhaled albuterol as follows: asthma: 53.8% after inhaled loxapine and 11.5% after placebo; and COPD: 23.1% after inhaled loxapine and 14.8% after placebo. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: A search of the literature in the PubMed database was undertaken using the keywords \"COPD,\" \"albuterol,\" \"ipratropium bromide,\" and \"Respimat\u00ae Soft Mist Inhaler\u2122\"; pertinent references within the identified citations were included. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The environmental effect of CFC-pMDIs, the invention of the Respimat\u00ae Soft Mist Inhaler\u2122 (SMI) (Boehringer Ingelheim, Ingelheim, Germany), and its use to deliver the combination of albuterol and ipratropium bromide for the treatment of COPD were reviewed. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The Respimat SMI delivery device is a novel, efficient, and well-received system for the delivery of aerosolized albuterol and ipratropium bromide to patients with COPD; however, the presence of longer-acting, less frequently dosed respiratory medications provide patients and providers with other therapeutic options. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " BACKGROUND: The evidence for the benefits of branded levalbuterol over generic albuterol in patients with chronic obstructive pulmonary disease (COPD) is inconclusive. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "OBJECTIVES: This study examined use and spending on albuterol and levalbuterol in a nationally representative sample of Medicare beneficiaries with COPD enrolled in Part D in 2006. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Patient characteristics and other COPD medication use were compared across albuterol-only users, levalbuterol-only users, and users of both albuterol and levalbuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In this sample of Medicare beneficiaries with COPD enrolled in Part D, mean annual spending in 2006 was significantly higher for levalbuterol than for albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Time-to-first COPD-related health care event beginning 30 days following therapy initiation with FSC (n = 16,684), ipratropium alone or in fixed dose combination with albuterol (n = 14,449), or tiotropium (n = 12,659) was estimated using Cox proportional hazard models that controlled for differences in patient demographic characteristics, health care utilization, and comorbidities at baseline. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: Epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and COPD (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (CSE) and/or Th2 cytokine IL-13, followed by Mp infection and treatment with beta2-agonists albuterol and formoterol for up to seven days. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Combination therapy with albuterol and ipratropium bromide was approved > 15 years ago for the treatment of COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "AREAS COVERED IN THIS REVIEW: We conducted a PubMed literature search using the keywords COPD, albuterol, ipratropium bromide and Combivent (Boehringer Ingelheim Corp., Ridgefield, CT, USA); pertinent references within the identified citations are included in the review. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "WHAT THE READER WILL GAIN: At the time of its approval, albuterol/ipratropium bromide was an innovative combination of existing medications for the treatment of COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "TAKE HOME MESSAGE: The recent development and approval of longer acting and more potent beta agonists, anticholinergics and newer combination treatments have surpassed many of the advantages of combined albuterol-ipratropium for the treatment of patients with stable COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " BACKGROUND: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: 676 patients with moderate to very severe stable COPD (mean FEV(1)=39% of predicted) maintained on ipratropium/albuterol were randomized to receive over an 84 day period either tiotropium (18 mcg) each morning, or continue with ipratropium (26 mcg)/albuterol (206 mcg), 2 actuations 4 times daily, using a parallel group, double-blind, double-dummy design. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " BACKGROUND: The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Demographic characteristics were similar between the 2 treatment groups, except that there were more females with COPD in the levalbuterol treatment group (63.88%) compared with the racemic albuterol treatment group (45.5%) (P = 0.005). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In these hospitalized patients with acute asthma or COPD treated with levalbuterol every 6 to 8 hours or racemic albuterol every 1 to 4 hours, significantly fewer total nebulizations were required with levalbuterol, without an increased need for rescue nebulizations during 14 days of hospitalization. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Patients age 40 years or older with a primary diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification code 490, 491, 492, or 496), at least 18 months of continuous eligibility, and an index prescription for fluticasone/salmeterol combination, salmeterol alone, inhaled corticosteroid alone, ipratropium/albuterol combination, or ipratropium alone (reference) were identified. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: Eighty stable patients with COPD performed forced vital capacity and slow vital capacity maneuvers, as well as the 6-min walk test, prior to and after receiving albuterol spray (400 microg). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "This analysis was performed to review expenditures and resource utilization of patients with chronic obstructive pulmonary disease (COPD) who were taking DN or generic ipratropium and albuterol (dual single agents [DSA]). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " PURPOSE: Patients using albuterol and ipratropium for treating chronic obstructive pulmonary disease (COPD) can use either nebulizers or metered dose inhalers. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " The efficacy and safety of nebulized levalbuterol in adults with chronic obstructive pulmonary disease (COPD) was evaluated in this multicenter, randomized, double-blind, parallel design study. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In this study, levalbuterol treatment in subjects with COPD was generally well tolerated, produced significant bronchodilation compared with PBO, and improved clinical control of COPD as evidenced by reductions in rescue medication use compared with PBO and/or RAC. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: We evaluated the response to albuterol inhalation in 10 healthy subjects, 9 subjects with asthma, and 15 subjects with chronic obstructive pulmonary disease (COPD) with mean (SD) age in years of 38 (SD, 11), 45 (SD, 11), and 64 (SD, 8), respectively. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In multiple regression analysis, the changes in TGC, inspiratory lung resistance, and ratio of residual volume to total lung capacity postalbuterol predicted more than 75% of FEV(1) improvement in patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSION: Improvements in FEV(1) after albuterol in patients with COPD are due to reduction of lung resistance, hyperinflation, and TGC. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Our aim was to determine whether high dose nebulized rac-albuterol could increase P(a)CO(2) in patients with COPD, limited bronchodilator reversibilty and hypercapnia. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: We compared 10 mg and 400 microg rac-albuterol, given in two doses 1 h apart on nonconsecutive days, in a double-blind randomized crossover study in 14 patients with severe COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Under stable conditions most subjects with severe COPD and hypercapnia will have a fall in P(a)CO(2) and P(a)O(2) following 10 mg rac-albuterol, suggesting that they maintain capacity to respond to any increase in VCO(2) and prevent a rise in P(a)CO(2). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "This paper presents results from clinical studies examining levalbuterol and racemic albuterol use among elderly patients who have asthma or COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Efficacy measures (spirometry, global COPD ratings, scores on the EuroQol Health Questionnaire [EQ-5D], albuterol inhaler as needed) were included to demonstrate that the study population exhibited the characteristic improvements observed in previous tiotropium studies. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Physician and patient global COPD ratings and the EQ-5D visual analog scale scores were improved with tiotropium (p<0.05); as-needed albuterol was reduced by 25% relative to placebo (p<0.05). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: In this randomized, double-blind study the effects of an inhaled bronchodilator (BD), albuterol/ipratropium bromide solution, were compared with normal saline (NS) in 30 patients with COPD (age, 66+/-9 yr; forced expiratory volume in 1 s, 48+/-14% pred). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " In acute exacerbation of chronic obstructive pulmonary disease (AECOPD), short-acting inhaled bronchodilators, such as salbutamol (albuterol) and ipratropium bromide, have proven useful. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In COPD patients, delta(e) T was increased (2.26 +/- 0.16 delta C x s(-1)) after the inhalation of 200 microg of albuterol, which is a known vasodilator, indicating that delta(e) T and bronchial blood flow may be correlated. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The second was a randomized trial involved 47 patients with acute COPD, who presented to an Emergency Department randomized to receive updraft nebulization of albuterol and ipratropium bromide using 80% helium and 20% oxygen or compressed air as the driving gas. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " OBJECTIVE: Compare the therapeutic efficacy of an oral/metered-dose inhaler (oral/MDI) regimen to an intravenous/nebulizer (I.V./neb) regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "SEARCH STRATEGY: A comprehensive search of the literature was carried out of EMBASE, MEDLINE, CINAHL and the Cochrane COPD trials register was carried out using the terms: bronchodilator* OR albuterol OR metaproterenol OR terbutaline OR isoetharine OR pirbuterol OR salbutamol OR beta-2 agonist. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those \"unresponsive\" to albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To determine whether the bronchodilator effects of albuterol and ipratropium bromide are greater if updraft nebulization is driven by 80% helium and 20% oxygen (HELIOX) than if driven by compressed room air (AIR) during the treatment of an acute exacerbations of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: Over a 12-month period, a convenience sample of 50 normoxic patients presenting with signs and symptoms of an acute exacerbation of COPD were prospectively randomized to receive either HELIOX or AIR as the driving gas for updraft nebulization of a mixture of albuterol 2.5 mg and ipratropium bromide 0.5 mg. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " OBJECTIVE: Four-hour comparison of the bronchodilator response of albuterol administered via metered-dose inhaler (MDI) with spacer versus small-volume nebulizer (SVN) to mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In stable, mechanically ventilated COPD patients, albuterol may be administered via MDI with spacer or via SVN every 4 hours. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " We tested the hypothesis that the decrease in dyspnea in patients with COPD with inhaled albuterol is in part due to increased diaphragmatic contractility. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Eleven patients with COPD inhaled albuterol or placebo in a double-blind randomized manner. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In conclusion, albuterol relieves dyspnea and enhances respiratory muscle output in patients with COPD primarily by improving the length-tension relationship of the diaphragm rather than by improving its contractility. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In COPD, the capacity of racemic albuterol to ameliorate these symptoms is more limited and suppression of edema and of infiltration and activation of leukocytes acquire greater significance. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "As would be expected, homochiral (R)-albuterol (levalbuterol) is more potent and effective in asthma and may have significant advantages if used in COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In the monitoring phase, patients with COPD were pretreated with an inhaled bronchodilator (albuterol) and had pulmonary function monitored during the infusion of a graduated dose of adenosine. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The objective of this double-blind, randomized, positive-control trial was to determine the effectiveness of an albuterol-ipratropium solution aerosol combination (Dey combination solution, Dey LP, Napa, Calif., USA) compared with solution aerosols of both component medications administered alone in patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " STUDY OBJECTIVE: To compare hourly administration of albuterol with more frequent administration of a higher cumulative dose in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSION: This study failed to demonstrate a statistically significant advantage to use of a higher cumulative dose of albuterol in patients with acute exacerbation of COPD, possibly because of type II statistical error. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We conclude that nebulization of either albuterol or metaproterenol can alleviate DPH resulting from mechanical ventilation in anesthetized patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We determined the response to increasing doses of albuterol administered by a MDI and cylindrical spacer to 12 mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Respiratory mechanics were also measured for 60 min in another group of seven patients with COPD who received four puffs of albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In conclusion, four puffs of albuterol given by a MDI and spacer provided the best combination of bronchodilator effect and safety in stable mechanically ventilated patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " The bronchodilator efficacy, safety, and persistence of effect of the anticholinergic agent ipratropium bromide and the beta-adrenergic agonist albuterol, both given by nebulization, were compared in 223 patients with stable, severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We studied the efficacy and safety of 10 puffs (90 micrograms/puff) of albuterol administered by an MDI in seven mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In summary, 10 puffs of albuterol given by an MDI and spacer produced significant bronchodilation in ventilator-supported patients with COPD, without producing side effects. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In conclusion, higher doses of albuterol given by an MDI and spacer could be used routinely in mechanically ventilated patients with COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " STUDY OBJECTIVE: To investigate whether the addition of a single aerosolized dose of glycopyrrolate leads to a greater improvement in pulmonary function than treatment with albuterol alone for patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSION: The combination of glycopyrrolate and albuterol produces a greater improvement in FEV1 than does albuterol alone in the treatment of patients with acute exacerbation of COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We conclude that the combination of theophylline and a beta agonist (albuterol) may increase the premature ventricular contraction rate and the complexity of ectopic activity in COPD patients. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We report the results of a 12-week prospective, double-blind, parallel-group evaluation of the use of the following: albuterol, a beta-adrenergic agent; ipratropium, an anticholinergic agent; or a combination of the two, administered by metered-dose inhaler to patients with moderately severe stable COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "We conclude that the combination of ipratropium and albuterol, when given by metered-dose inhaler to patients with COPD, is more effective than either of the two agents alone. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "The WBC count (in 1,000) before (mean, 10.33 +/- 3.48) and after (mean, 10.66 +/- 4.02) albuterol were compared using the two-tailed paired t test.(ABSTRACT TRUNCATED AT 250 WORDS)  Chronic obstructive pulmonary disease (COPD), which is estimated to affect 32 million Americans, is the fifth leading cause of death in the United States. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "During the first 6 months post-diagnosis for COPD, results indicated a significant (P < or = 0.05) increase in expenditures for physicians, hospital care, and total health service utilization for patients prescribed theophylline, a corticosteroid (triamcinolone or beclomethasone) delivered via a metered-dose inhaler, or albuterol delivered via a metered-dose inhaler as initial monotherapy compared with patients prescribed ipratropium bromide (IB) delivered via a metered-dose inhaler. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Patients receiving initial pharmacotherapy with ipratropium bromide and subsequently adding albuterol used significantly less health care services (P < or = 0.05) during the first 15 months post-diagnosis for COPD than did patients prescribed all other combination therapies we evaluated. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " PURPOSE: Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "METHODS: In a single-center open-label study, selected adults hospitalized for asthma or COPD exacerbations over a 21-month period were randomly assigned to receive levalbuterol 1.25 mg three times daily (n = 55) or albuterol 2.5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSION: Clinical outcomes were similar with the use of levalbuterol versus albuterol for exacerbations of COPD or asthma. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " BACKGROUND: The evidence for the benefits of branded levalbuterol over generic albuterol in patients with chronic obstructive pulmonary disease (COPD) is inconclusive. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "OBJECTIVES: This study examined use and spending on albuterol and levalbuterol in a nationally representative sample of Medicare beneficiaries with COPD enrolled in Part D in 2006. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Patient characteristics and other COPD medication use were compared across albuterol-only users, levalbuterol-only users, and users of both albuterol and levalbuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In this sample of Medicare beneficiaries with COPD enrolled in Part D, mean annual spending in 2006 was significantly higher for levalbuterol than for albuterol. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " BACKGROUND: The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "Demographic characteristics were similar between the 2 treatment groups, except that there were more females with COPD in the levalbuterol treatment group (63.88%) compared with the racemic albuterol treatment group (45.5%) (P = 0.005). ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In these hospitalized patients with acute asthma or COPD treated with levalbuterol every 6 to 8 hours or racemic albuterol every 1 to 4 hours, significantly fewer total nebulizations were required with levalbuterol, without an increased need for rescue nebulizations during 14 days of hospitalization. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": " The efficacy and safety of nebulized levalbuterol in adults with chronic obstructive pulmonary disease (COPD) was evaluated in this multicenter, randomized, double-blind, parallel design study. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In this study, levalbuterol treatment in subjects with COPD was generally well tolerated, produced significant bronchodilation compared with PBO, and improved clinical control of COPD as evidenced by reductions in rescue medication use compared with PBO and/or RAC. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "This paper presents results from clinical studies examining levalbuterol and racemic albuterol use among elderly patients who have asthma or COPD. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "In COPD, the capacity of racemic albuterol to ameliorate these symptoms is more limited and suppression of edema and of infiltration and activation of leukocytes acquire greater significance. ", "polarity": 1}, {"drug": "Albuterol", "disease": "COPD", "orig_sen": "As would be expected, homochiral (R)-albuterol (levalbuterol) is more potent and effective in asthma and may have significant advantages if used in COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "New inhaled ICS/LABA/LAMA FDCs, including fluticasone furoate/vilanterol/umeclidinium, budesonide/formoterol/glycopyrronium and beclometasone/formoterol/glycopyrronium, are in Phase III of clinical development for COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae)) over 1\u00a0year in Spain, Sweden and the United Kingdom (UK). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The direct cost burden of managing asthma and COPD for people using budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae) in 2015 was estimated at \u20ac813 million, \u20ac560 million, and \u20ac774 million for Spain, Sweden and the UK, respectively. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study was designed to evaluate the clinical and economic consequences of salmeterol/fluticasone (SF), formoterol/budesonide (FB), and formoterol/fluticasone (FF) in severe and very severe chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "One retrospective cohort study suggested a greater efficacy for the budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of COPD exacerbations with budesonide/formoterol than with fluticasom/salmeterol combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "On the other hand, no similar increased risk of pneumonia has been reported in patients with COPD treated with the budesonide/formoterol combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide/formoterol and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of \u20ac499.90 (\u20ac195.10 for drugs, \u20ac193.10 for COPD hospitalizations, and \u20ac111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Both asthma and chronic obstructive pulmonary disease (COPD) users of ICS were at risk of pneumonia, with fluticasone appearing to confer higher risk than budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "PARTICIPANTS: Patients with COPD diagnosed by a physician and prescriptions of either budesonide/formoterol or fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The exacerbation rates were 0.80 and 1.09 per patient-year in the budesonide/formoterol and fluticasone/salmeterol groups, respectively (difference of 26.6%; P\u00a0<\u00a00.0001); yearly rates for COPD-related hospitalizations were 0.15 and 0.21, respectively (difference of 29.1%; P\u00a0<\u00a00.0001). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Long-term treatment with fixed combination budesonide/formoterol was associated with fewer healthcare utilization-defined exacerbations than fluticasone/salmeterol in patients with moderate and severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: The aim of this study was to compare the effect of inhaled budesonide/formoterol with inhaled fluticasone/salmeterol in severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled budesonide and fluticasone have no significantly different effect on adrenal function in moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: A retrospective analysis evaluated all double-blind, placebo-controlled, trials in patients \u22654 years of age involving budesonide or budesonide/formoterol in asthma (26 trials; budesonide: n\u00a0=\u00a09067; placebo: n\u00a0=\u00a05926), and in COPD (8 trials; budesonide: n\u00a0=\u00a04616; non-ICS: n\u00a0=\u00a03643). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the COPD dataset, the occurrence of diabetes mellitus/hyperglycaemia AEs was 1.3% for budesonide and 1.2% for non-ICS (HR 0.99 [95% CI: 0.67-1.46], p\u00a0=\u00a00.96) and SAEs was 0.1% for budesonide and 0.03% for non-ICS. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 \u03bcg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (delivered dose 320\u2009\u03bcg/9\u2009\u03bcg) is recommended for the symptomatic treatment of adult patients with severe COPD (forced expiratory volume in 1 second <50% of predicted value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This article reviews the pharmacological properties and clinical use of budesonide/formoterol Turbuhaler\u00ae in adult patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (320\u2009\u03bcg/9\u2009\u03bcg twice daily) was effective and well tolerated in adult patients with moderate to severe COPD participating in large, multicentre trials of up to 12 months' duration. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, inhaled budesonide/formoterol, either alone or as add-on therapy to other medications, continues to be a useful option for the management of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Other investigations, with the addition of in vitro and in vivo comparison studies, have shown that nebulized beclomethasone, fluticasone, and flunisolide are effective alternatives to nebulized budesonide in asthma and COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "EXPERIMENTAL APPROACH: Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-\u03b1-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Combination therapy with tiotropium bromide plus formoterol with or without budesonide improved lung function to a significantly greater extent than tiotropium bromide alone in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Randomised controlled trials (RCTs) of budesonide or fluticasone versus control treatment for COPD (\u226524 weeks duration) and controlled observational studies reporting on fracture risk with ICS exposure vs no exposure in COPD were included. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Among patients with COPD, long-term exposure to fluticasone and budesonide is consistently associated with a modest but statistically significant increased likelihood of fractures. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Furthermore it will be important to determine whether the risk of pneumonia is apparent with both FP and budesonide and to identify factors which may predict steroid responsiveness in COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Other maintenance long-acting bronchodilators-salmeterol, formoterol, and budesonide/formoterol-are FDA approved to treat airway obstruction in COPD but lack an approved indication against exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered via combination inhalers with the respective long-acting beta2-agonists, formoterol and salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Following a run-in period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of budesonide/formoterol (400/12 microg) and salmeterol/fluticasone (50/500 microg), separated by a 4-14-day washout period. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The primary end point was the area under the curve (AUC) of budesonide and fluticasone plasma concentrations in COPD patients relative to healthy subjects. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: The relative systemic availabilities of budesonide and fluticasone between patients with severe COPD and healthy subjects were similar. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In patients with COPD, a larger fraction of fluticasone was expectorated in the sputum as compared with budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In a randomised, double-blind, multicentre, cross-over study, 442 patients with COPD aged >or=40 years (pre-bronchodilator FEV(1) <or=50%; FEV(1)/vital capacity <70%) received budesonide/formoterol (320/9 microg, one inhalation twice daily) dry powder inhaler (DPI) or salmeterol/fluticasone (50/500 microg, one inhalation twice daily) DPI daily, for 1 week each, separated by a 1- to 2-week washout. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with budesonide/formoterol DPI or salmeterol/fluticasone DPI was effective in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Four prospective placebo-controlled clinical trials of 2-6 years duration with inhaled budesonide in patients with asthma or COPD were found. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Symbicort is a combination inhaler used in asthma and chronic obstructive pulmonary disease (COPD) that contains budesonide and formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting beta2-agonist alone. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "However, when patients with more severe COPD (an FEV(1) of less than 36% predicted) were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rate compared with the beta-agonist alone. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "budesonide 800 microg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20-30% and improve the health status of COPD patients by a similar amount compared with placebo. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Inhaled steroids (fluticasone, budesonide) are also able to improve lung function slightly and to relieve symptoms, but have no beneficial effect on the accelerated rate of decline in lung function that characterizes COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " In the present trial, we compared the broncholytic efficacy of the combination therapy with 50 microg salmeterol + 250 microg fluticasone and 12 microg formoterol + 400 microg budesonide, both in a single inhaler device, in 16 patients with moderate-to-severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae)) over 1\u00a0year in Spain, Sweden and the United Kingdom (UK). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The direct cost burden of managing asthma and COPD for people using budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae) in 2015 was estimated at \u20ac813 million, \u20ac560 million, and \u20ac774 million for Spain, Sweden and the UK, respectively. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study was designed to evaluate the clinical and economic consequences of salmeterol/fluticasone (SF), formoterol/budesonide (FB), and formoterol/fluticasone (FF) in severe and very severe chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "One retrospective cohort study suggested a greater efficacy for the budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of COPD exacerbations with budesonide/formoterol than with fluticasom/salmeterol combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "On the other hand, no similar increased risk of pneumonia has been reported in patients with COPD treated with the budesonide/formoterol combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide/formoterol and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of \u20ac499.90 (\u20ac195.10 for drugs, \u20ac193.10 for COPD hospitalizations, and \u20ac111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "PARTICIPANTS: Patients with COPD diagnosed by a physician and prescriptions of either budesonide/formoterol or fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The exacerbation rates were 0.80 and 1.09 per patient-year in the budesonide/formoterol and fluticasone/salmeterol groups, respectively (difference of 26.6%; P\u00a0<\u00a00.0001); yearly rates for COPD-related hospitalizations were 0.15 and 0.21, respectively (difference of 29.1%; P\u00a0<\u00a00.0001). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Long-term treatment with fixed combination budesonide/formoterol was associated with fewer healthcare utilization-defined exacerbations than fluticasone/salmeterol in patients with moderate and severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: The aim of this study was to compare the effect of inhaled budesonide/formoterol with inhaled fluticasone/salmeterol in severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled budesonide and fluticasone have no significantly different effect on adrenal function in moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 \u03bcg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (delivered dose 320\u2009\u03bcg/9\u2009\u03bcg) is recommended for the symptomatic treatment of adult patients with severe COPD (forced expiratory volume in 1 second <50% of predicted value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This article reviews the pharmacological properties and clinical use of budesonide/formoterol Turbuhaler\u00ae in adult patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (320\u2009\u03bcg/9\u2009\u03bcg twice daily) was effective and well tolerated in adult patients with moderate to severe COPD participating in large, multicentre trials of up to 12 months' duration. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, inhaled budesonide/formoterol, either alone or as add-on therapy to other medications, continues to be a useful option for the management of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "EXPERIMENTAL APPROACH: Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-\u03b1-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Combination therapy with tiotropium bromide plus formoterol with or without budesonide improved lung function to a significantly greater extent than tiotropium bromide alone in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Furthermore it will be important to determine whether the risk of pneumonia is apparent with both FP and budesonide and to identify factors which may predict steroid responsiveness in COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Other maintenance long-acting bronchodilators-salmeterol, formoterol, and budesonide/formoterol-are FDA approved to treat airway obstruction in COPD but lack an approved indication against exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered via combination inhalers with the respective long-acting beta2-agonists, formoterol and salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Following a run-in period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of budesonide/formoterol (400/12 microg) and salmeterol/fluticasone (50/500 microg), separated by a 4-14-day washout period. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The primary end point was the area under the curve (AUC) of budesonide and fluticasone plasma concentrations in COPD patients relative to healthy subjects. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: The relative systemic availabilities of budesonide and fluticasone between patients with severe COPD and healthy subjects were similar. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In patients with COPD, a larger fraction of fluticasone was expectorated in the sputum as compared with budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In a randomised, double-blind, multicentre, cross-over study, 442 patients with COPD aged >or=40 years (pre-bronchodilator FEV(1) <or=50%; FEV(1)/vital capacity <70%) received budesonide/formoterol (320/9 microg, one inhalation twice daily) dry powder inhaler (DPI) or salmeterol/fluticasone (50/500 microg, one inhalation twice daily) DPI daily, for 1 week each, separated by a 1- to 2-week washout. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with budesonide/formoterol DPI or salmeterol/fluticasone DPI was effective in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Symbicort is a combination inhaler used in asthma and chronic obstructive pulmonary disease (COPD) that contains budesonide and formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "However, when patients with more severe COPD (an FEV(1) of less than 36% predicted) were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rate compared with the beta-agonist alone. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "New inhaled ICS/LABA/LAMA FDCs, including fluticasone furoate/vilanterol/umeclidinium, budesonide/formoterol/glycopyrronium and beclometasone/formoterol/glycopyrronium, are in Phase III of clinical development for COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "COPD rats were treated with saline or budesonide inhalation, or with budesonide inhalation followed by saline inhalation or Pinellia ternata gavage. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae)) over 1\u00a0year in Spain, Sweden and the United Kingdom (UK). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The direct cost burden of managing asthma and COPD for people using budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae) in 2015 was estimated at \u20ac813 million, \u20ac560 million, and \u20ac774 million for Spain, Sweden and the UK, respectively. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuhaler and a pressurized metered dose inhaler (pMDI) for use in patients with asthma or chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Our results confirm the rapid onset of action of formoterol when combined with budesonide in patients with COPD and indicate that the onset of bronchodilation induced by BF Spiromax is faster than that elicited by BF Turbuhaler. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " AIM: To investigate the efficacy and safety of nebulized budesonide and systemic glucocorticosteroids (GCS) (SGCS) in the treatment of an exacerbation of chronic obstructive pulmonary disease (COPD) and their effects on the serum concentration of soluble leukocyte differentiation antigens. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "MATERIALS AND METHODS: Seventy-eight hospitalized patients with an acute exacerbation of COPD were randomized into two groups: 1) 37 patients took nebulized budesonide 4 mg/day; 2) 41 patients received intravenous prednisolone. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Nebulized budesonide is an effective and safe alternative to SGCS in treating an exacerbation of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: This post hoc analysis is based on data from three double-blind, randomized studies in patients with moderate-to-very-severe COPD receiving twice-daily budesonide/formoterol or formoterol alone for 6 or 12 months. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study was to observe whether erythromycin could enhance the anti-inflammatory activity of budesonide in COPD model rats and to explore the mechanism involved. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In this study, male Sprague-Dawley rats were divided into five groups: healthy control group (H group), COPD model group (C group), erythromycin group (E group), budesonide group (B group) and erythromycin + budesonide group (E+B group). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "We conclude that erythromycin can enhance the anti-inflammatory activity of budesonide in COPD model rats, possibly through inhibiting the PI3K/AKT pathway and enhancing the activity of HDAC2. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "He had a background of chronic obstructive pulmonary disease (COPD) and had been taking inhaled steroids (budesonide) 800 \u00b5g per day for 10 years. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the COPD cohort, recent ICS use was independently associated with pneumonia (hazard ratio: 1.06 [1.02-1.11] for per 80 mg of budesonide). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: Since non-typeable Haemophilus influenzae (NTHi) is the most common pathogen associated with acute exacerbations of COPD, we investigated the effects of budesonide (BUD) on NTHi-induced inflammation and invasive infection. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: Triple combination therapy with tiotropium plus budesonide/formoterol has improved lung function and reduced exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) in Western countries, but no such data exist for East Asian patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study aimed to evaluate the efficacy and tolerability of adding budesonide/formoterol to tiotropium compared with tiotropium alone in East Asian patients with severe/very severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: In East Asian patients with severe/very severe COPD, adding budesonide/formoterol to tiotropium was associated with significant improvements in FEV1 and HRQoL and lower COPD exacerbation rates. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide-formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: We performed a retrospective analysis of data from a study (ClinicalTrials.gov registration: NCT00419744) comparing budesonide/formoterol 320/9 \u03bcg with formoterol 9 \u03bcg (both twice daily) in patients with moderate-to-very-severe COPD; reliever salbutamol 90 \u03bcg was provided. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: SABA reliever use is a predictor of short- and long-term exacerbation risk in moderate-to-very-severe COPD patients with a history of exacerbations receiving budesonide/formoterol or formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study was designed to evaluate the clinical and economic consequences of salmeterol/fluticasone (SF), formoterol/budesonide (FB), and formoterol/fluticasone (FF) in severe and very severe chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "AIM: To study the effects of addition of Theophylline to the combination of Formoterol plus Budesonide on various objective and subjective parameters in moderate to severe COPD patients and to assess the safety profile of the combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Addition of Theophylline to Formoterol plus Budesonide reduces dyspnea, improves exercise performance and pulmonary functions in moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "We aimed to derive this by analyzing data from three existing COPD clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "One retrospective cohort study suggested a greater efficacy for the budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of COPD exacerbations with budesonide/formoterol than with fluticasom/salmeterol combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "On the other hand, no similar increased risk of pneumonia has been reported in patients with COPD treated with the budesonide/formoterol combination. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: To compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Inhaled budesonide and systemic methylprednisolone have the same effects on systemic inflammation of AECOPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "MATERIALS AND METHODS: COPD patients (n=40), mean FEV1 58% predicted normal, received single-dose inhaled formoterol 9\u03bcg, or placebo, followed by 8 weeks treatment bid with a combination of budesonide and formoterol Turbuhaler(\u00ae) 320/9\u03bcg or formoterol Turbuhaler(\u00ae). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: In COPD, OE-MRI parameters showed response to both single-dose bronchodilatory effects of a \u03b22-agonist, formoterol, and 8-week treatment with an inhaled corticosteroid, budesonide, and the measurements are feasible in a small-scale multi-center trial setting. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare clinical and demographic characteristics, resource utilization and costs of chronic obstructive pulmonary disease (COPD) patients prior to initiating budesonide-formoterol combination (BFC) or tiotropium-maintenance therapy. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: The Easyhaler(\u00ae) (EH) device-metered dry powder inhaler containing budesonide and formoterol is being developed for asthma and chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide/formoterol and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of \u20ac499.90 (\u20ac195.10 for drugs, \u20ac193.10 for COPD hospitalizations, and \u20ac111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Both asthma and chronic obstructive pulmonary disease (COPD) users of ICS were at risk of pneumonia, with fluticasone appearing to confer higher risk than budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In COPD subjects, budesonide/formoterol significantly increased the BAL concentrations of pro-SFTPB by a median of 62.46 ng/ml (p=0.022) or 48.7% from baseline median value. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The purpose of this study was to explore the effects of an inhaled salbutamol sulfate solution and an inhalation suspension of the glucocorticoid budesonide that were atomized with heliox to treat patients with AECOPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This population of macrophages from patients with COPD was less responsive to budesonide compared with those from nonsmokers and smokers when stimulated with LPS. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Furthermore, budesonide significantly blocked release of cytokines and MMPs to a similar degree in normal and COPD lung fibroblasts as well as in HFL-1 cells exposed or not exposed to cigarette smoke extract. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: These findings suggest that, in contrast to airway epithelial cells and monocytes/macrophages, HDAC2 is not required for budesonide to inhibit MMP and cytokine release by lung fibroblasts and this inhibitory pathway appears to be intact in cultured fibroblasts from COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "These results also suggest that budesonide has the potential to modulate fibroblast-mediated tissue remodeling following airway inflammation in COPD, which is mediated via an HDAC2 independent pathway. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Importantly, PBECs from asthma and COPD patients were less sensitive to budesonide with respect to cytokine production and barrier function than PBECs from control subjects. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Together, our data indicate that budesonide suppresses epithelial proinflammatory responses and barrier dysfunction and that oxidative stress reduces these effects in airway epithelium from asthma and COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "PARTICIPANTS: Patients with COPD diagnosed by a physician and prescriptions of either budesonide/formoterol or fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: The efficacy and tolerability of budesonide/formoterol versus formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD) was evaluated. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: In this randomized, double-blind, parallel-group, phase III study (NCT01069289), patients with moderate to severe COPD for \u22652 years received either budesonide/formoterol 160/4.5\u2009\u03bcg two inhalations twice daily via Turbuhaler\u00ae or formoterol 4.5\u2009\u03bcg two inhalations twice daily via Turbuhaler\u00ae for 12 weeks. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Both treatments were well tolerated; the incidence and type of adverse events were similar: most commonly reported (budesonide/formoterol vs formoterol): COPD (8.0% vs 9.4%) and nasopharyngitis (5.5% vs 4.9%). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Budesonide/formoterol 160/4.5\u2009\u03bcg two inhalations twice daily was effective and well tolerated in patients with moderate to severe COPD, offering benefits over formoterol alone in terms of improved lung function and reduced risk of exacerbation. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The exacerbation rates were 0.80 and 1.09 per patient-year in the budesonide/formoterol and fluticasone/salmeterol groups, respectively (difference of 26.6%; P\u00a0<\u00a00.0001); yearly rates for COPD-related hospitalizations were 0.15 and 0.21, respectively (difference of 29.1%; P\u00a0<\u00a00.0001). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Long-term treatment with fixed combination budesonide/formoterol was associated with fewer healthcare utilization-defined exacerbations than fluticasone/salmeterol in patients with moderate and severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The European Respiratory Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP) investigated long-term effects of budesonide; 18% of the COPD participants were atopic. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Atopic COPD patients not treated with budesonide had an increased incidence of cough over time (OR: 1.79, 95% CI: 1.03-3.08, p\u2009=\u20090.038), while those treated with budesonide had increased remission of cough (OR: 1.93, 95% CI: 1.11-3.37, p\u2009=\u20090.02) compared to non-atopic COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "If atopic COPD patients are treated with budesonide, they more often show remission of symptoms compared to non-atopic COPD patients who are treated with budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Here we aimed to evaluate the morphological effect by adding a budesonide/formoterol combination to tiotropium in COPD patients using three-dimensional MDCT. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "George's Respiratory Questionnaire (SGRQ) and MDCT imaging studies were performed at the beginning and after budesonide/formoterol combination treatment for 12 weeks in 14 patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " INTRODUCTION: The present study was designed to evaluate inhaler techniques and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler chronic obstructive pulmonary disease (COPD) in Turkey in real-life clinical practice. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: This study investigated the rapid onset of bronchodilation effect and compared lung function changes following budesonide/formoterol (Symbicort Turbuhaler\u00ae) inhalation in Chinese patients with moderate-severe chronic obstructive pulmonary disease (COPD) and bronchial asthma. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The primary end-point was lung function change 3 min after drug inhalation, and the secondary end-points were comparison of the gas flow rate (\u0394FEV1) and volume responses (\u0394FVC, \u0394IC) between COPD and asthma patients after inhalation of budesonide/formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Budesonide/formoterol has a fast onset of bronchodilation effect in patients with moderate-severe COPD and asthma. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The gas flow rate and volume responses in patients with COPD differ from those with asthma after inhalation of Budesonide/formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: The asthma phenotype was significantly younger, had a strong association with hypertrophy of nasal turbinates, and registered a significant improvement of FEV(1) (350 ml) vs a decline of - 26.5 ml in the COPD phenotype following therapy with budesonide/formoterol for one year. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Withdrawal of budesonide for 4 weeks in the COPD phenotype resulted in FEV(1) + 1.33% (SD \u00b1 5.71) and FVC + 1.24% (SD \u00b1 5.32); a change of <12% in all patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNF\u03b1) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVES: The aim of this study was to compare the effect of inhaled budesonide/formoterol with inhaled fluticasone/salmeterol in severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled budesonide and fluticasone have no significantly different effect on adrenal function in moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " BACKGROUND: The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 \u03bcg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Its expression was significantly downregulated by budesonide alone and in combination with formoterol in COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide is widely used for COPD treatment as anti-inflammatory drug. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In this study, we used a rat model with COPD to investigate the effect of budesonide on IL-32 expression in lung tissue. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (delivered dose 320\u2009\u03bcg/9\u2009\u03bcg) is recommended for the symptomatic treatment of adult patients with severe COPD (forced expiratory volume in 1 second <50% of predicted value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This article reviews the pharmacological properties and clinical use of budesonide/formoterol Turbuhaler\u00ae in adult patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (320\u2009\u03bcg/9\u2009\u03bcg twice daily) was effective and well tolerated in adult patients with moderate to severe COPD participating in large, multicentre trials of up to 12 months' duration. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, inhaled budesonide/formoterol, either alone or as add-on therapy to other medications, continues to be a useful option for the management of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "EXPERIMENTAL APPROACH: Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-\u03b1-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Combination therapy with tiotropium bromide plus formoterol with or without budesonide improved lung function to a significantly greater extent than tiotropium bromide alone in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: This 12-week, randomised, double-blind, placebo-controlled, Phase IIb, trial (NCT01023516), investigated the efficacy and safety of AZD9668 (60 mg bid) versus placebo in patients with symptomatic COPD and a history of exacerbation receiving maintenance budesonide/formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Three months' treatment with AZD9668 did not improve lung function, respiratory signs and symptoms or SGRQ-C score when added to budesonide/formoterol maintenance therapy in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This randomized, double-blind, double-dummy, parallel-group, 12-month multicenter study evaluated the effect of budesonide/formoterol pressurized metered-dose inhaler (pMDI) on COPD exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Following a 2-week run-in during which COPD patients aged \u226540 years with an exacerbation history discontinued medications except ICSs, 1219 patients were randomized 1:1:1 to twice-daily budesonide/formoterol pMDI 320/9 \u03bcg, budesonide/formoterol pMDI 160/9 \u03bcg, or formoterol dry powder inhaler 9 \u03bcg. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol pMDI is an appropriate treatment for reducing exacerbations in COPD patients with a history of exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Randomised controlled trials (RCTs) of budesonide or fluticasone versus control treatment for COPD (\u226524 weeks duration) and controlled observational studies reporting on fracture risk with ICS exposure vs no exposure in COPD were included. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Among patients with COPD, long-term exposure to fluticasone and budesonide is consistently associated with a modest but statistically significant increased likelihood of fractures. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Most patients with moderate to very severe COPD exhibit ATS-defined bronchodilator reversibility based on flow and lung volume measures after budesonide/formoterol pMDI or formoterol treatment. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate retrospectively over a 3-month period, the cost effectiveness of budesonide/formoterol added to tiotropium bromide (tiotropium) compared with placebo added to tiotropium in COPD patients eligible for ICS/LABA combination therapy, based on the CLIMB study (NCT00496470). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: A cost-effectiveness analysis of data from the 12-week, randomized, double-blind CLIMB study of COPD patients (n\u2009=\u2009659; eligible for ICS/LABA; aged \u2265 40 years) comparing budesonide/formoterol (Symbicort\u00ae Turbuhaler\u00ae 320/9 \u03bcg twice daily) added to tiotropium (18 \u03bcg daily) or placebo added to tiotropium was conducted. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol added to tiotropium was the dominant strategy compared with placebo added to tiotropium based on a 12-week study in COPD patients eligible for ICS/LABA combination therapy in Australia and Canada, and appears to be a cost-effective strategy in Sweden. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Furthermore it will be important to determine whether the risk of pneumonia is apparent with both FP and budesonide and to identify factors which may predict steroid responsiveness in COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The US Food and Drug Administration, recently, approved the combination of budesonide/formoterol (160/4.5 \u03bcg; Symbicort\u2122, AstraZeneca, Sweden) delivered via a pressurized meter dose inhaler for maintenance management of stable COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVES: To evaluate the effect of beclomethasone/formoterol versus budesonide/formoterol (non-inferiority) and versus formoterol (superiority) in patients with severe stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The overall rate of COPD exacerbations/patient/year was similar and not statistically significantly different among treatments (beclomethasone/formoterol 0.414, budesonide/formoterol 0.423 and formoterol 0.431). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Other maintenance long-acting bronchodilators-salmeterol, formoterol, and budesonide/formoterol-are FDA approved to treat airway obstruction in COPD but lack an approved indication against exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: We assessed changes in nuclear/cytosolic FKBP51 protein using SDS-PAGE/WB and FKBP51 mRNA by qRT-PCR in cells isolated from induced sputum of stable COPD patients treated with formoterol/budesonide or formoterol/budesonide/theophylline for 4 wk. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Increased FKBP51 in COPD patients treated with formoterol/ budesonide/theophylline may be important in altering signaling from corticosteroid receptors. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide, formoterol or azithromycin did not suppress phagocytosis suggesting that reduced responses in COPD MDM were not due to medications. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered via combination inhalers with the respective long-acting beta2-agonists, formoterol and salmeterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Following a run-in period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of budesonide/formoterol (400/12 microg) and salmeterol/fluticasone (50/500 microg), separated by a 4-14-day washout period. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The primary end point was the area under the curve (AUC) of budesonide and fluticasone plasma concentrations in COPD patients relative to healthy subjects. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "RESULTS: Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: The relative systemic availabilities of budesonide and fluticasone between patients with severe COPD and healthy subjects were similar. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In patients with COPD, a larger fraction of fluticasone was expectorated in the sputum as compared with budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In a randomised, double-blind, multicentre, cross-over study, 442 patients with COPD aged >or=40 years (pre-bronchodilator FEV(1) <or=50%; FEV(1)/vital capacity <70%) received budesonide/formoterol (320/9 microg, one inhalation twice daily) dry powder inhaler (DPI) or salmeterol/fluticasone (50/500 microg, one inhalation twice daily) DPI daily, for 1 week each, separated by a 1- to 2-week washout. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with budesonide/formoterol DPI or salmeterol/fluticasone DPI was effective in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: We pooled patient data from seven large clinical trials of inhaled budesonide (320-1280 mug/day), with or without formoterol, versus control regimen (placebo or formoterol alone) in patients with stable COPD and at least 6 months of follow-up. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "INTERPRETATION: Budesonide treatment for 12 months does not increase the risk of pneumonia in patients with COPD during that time and therefore is safe for clinical use in such patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " The corticosteroid budesonide and the rapid-onset, long-acting beta(2)-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Well designed 6- and 12-month clinical trials, twice-daily budesonide/formoterol pMDI 320 microg/9 microg effectively improved lung function in patients with moderate to very severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol pMDI was also associated with improvements from baseline in other measures of lung function, COPD control (including the time to first COPD exacerbation in the 12-month trial), symptoms and health status. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol pMDI was well tolerated in clinical trials in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This article reviews the evidence for treatment strategies used in COPD with a focus on combination therapies and introduces the 3-month CLIMB study (Evaluation of Efficacy and Safety of Symbicort as an Add-on Treatment to Spiriva in Patients With Severe COPD) which investigated the potential treatment benefits of combining tiotropium with budesonide/formoterol in patients with COPD with regard to lung function, exacerbations, symptoms and morning activities. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide (BUD) and formoterol (FORM) synergize in controlling asthma and COPD exacerbations; however, their effects on virus-induced inflammation and remodelling are less known. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Regarding the available data, high dose nebulized budesonide was found as effective as systemic corticosteroids in exacerbations of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "SUMMARY: Findings from recent studies are giving a positive impression on the role of high dose nebulized budesonide in exacerbations of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Two hundred and fifty-four current smokers with COPD were randomised to treatment with either an inhaled corticosteroids (ICS), budesonide 400 microg bid, or placebo. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Long-term budesonide inhalation shows a non-significant trend towards reducing the progression of emphysema as determined by the CT-derived 15th percentile lung density from annual CT scans in current smokers with moderate to severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The efficacy and tolerability of the combination of budesonide/formoterol have been demonstrated in patients with COPD when administered via the dry powder inhaler (DPI) in a 1-year study and when administered via the hydrofluoroalkane (HFA) pressurized metered-dose inhaler (pMDI) in a 6-month study. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: This study assessed the long-term efficacy and tolerability of budesonide/formoterol HFA pMDI in patients with moderate to very severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The rate of COPD exacerbations was lower in both budesonide/formoterol groups compared with formoterol and placebo (p <or= 0.004). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Budesonide/formoterol pMDI (320/9 microg and 160/9 microg) improved pulmonary function and reduced symptoms and exacerbations over 1 year in patients with moderate to very severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " In 3 open-label studies, the systemic bioavailability of budesonide and formoterol administered via pressurized metered-dose inhaler (pMDI) or dry powder inhaler (DPI) formulations was evaluated in asthma (24 children, 55 adults) or chronic obstructive pulmonary disease (COPD; n = 26) patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In study 3 (COPD/asthma, adults), budesonide AUC and C(max) were similar and formoterol AUC and C(max) 18% and 22% greater after budesonide/formoterol pMDI versus budesonide pMDI + formoterol DPI (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide and formoterol AUC were 12% and 15% higher in COPD versus asthma patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In conclusion, systemic exposure generally is similar or lower with budesonide/formoterol pMDI versus combination therapy via separate DPIs or monotherapy and comparable between asthma and COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Forty-five patients not using steroids (37 male, 21/24 current/ex smoker, median packyears 38, age 65 years, FEV(1) 61% predicted), experiencing a COPD exacerbation, were treated at home with budesonide/formoterol (320/9 microg 4 times daily), prednisolone (30 mg daily), or placebo for 14 days. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In conclusion, budesonide/formoterol reduces sputum eosinophils and improves symptoms in the treatment of out-patient COPD exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Four prospective placebo-controlled clinical trials of 2-6 years duration with inhaled budesonide in patients with asthma or COPD were found. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate the efficacy and tolerability of budesonide/formoterol administered via one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) in patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The incidence of individual non-fatal serious adverse events was similar across all treatment groups, except COPD, which was highest in the budesonide/formoterol 320/9 microg group (6.1%) and lowest in the budesonide (3.6%) and formoterol (3.9%) groups, with a range of 4.3-4.6% in the budesonide/formoterol 160/9 microg, budesonide plus formoterol and placebo groups. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In this study, atomization inhalation of budesonide and terbutaline plus conventional therapies was applied to treat AECOPD (acute exacerbation of chronic obstructive pulmonary disease) patients for two weeks. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Thus, atomization inhalation of terbutaline and budesonide can control AECOPD effectively, and has wide clinical perspective in controlling and preventing the exacerbation of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "METHODS: A pooled analysis of patients with severe COPD, from two well-controlled 1-year studies, was conducted using Cox regression and spline analysis to evaluate predictability of baseline demographic data and in-study variables for mortality risk, and to evaluate the effect of treatment allocation to budesonide and formoterol, versus their respective control groups, on these outcomes. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the present study we assessed changes in subcellular CREB distribution and activation (CREB-P) in 35 stable COPD patients treated with formoterol (F), formoterol+budesonide (F/ICS), and formoterol+budesonide+theophylline (F/ICS/Th) b.i.d. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Symbicort is a combination inhaler used in asthma and chronic obstructive pulmonary disease (COPD) that contains budesonide and formoterol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "A total of 12 patients with asthma and 6 with COPD who were not previously treated with oral corticosteroids or ICSs were treated with budesonide, 400 microg twice daily for 8 wk, via dry powder inhaler through the Aerolizer. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The current authors performed a post hoc analysis of the European Respiratory Society's study on Chronic Obstructive Pulmonary Disease (EUROSCOP); a 3-yr, placebo-controlled study of an inhaled corticosteroid budesonide 800 microg.day(-1) in smokers (mean age 52 yrs) with mild COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " The present study was designed to evaluate the hypothesis that nebulised budesonide (NB) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (ECOPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol is a combination inhaled steroid and long-acting bronchodilator delivered by a dry-powder inhaler, approved for use in COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Two large, randomised, double-blind, 12-month studies found that combination budesonide/formoterol is more effective than either component alone in addressing many important aspects of the disease, such as pulmonary function, symptoms, use of relief medication, health-related quality of life and exacerbation in patients suffering from severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "This review evaluates the applicability and clinical relevance of NNT analysis for determining the effectiveness of combination therapies against COPD exacerbations, focusing on budesonide/ formoterol in the same inhaler. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Data were collected during a 1-yr study of the budesonide/formoterol combination in COPD patients, where exacerbations, defined by increases in treatment, were compared with daily records of respiratory symptoms, rescue medication use and peak expiratory flow (PEF). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "However, when patients with more severe COPD (an FEV(1) of less than 36% predicted) were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rate compared with the beta-agonist alone. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In the last few years, evidence is mounting that nebulized budesonide and inhaled formoterol might be an alternative to oral prednisolone and short-acting beta(2)-agonists, respectively, in the treatment of acute exacerbations of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "However, since individual studies are typically statistically underpowered and are remarkably heterogeneous with regard to their conclusions, larger studies are needed to confirm these preliminary findings and determine conclusively any impact of budesonide/formoterol combination in acutely ill COPD patients. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Twenty-six patients with stable COPD were randomised, in a double-blinded, placebo-controlled trial with either 800 microg of inhaled budesonide or placebo for a 6-month period. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In stable patients with COPD, treatment with inhaled budesonide for a period of 6 months has a positive effect on markers of lung inflammation, as assessed by reduction in percentage neutrophils and IL-8 concentration in BAL. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "The current review summarises the differences and similarities of asthma and COPD, in terms of risk factors, pathophysiology, symptoms and diagnosis, to provide greater understanding of the role of budesonide/formoterol in a single inhaler in both diseases. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the healthcare costs and effects of budesonide/formoterol in a single inhaler with those of budesonide and formoterol monotherapies, and placebo, in a multinational study in patients with chronic obstructive pulmonary disease (COPD), National Heart, Lung and Blood Institute (NHLBI)/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III or IV. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol in patients with severe COPD (GOLD stages III or IV) may be cost effective, from the healthcare provider perspective, compared with either monocomponent. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "budesonide 800 microg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20-30% and improve the health status of COPD patients by a similar amount compared with placebo. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "TGF-beta1 may play an important role during the process of airway remodeling, and could be influenced by early drugs intervention such as budesonide and erythromycin, which may imply their potency in the treatment of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "However, data from two clinical trials of moderately high doses of inhaled corticosteroids in patients with COPD have produced conflicting results and while the larger study of triamcinolone found a significant impact of this drug on bone mineral density, a smaller study of budesonide found no effect. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In two large, randomised, double-blind, 12-month studies, patients with severe chronic obstructive pulmonary disease (COPD) receiving budesonide/formoterol 320/9 microg twice daily had a significantly higher forced expiratory volume in 1 second (FEV1) and significantly higher morning and evening peak expiratory flow at trial endpoint than recipients of budesonide or placebo; FEV1 was significantly higher than with formoterol in the larger study. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In both studies, the rate of COPD exacerbations and exacerbations requiring oral corticosteroids was significantly reduced with budesonide/formoterol versus formoterol and placebo. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Budesonide/formoterol was generally well tolerated by patients with severe COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the efficacy and safety of nebulised budesonide and systemic corticosteroid in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Our study suggests that nebulised budesonide may be an alternative to parenteral corticosteroids in the treatment of acute exacerbations of COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Patients (n=912, mean age 52 yrs) with mild COPD (mean forced expiratory volume in one second (FEV1) 77% of predicted; mean FEV1/slow vital capacity ratio 62%) were randomized to receive budesonide 400 microg, or placebo twice daily via Turbuhaler. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " Nebulized budesonide has been used successfully to treat acute asthma exacerbation, and we hypothesized that it could also be effective for exacerbations of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In this multicenter, double-blind, randomized, placebo-controlled trial, the efficacy of nebulized budesonide (Pulmicort Respules/Nebuamp), oral prednisolone, and placebo was compared in 199 patients with acute exacerbations of COPD requiring hospitalization. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Nebulized budesonide may be an alternative to oral prednisolone in the treatment of nonacidotic exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " We compared the effect of inhaled budesonide with placebo on decline in lung function and respiratory symptoms in a three-year study of patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " The aim of this study was evaluate the predictive value of a 2 week course of prednisolone on the effect of 6 months treatment with inhaled budesonide in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In a double-blind, placebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in patients with mild COPD who continued smoking. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: In patients with mild COPD who continue smoking, the use of inhaled budesonide is associated with a small one-time improvement in lung function but does not appreciably affect the long-term progressive decline. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "INTERPRETATION: Inhaled budesonide was of no clinical benefit in COPD patients recruited from the general population by screening. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "We conclude that AMP did not elicit greater sensitivity than MCh in assessing short-term effects of budesonide on AHR in smokers with COPD. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "We hypothesized that treatment with inhaled budesonide would improve clinical symptoms and pulmonary function in subjects with COPD, and that the response to an inhaled B2-agonist would individualize steroid responders. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "In 44 patients with stable COPD in a double- blind crossover trial, we compared a 6-week course of inhalations of 800 micrograms/d budesonide with a placebo, separated by a 4-week interval when no medication was taken. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "Initially, we studied the effect of a 2-wk course of inhaled budesonide (800 mg twice daily for 2 wk) in 13 patients with severe COPD (mean FDV1: 35% predicted). ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": " In four patients, men of 64, 66 and 69 years old and a woman of 65 years, who suffered from chronic obstructive pulmonary disease (COPD) and used inhalation corticosteroids in a relatively high dose (800-1600 micrograms of budesonide per day), a pulmonary infection was diagnosed caused by Mycobacterium malmoense (the first two patients) and Aspergillus (the other two) respectively. ", "polarity": 1}, {"drug": "Budesonide", "disease": "COPD", "orig_sen": "CONCLUSIONS: Most patients with moderate to very severe COPD exhibit ATS-defined bronchodilator reversibility based on flow and lung volume measures after budesonide/formoterol pMDI or formoterol treatment. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": " PURPOSE: Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "METHODS: In a single-center open-label study, selected adults hospitalized for asthma or COPD exacerbations over a 21-month period were randomly assigned to receive levalbuterol 1.25 mg three times daily (n = 55) or albuterol 2.5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "CONCLUSION: Clinical outcomes were similar with the use of levalbuterol versus albuterol for exacerbations of COPD or asthma. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": " BACKGROUND: The evidence for the benefits of branded levalbuterol over generic albuterol in patients with chronic obstructive pulmonary disease (COPD) is inconclusive. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "OBJECTIVES: This study examined use and spending on albuterol and levalbuterol in a nationally representative sample of Medicare beneficiaries with COPD enrolled in Part D in 2006. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "Patient characteristics and other COPD medication use were compared across albuterol-only users, levalbuterol-only users, and users of both albuterol and levalbuterol. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In this sample of Medicare beneficiaries with COPD enrolled in Part D, mean annual spending in 2006 was significantly higher for levalbuterol than for albuterol. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "Demographic characteristics were similar between the 2 treatment groups, except that there were more females with COPD in the levalbuterol treatment group (63.88%) compared with the racemic albuterol treatment group (45.5%) (P = 0.005). ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In these hospitalized patients with acute asthma or COPD treated with levalbuterol every 6 to 8 hours or racemic albuterol every 1 to 4 hours, significantly fewer total nebulizations were required with levalbuterol, without an increased need for rescue nebulizations during 14 days of hospitalization. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": " The efficacy and safety of nebulized levalbuterol in adults with chronic obstructive pulmonary disease (COPD) was evaluated in this multicenter, randomized, double-blind, parallel design study. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "In this study, levalbuterol treatment in subjects with COPD was generally well tolerated, produced significant bronchodilation compared with PBO, and improved clinical control of COPD as evidenced by reductions in rescue medication use compared with PBO and/or RAC. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "This paper presents results from clinical studies examining levalbuterol and racemic albuterol use among elderly patients who have asthma or COPD. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "As would be expected, homochiral (R)-albuterol (levalbuterol) is more potent and effective in asthma and may have significant advantages if used in COPD. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": " PURPOSE: Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "METHODS: In a single-center open-label study, selected adults hospitalized for asthma or COPD exacerbations over a 21-month period were randomly assigned to receive levalbuterol 1.25 mg three times daily (n = 55) or albuterol 2.5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "CONCLUSION: Clinical outcomes were similar with the use of levalbuterol versus albuterol for exacerbations of COPD or asthma. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": " BACKGROUND: The evidence for the benefits of branded levalbuterol over generic albuterol in patients with chronic obstructive pulmonary disease (COPD) is inconclusive. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "OBJECTIVES: This study examined use and spending on albuterol and levalbuterol in a nationally representative sample of Medicare beneficiaries with COPD enrolled in Part D in 2006. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "Patient characteristics and other COPD medication use were compared across albuterol-only users, levalbuterol-only users, and users of both albuterol and levalbuterol. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In this sample of Medicare beneficiaries with COPD enrolled in Part D, mean annual spending in 2006 was significantly higher for levalbuterol than for albuterol. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "Demographic characteristics were similar between the 2 treatment groups, except that there were more females with COPD in the levalbuterol treatment group (63.88%) compared with the racemic albuterol treatment group (45.5%) (P = 0.005). ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In these hospitalized patients with acute asthma or COPD treated with levalbuterol every 6 to 8 hours or racemic albuterol every 1 to 4 hours, significantly fewer total nebulizations were required with levalbuterol, without an increased need for rescue nebulizations during 14 days of hospitalization. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": " The efficacy and safety of nebulized levalbuterol in adults with chronic obstructive pulmonary disease (COPD) was evaluated in this multicenter, randomized, double-blind, parallel design study. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "In this study, levalbuterol treatment in subjects with COPD was generally well tolerated, produced significant bronchodilation compared with PBO, and improved clinical control of COPD as evidenced by reductions in rescue medication use compared with PBO and/or RAC. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "This paper presents results from clinical studies examining levalbuterol and racemic albuterol use among elderly patients who have asthma or COPD. ", "polarity": 1}, {"drug": "Levalbuterol", "disease": "COPD", "orig_sen": "As would be expected, homochiral (R)-albuterol (levalbuterol) is more potent and effective in asthma and may have significant advantages if used in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The LANTERN study evaluated the efficacy of IND/GLY compared with inhaled long-acting \u03b22-agonist (LABA)/inhaled corticosteroid (ICS) or salmeterol/fluticasone (SFC) in patients with moderate-to-severe COPD with a history of \u22641 exacerbation in the previous year. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A post hoc analysis of a previous prospective randomized study was performed for COPD patients using higher dose (HD: Fluticasone 1,000 \u03bcg/day) or medium dose (MD: Fluticasone 500 \u03bcg/day) of ICS combined with Salmeterol (100 \u03bcg/day). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: The objective of this study was to compare persistence to salmeterol/fluticasone propionate combination treatment as AirFluSal Forspiro with persistence to Seretide Diskus in patients with asthma or COPD aged 12 years and above. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The WISDOM study (NCT00975195) reported a change in lung function following withdrawal of fluticasone propionate in patients with severe to very severe COPD treated with tiotropium and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who had a history of one or no exacerbations in the previous year, in Canada, France, Italy, and Portugal. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "While both treatments were well tolerated, pneumonia occurred less frequently with aclidinium/formoterol than salmeterol/fluticasone.In stable COPD, aclidinium/formoterol significantly improved bronchodilation versus salmeterol/fluticasone, with equivalent benefits in symptom control and reduction in exacerbation risk. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study was thus designed to compare the efficacy and tolerability of salmeterol/fluticasone combination with tiotropium in patients with moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: From the GlaxoSmithKline trial registry, we selected randomised, double-blind, clinical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in duration. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae)) over 1\u00a0year in Spain, Sweden and the United Kingdom (UK). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: The direct cost burden of managing asthma and COPD for people using budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae) in 2015 was estimated at \u20ac813 million, \u20ac560 million, and \u20ac774 million for Spain, Sweden and the UK, respectively. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 \u03bcg) plus the LAMA glycopyrronium (50 \u03bcg) once daily or the LABA salmeterol (50 \u03bcg) plus the inhaled glucocorticoid fluticasone (500 \u03bcg) twice daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exacerbations; the rate was 11% lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The effect of indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was independent of the baseline blood eosinophil count. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Based on these data, a therapeutic interchange was implemented in the Kaiser Permanente Mid-Atlantic States region to convert patients with a COPD diagnosis from fluticasone/salmeterol to mometasone/formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate the impact of a therapeutic interchange from fluticasone/salmeterol to mometasone/formoterol on health outcomes in patients with COPD in a large ambulatory and managed care setting. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The investigators retrospectively reviewed the electronic medical records of patients with a COPD diagnosis who had a prescription for fluticasone/salmeterol converted to mometasone/formoterol between March 6, 2011, to March 6, 2013. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The primary endpoint was the determination of the difference in the occurrence of COPD exacerbations 6 months pre- and postconversion from fluticasone/salmeterol to mometasone/formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: Within our patient population, 34.2% (n = 178) of patients experienced at least 1 COPD exacerbation while prescribed fluticasone/salmeterol compared with 28.6% (n = 149) of patients while prescribed mometasone/formoterol (P = 0.030). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A later subgroup analysis of the primary outcome revealed that factors associated with a statistically significant decrease in the occurrence of COPD exacerbations were male sex (P = 0.023), comorbid asthma (P = 0.026), and conversion from fluticasone/salmeterol to a more potent dose of mometasone/formoterol (P = 0.014). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: There was a statistically significant decrease in the proportion of patients who experienced COPD exacerbations postconversion from fluticasone/salmeterol to mometasone/formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: The study aimed to assess the effect on lung function of once-daily tiotropium + olodaterol versus twice-daily salmeterol + fluticasone propionate in all participants with Global initiative for chronic Obstructive Lung Disease 2 or 3 (moderate to severe) COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Once-daily tiotropium + olodaterol in participants with moderate-to-severe COPD provided superior lung function improvements to twice-daily salmeterol + fluticasone propionate. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Biopsy samples were taken from patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 wk). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: The combination of salmeterol/fluticasone-inhaled therapy in mechanically ventilated patients with COPD had a significant benefit in reducing Rrs and PIP. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Triple therapy using salmeterol/fluticasone propionate (FP) and tiotropium bromide is commonly used to treat chronic obstructive pulmonary disease (COPD), but sparse efficacy data exist in COPD patients with fewer symptoms and with a lower dose of inhaled corticosteroid in Japanese patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: We performed a review of studies of fluticasone propionate (FP)/salmeterol (SAL) (combination inhaled corticosteroid (ICS)/long-acting \u03b22-agonist (LABA)) in patients with COPD, which measured baseline (pretreatment) blood eosinophil levels, to test whether blood eosinophil levels \u22652% were associated with a greater reduction in exacerbation rates with ICS therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVES: To investigate the relationship between ABCB1 single-nucleotide polymorphisms and the efficacy of salmeterol/fluticasone combination (SFC) inhalation therapy for stable chronic obstructive pulmonary disease (COPD) in a Chinese Han population. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Authors: Rossi A, van der Molen T, Ricardo del Olmo, et al. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study was designed to evaluate the clinical and economic consequences of salmeterol/fluticasone (SF), formoterol/budesonide (FB), and formoterol/fluticasone (FF) in severe and very severe chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Twenty-one patients diagnosed with COPD received roflumilast once daily for 6 months in combination with fluticasone (an inhaled corticosteroid), salmeterol (a long-acting \u03b22-agonist), and tiotropium (a long-acting muscarinic antagonist) or combinations of these agents. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The LANTERN study evaluated the effect of the long-acting \u03b22-agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator, QVA149 (indacaterol/glycopyrronium), as compared with the LABA/inhaled corticosteroid, salmeterol/fluticasone (SFC), in patients with moderate-to-severe COPD with a history of \u22641 exacerbation in the previous year. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA) are approved maintenance therapies for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Our meta-analysis indicated that QVA149 is superior to the salmeterol-fluticasone combination to treat COPD in respect of the frequency of adverse effects, exacerbation, pneumonia, and improvement of trough forced expiratory volume in 1 second (FEV1). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50 mcg and fluticasone propionate 250 mcg (SFC 250) in Japanese patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "AREAS COVERED: We performed an analysis of a recent study evaluating the efficacy and safety of inhaled indacaterol versus inhaled salmeterol/fluticasone in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50\u2005\u00b5g, once-daily tiotropium (TIO) 18\u2005\u00b5g or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500\u2005\u00b5g twice daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: One hundred fourteen patients with moderate to severe COPD finished randomized 6-month or 30-month treatment with fluticasone (500 \u03bcg bid), 30-month treatment with fluticasone and salmeterol (500/50 \u03bcg bid), or placebo (first part of the Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease [GLUCOLD] study [GL1]). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "One retrospective cohort study suggested a greater efficacy for the budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of COPD exacerbations with budesonide/formoterol than with fluticasom/salmeterol combination. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Among the potential side effects of chronic ICS treatment in patients with COPD, recently the use of fluticasone or fluticasone/salmeterol combination has been associated with a higher prevalence of pneumonia in the major long-term studies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This review focuses on the clinical evidence for the benefit of LABA/LAMA FDCs compared with monocomponent treatments, and also compared with active comparators that are widely used for the treatment of COPD, namely tiotropium and salmeterol-fluticasone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The Indacaterol: Switching Non-exacerbating Patients with Moderate COPD From Salmeterol/Fluticasone to Indacaterol (INSTEAD) study investigated the effect of switching patients at low risk of chronic obstructive pulmonary disease (COPD) exacerbations from salmeterol/fluticasone (SFC; inhaled corticosteroid (ICS) regimen) to indacaterol monotherapy (non-ICS regimen). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To determine the economic benefits of IND/GLY compared with the free combination of indacaterol and glycopyrronium (IND\u00a0+\u00a0GLY), and with the fixed-dose combination of salmeterol/fluticasone (SFC), in a moderate-to-severe COPD population with low-exacerbation risk. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study compared the rate of COPD exacerbations over the 26 weeks after an initial exacerbation in patients receiving the combination of fluticasone propionate and salmeterol (FP/SAL) or SAL alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 \u03bcg once daily), salmeterol (50 \u03bcg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 \u03bcg twice daily) during a 6-week run-in period. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we applied IOS and spirometry to evaluate the effectiveness of fluticasone propionate and salmeterol (SFC) combined with tiotropium (TIO) in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "COPD subjects were randomized to twice daily MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, MF 400\u00a0\u03bcg, F 10\u00a0\u03bcg, and placebo; asthma subjects were randomized to MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, fluticasone propionate/salmeterol (FP/S) 250/50\u00a0\u03bcg, and FP/S 500/50\u00a0\u03bcg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide/formoterol and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of \u20ac499.90 (\u20ac195.10 for drugs, \u20ac193.10 for COPD hospitalizations, and \u20ac111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of adding fluticasone propionate/salmeterol (FSC) to tiotropium (Tio) in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Compared with single therapy with other long-acting bronchodilators (indacaterol, glycopyrronium, and tiotropium) and fixed-combination long-acting \u03b22-agonist/inhaled corticosteroid (salmeterol/fluticasone twice daily), once-daily fixed-dose indacaterol/glycopyrronium has clinically important effects on symptoms, including dyspnea score, health status, level of lung function, and rate of moderate or severe exacerbations in patients with moderate-to-very severe COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] spirometric criteria). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Minimal data are available on the use of the fluticasone propionate/salmeterol xinafoate combination (FSC) in the real-life COPD setting and prescription compliance with the licensed specifications. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All patients older than 40 years with a diagnosis of COPD between 2001 and 2010 were entered in the study cohort at the time of their first prescription for tiotropium (TIO) alone or co-administered with fluticasone propionate/salmeterol (TIO\u2009+\u2009FSC). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We aimed to compare the efficacy, safety, and tolerability of QVA149 versus salmeterol-fluticasone (SFC) over 26 weeks in patients with moderate-to-severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: 14 subjects with COPD were commenced on combination fluticasone propionate/salmeterol therapy for 3 months. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "For the combined asthma and COPD subjects, the plasma AUC and Cmax for FP and salmeterol were higher for Rotahaler:Rotahaler/Diskus geometric mean ratios (90% confidence intervals) for FP AUC0-\u03c4 of 1.52 (1.37-1.67) and Cmax of 1.94 (1.75-2.10) and salmeterol AUC0-\u03c4 of 1.15 (1.09-1.21) and Cmax of 1.56 (1.42-1.67). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 \u03bcg, FP 500 \u03bcg, salmeterol xinafoate (SLM) 50 \u03bcg, and combination FP 100 \u03bcg + SLM 50 \u03bcg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The recent Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study suggested that particular phenotypes of COPD benefit from fluticasone\u00b1salmeterol by reducing the rate of FEV1 decline, yet the underlying mechanisms are unknown. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone\u00b1salmeterol and placebo treatment in GLUCOLD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Thirty-three COPD patients on stable bronchial therapy (salmeterol/fluticasone propionate 50/500 mg b.i.d. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: The aim of the study was to assess the effects of Tio, salmeterol (SM), SFC and Tio plus SFC on airway dimensions in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PARTICIPANTS: Patients with COPD diagnosed by a physician and prescriptions of either budesonide/formoterol or fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The exacerbation rates were 0.80 and 1.09 per patient-year in the budesonide/formoterol and fluticasone/salmeterol groups, respectively (difference of 26.6%; P\u00a0<\u00a00.0001); yearly rates for COPD-related hospitalizations were 0.15 and 0.21, respectively (difference of 29.1%; P\u00a0<\u00a00.0001). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Long-term treatment with fixed combination budesonide/formoterol was associated with fewer healthcare utilization-defined exacerbations than fluticasone/salmeterol in patients with moderate and severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The purpose of this exploratory physiological study was to evaluate the effects of inhaled fluticasone/salmeterol combination (FSC) on sensory and physiological responses to exercise in subjects with mild-to-moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The long-acting beta(2)-agonists (LABAs), including salmeterol and formoterol, have 12-hour duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: Our aim was to obtain descriptive data on exacerbation rates in patients with severe or very severe COPD (GOLD Stages III and IV as per GOLD 2009 classification) receiving salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC) or via separate inhalers (Sal/FP) in addition to individual existing therapy in order to investigate the potential benefit of a fixed combination device as compared with two separate devices due to potentially improved patients' compliance. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Several recent trials in chronic obstructive pulmonary disease (COPD) have assessed the effectiveness of the fluticasone-salmeterol combination inhaler in preventing COPD exacerbations, while finding an increased risk of pneumonia. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We describe the proper methods to calculate the NNT and, using data from published trials, apply them to evaluate the relative impact of fluticasone-salmeterol treatment on exacerbations and pneumonias in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: We show that a 1-year trial of the fluticasone-salmeterol combination versus salmeterol used the incorrect event-based approach to calculate the NNT as two patients that need to be treated for 1 year to prevent one COPD exacerbation, when the proper calculation results in a NNT of 14. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The aim of this study was to compare the effect of inhaled budesonide/formoterol with inhaled fluticasone/salmeterol in severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 \u03bcg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We performed a randomized, crossover clinical trial of two\u00a0\u00d7\u00a08 weeks comparing tiotropium (18\u00a0\u03bcg once daily)\u00a0+\u00a0salmeterol (50\u00a0\u03bcg twice daily) (T\u00a0+\u00a0S) to salmeterol\u00a0+\u00a0fluticasone (50/500\u00a0\u03bcg twice daily) (S\u00a0+\u00a0F) in COPD (forced expiratory volume in 1\u00a0s (FEV(1)) \u226465% predicted, and thoracic gas volume (TGV) \u2265120% predicted). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "COPD-related outcomes were compared between patients initiating fluticasone propionate-salmeterol 250/50\u2009mcg (FSC) vs anticholinergics (ACs) following a moderate COPD exacerbation. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Bronchodilators - long-acting b2-adrenergic agonists (formoterol and salmeterol) and a long-acting antimuscarinic drug (tiotropium), are the main drugs applied in symptomatic treatment of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Beclomethasone/formoterol - 400/24 mcg/die, in comparison with fluticasone/salmeterol - 500/100 mcg/die significantly reduced air-trapping and dyspnea in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Our hypothesis was tested in 114 COPD patients (median age 62.9 years, smoking exposure 45.9 pack-yrs) participating in the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) study, which previously showed an improvement in BHR with fluticasone and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In this retrospective, observational study using administrative claims data, we identified COPD patients age \u226540 years who received maintenance therapy within 30 days of an initial COPD-related hospitalization or ED visit with: (1) fluticasone propionate/salmeterol combination (FSC 250 mcg/50 mcg) as new therapy, or (2) an anticholinergic (AC; tiotropium or ipratropium with or without albuterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: This retrospective cohort study compared the risks of exacerbations and COPD-related healthcare costs between patients with chronic obstructive pulmonary disease (COPD) initiating tiotropium (TIO) alone and patients initiating triple therapy with fluticasone-salmeterol combination (FSC) added to TIO. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Both FM (10(-9) \u2003M) and salmeterol (SM, 10(-8) \u2003M) reversed Dex insensitivity in severe asthma, but only FM restored Dex sensitivity in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium bromide prevented exacerbations in patients with COPD, with a significantly lower exacerbation rate and a significantly longer time to first exacerbation seen with tiotropium bromide than with placebo or salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Although the addition of salmeterol/fluticasone propionate to tiotropium bromide did not reduce the COPD exacerbation rate, it did improve lung function and HR-QOL. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 \u00b5g/500 \u00b5g combination (SFC), or placebo in a 12-week, randomized, double-blind, double-dummy study (MKI102428/NCT00642148). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study we evaluated the efficacy and safety of fluticasone/salmeterol (FSC) (250/50\u00a0mcg twice daily) when added to tiotropium (18\u00a0mcg once daily) (TIO) in subjects with symptomatic moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical symptoms in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of tiotropium and fluticasone propionate/salmeterol (FSC) is commonly used to treat chronic obstructive pulmonary disease (COPD), but no study had evaluated the effectiveness of tiotropium plus FSC with 250\u00a0\u03bcg of fluticasone propionate. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To compare, in commercially-insured individuals 240 years old, the risk of chronic obstructive pulmonary disease (COPD) exacerbations and COPD-related health care utilization and costs in patients initiating maintenance treatment with fluticasone propionate/salmeterol xinafoate 250 microg/50 microg (FSC) with those in patients initiating treatment with tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PURPOSE: To compare adherence between patients with COPD initiating therapy on tiotropium or fluticasone/salmeterol and examine the association between adherence and respiratory-related costs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Patients with COPD initiating long-acting bronchodilator therapy were more likely to be adherent to tiotropium than to fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Prior studies suggest that fluticasone propionate/salmeterol (FSC) may improve cardiovascular outcomes in COPD and we hypothesized that FSC would reduce arterial stiffness in these patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVES: To quantify healthcare use and costs associated with chronic obstructive pulmonary disease (COPD) among patients discharged from a COPD-related hospitalization or emergency department (ED) visit on a regimen of fluticasone propionate-salmeterol combination versus other inhaled maintenance therapies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The adjusted rate of COPD-related hospitalizations or ED visits was 35% lower in the fluticasone propionate-salmeterol cohort (P <.05). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Adjusted COPD-related total (medical plus pharmacy) costs were lower in the fluticasone propionate-salmeterol cohort ($240 vs $279 per patient per month, P <.05), mostly because of lower medical costs ($113 vs $160 per patient per month, P <.05). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Initiation of fluticasone propionate-salmeterol after discharge from a COPD-related hospitalization or ED visit significantly reduced the risk of a recurrent event during the ensuing months and decreased COPD-related medical costs, without an increase in COPD-related pharmacy costs, in a real-world setting. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study was to identify the predictors of pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Wheezing history, pre-bronchodilator pulmonary function, bronchodilator responsiveness, and emphysema extent may be used for predicting the pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Relative costs and utilization-related outcomes of a fluticasone propionate 250 \u03bcg + salmeterol 50 \u03bcg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "COPD patients \u2265 35 years with at least one LABD claim between July 1, 2004 and June 30, 2006 were classified into five cohorts based on index LABD: monotherapy with tiotropium, salmeterol/fluticasone propionate, formoterol fumarate, or salmeterol or combination therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients treated with salmeterol/fluticasone propionate (p < 0.001), formoterol fumarate (p = 0.032), salmeterol (p = 0.004), or with combination therapy (p < 0.001) had higher COPD-related costs and a greater risk of inpatient admission (p < 0.01 for all) versus tiotropium. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a large population-based study in the United Kingdom, we estimated the association between fluticasone propionate/salmeterol fixed-dose combination (FSC) and other ICS use and nonvertebral fracture incidence among patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: Although salmeterol/fluticasone propionate combination (SFC) therapy has been widely used for the treatment of COPD, the relationship between airway dimensions and improvement in pulmonary function remains unknown. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We examined the effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on the management of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium is US Food and Drug Administration (FDA) approved to treat bronchospasm and reduce exacerbations in patients with COPD; salmeterol/fluticasone is FDA approved to treat airflow obstruction in COPD and reduce exacerbations in patients with a history of exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Other maintenance long-acting bronchodilators-salmeterol, formoterol, and budesonide/formoterol-are FDA approved to treat airway obstruction in COPD but lack an approved indication against exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: this study compared the onset of action of single doses of indacaterol 150 and 300 \u03bcg with salbutamol 200 \u03bcg, salmeterol-fluticasone 50/500 \u03bcg, and placebo in moderate-to-severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A total of 1,481 women and 4,631 men with COPD were enrolled in TORCH, a trial comparing salmeterol, 50 \u03bcg, plus fluticasone propionate, 500 \u03bcg, twice a day and each component individually. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To estimate the cost-effectiveness of fluticasone propionate-salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We performed an economic analysis of pooled data from two randomized clinical trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 microg twice daily) or salmeterol (50 microg twice daily) on exacerbation rates in patients with severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Total adjusted annual COPD related exacerbation and therapeutic costs were $4,842 (95% CI; $4,731-$4,952) in the FSC group and $5,066 (95% CI; $4,937-$5,195) in the salmeterol group. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: FSC combination therapy is associated with reduced risk of any exacerbation and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs compared to treatment with salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We investigated predictive factors for response to fluticasone propionate/salmeterol (FSC) in severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this post hoc analysis, data from the TOwards a Revolution in COPD Health (TORCH) study were used to investigate whether use of the long-acting beta(2) agonist salmeterol over 3 years increased the risk of cardiovascular adverse events in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Post hoc analysis of the 3-year TORCH dataset showed that salmeterol alone or in combination (SFC) did not increase the risk of cardiovascular events in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 microg) and the long-acting beta(2)-agonist salmeterol (50 microg) in a single inhaler (250/50 microg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium, a long-acting anticholinergic, and salmeterol/fluticasone, a long-acting \u03b2-agonist/inhaled corticosteroid combination, are Food and Drug Administration-approved maintenance therapies to reduce exacerbations of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In chronic respiratory diseases in general, and chronic obstructive pulmonary disease (COPD) in particular, adherence to inhaled therapy can potentially influence disease prognosis, as demonstrated in the analyses discussed in this article and a 3-year study assessing the effects of inhaled salmeterol, inhaled fluticasone and an inhaled combination over placebo in patients with moderate-to-severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A fixed-dose dry powder combination inhaler, Seretide/Advair, containing salmeterol and fluticasone, is licensed in the European Community for the treatment of moderate to severe COPD in the strength of 50/500 microg twice daily (BID). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " AIM: To assess the risk of pneumonia among COPD patients using salmeterol/fluticasone propionate combination inhalers (SFC), inhaled corticosteroids (ICS), or long-acting beta-agonists (LABA), alone or in combination, compared to those using only short-acting bronchodilators (SABD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered via combination inhalers with the respective long-acting beta2-agonists, formoterol and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Following a run-in period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of budesonide/formoterol (400/12 microg) and salmeterol/fluticasone (50/500 microg), separated by a 4-14-day washout period. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: In 39 (18 women), clinically stable ex-smokers with COPD aged 73 +/- 9 years (mean +/- SD) on salmeterol 50 microg (S50) bid, after 180 microg aerosolized albuterol, FEV(1) (L) was 52% +/- 12% predicted and FEV(1)/FVC was 55% +/- 6%. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The effect of the long acting beta(2)-agonist/corticosteroid combination salmeterol-fluticasone propionate (SFC) on respiratory muscles and ventilation in severe COPD is unknown. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We examined directly the effect on the parasternal intercostal respiratory chest wall muscle and ventilation of four puffs of salmeterol 25 microg and fluticasone propionate 125 microg via the metered dose combination inhaler in 12 patients with severe Global Initiative on Obstructive Lung Disease stage III-IV COPD, mean FEV(1) = 0.91 L (32% predicted). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In severe COPD, with minimal change in hyperinflation or pulmonary mechanics, salmeterol-fluticasone induced a significant decrease in activity of the chest wall parasternal inspiratory muscle. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The study aims to compare healthcare resource utilization associated with hospitalization or emergency department (ED) visits between FDA-approved inhaled corticosteroid/long-acting beta-agonist combinations [fluticasone propionate 250 microg/salmeterol 50 microg combination (FSC)] and anticholinergic treatments (ATC) in managed-care Medicare beneficiaries with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a randomised, double-blind, multicentre, cross-over study, 442 patients with COPD aged >or=40 years (pre-bronchodilator FEV(1) <or=50%; FEV(1)/vital capacity <70%) received budesonide/formoterol (320/9 microg, one inhalation twice daily) dry powder inhaler (DPI) or salmeterol/fluticasone (50/500 microg, one inhalation twice daily) DPI daily, for 1 week each, separated by a 1- to 2-week washout. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with budesonide/formoterol DPI or salmeterol/fluticasone DPI was effective in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The TOwards a Revolution in COPD Health (TORCH) study was a 3-yr multicentre trial of 6,112 patients randomised to salmeterol (Salm), fluticasone propionate (FP), a Salm/FP combination (SFC) or placebo (P). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) was a RCT that compared the combination of salmeterol plus fluticasone against tiotropium in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol (SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe COPD in the TOwards a Revolution in COPD Health (TORCH) study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 microg, fluticasone propionate (FP) 500 microg, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: This study investigated the value of adding Ismigen, a polyvalent mechanical bacterial lysate, to therapy of COPD patients (FEV(1) <60% predicted) under regular treatment with salmeterol/fluticasone (SFC). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "STUDY DESIGN: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "An anti-inflammatory effect of salmeterol (S)/fluticasone propionate (FP) combination (SFC), as demonstrated in a number of biopsy studies, may be the mechanism by which it provides a potential survival benefit in COPD patients in the TORCH study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Both salmeterol/fluticasone and tiotropium also reduced COPD hospitalization rates. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: The effects of tiotropium, a long-acting anticholinergic drug, were compared with those of the combination of salmeterol, a long-acting beta(2)-agonist, and fluticasone, an inhaled corticosteroid, in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A 4-month, randomized, open cross-over study of tiotropium, 18 microg once daily, versus salmeterol, 50 microg, plus fluticasone, 200 microg, twice daily, was conducted in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "However, tiotropium and salmeterol plus fluticasone had similar overall effects on pulmonary function and SGRQ scores in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To observe the efficacy of combination therapy with inhaled salmeterol/fluticasone and tiotropium in reducing the frequency of acute episodes of symptom exacerbation and improving lung function and health status in chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: One hundred and twenty-six patients (M/F: 92/34) with COPD were treated in a randomised, parallel-group, controlled study with salmeterol/fluticasone (50/250 microg) twice daily and tiotropium 18 microg once daily (n = 33, M/F: 23/10); salmeterol/fluticasone (50/250 microg) twice daily (n = 32, M/F: 24/8); or tiotropium 18 microg once daily (n = 32, M/F: 23/9) for 12 months. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Combination therapy with salmeterol/fluticasone and tiotropium leads to better control of symptoms and improved lung function, with no greater risk of side-effects, as compared to salmeterol/fluticasone or tiotropium alone in the treatment of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: We examine the lifetime cost-effectiveness of treatment with fluticasone propionate/salmeterol (500/50 microg) compared with no maintenance treatment in COPD in the US. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A decision-analytic model was developed to estimate lifetime costs and outcomes associated with fluticasone propionate/salmeterol 500/50 microg treatment, salmeterol 50 microg, and fluticasone propionate 500 microg compared to no maintenance treatment in treating COPD from a third-party US payer perspective. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Treatment of COPD with fluticasone propionate/salmeterol 500/50 microg appears to be cost-effective (<or=$50,000/QALY) compared to no maintenance treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The objectives of this retrospective study were to compare the effects of fluticasone propionate 500 microg/salmeterol 50 microg (FSC 500/50) with those of ipratropium (IPR) in older adult patients with COPD on the following factors: (1) the risk of all-cause and COPD-related hospitalization and emergency department (ED) visits; and (2) all-cause and COPD-related treatment costs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study determined the cost effectiveness of adding salmeterol (S) or fluticasone/salmeterol (FS) to tiotropium (T) for COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: In 782 patients with COPD (mean FEV(1)=0.94+/-0.36 L, 33% predicted normal), treatment with fluticasone propionate/salmeterol 250/50 significantly reduced (1) the annual rate of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per subject per year, respectively, p<0.001), (2) the risk of time to first exacerbation by 25% (hazard ratio=0.750, p=0.003) and (3) the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study supports the use of fluticasone propionate/salmeterol 250/50 for the reduction of COPD exacerbations in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effects of initial maintenance therapy with fluticasone 250 microgram plus salmeterol 50 microgram in a single inhaler versus other inhaled medications on exacerbation risks and treatment costs among chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients age 40 years or older with a primary diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification code 490, 491, 492, or 496), at least 18 months of continuous eligibility, and an index prescription for fluticasone/salmeterol combination, salmeterol alone, inhaled corticosteroid alone, ipratropium/albuterol combination, or ipratropium alone (reference) were identified. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " This retrospective analysis of data from two multi-center, randomized, double-blind, parallel group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50 mcg twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in albuterol-reversible (n=320 [44%]) and non-reversible (n=399 [56%]) patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "An increased risk of pneumonia with inhaled corticosteroids was first reported from the Toward Revolution in COPD Health (TORCH) study, a large randomized clinical trial comparing fluticasone, salmeterol, or a combination of the two medications with placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: A 6-week, multicenter, randomized, double-blind, parallel-group study was conducted in patients with COPD to compare lung function improvements of tiotropium, 18 microg qd, plus formoterol, 12 microg bid, to salmeterol, 50 microg bid, plus fluticasone, 500 microg bid. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Tiotropium plus formoterol was superior in lung function over the day compared to salmeterol plus fluticasone in patients with moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we have compared the acute effects of tiotropium 18 microg and salmeterol/fluticasone combination (SFC) 50/250 microg on arterial blood gases in 20 patients with stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Within the different studies, questionnaires including the George's Respiratory Questionnaire (SGRQ) the Chronic Respiratory Disease Questionnaire (CRDQ) and the Clinical COPD Questionnaire (CCQ) were used and differing results in quality of life were obtained when combination therapies such as fluticasone/salmeterol or fluticasone/salmeterol were compared with monotherapies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but there are few data on their effectiveness when used together. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To review the pharmacoeconomic impact of the fixed-dose combination of inhaled fluticasone and salmeterol in asthma and COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "For COPD, a clear reduction in exacerbation rates and improvement in quality of life has been demonstrated with salmeterol/fluticasone along with a likely improvement in survival rates. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: The data currently available suggest that the cost effectiveness of combination therapy with fluticasone and salmeterol is favourable for asthma and COPD in a variety of clinical settings. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Results of the INSPIRE trial suggest that salmeterol/fluticasone propionate is associated with a significantly lower mortality rate than tiotropium bromide monotherapy in patients with COPD; the two treatments had similar effects in terms of exacerbation rates and lung function. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Recently, a worldwide double-blind placebo-controlled study 'Towards a revolution in COPD health' (TORCH) was published in which salmeterol 50 microg and fluticasone 500 microg twice daily was compared with placebo, salmeterol alone or fluticasone alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Few studies of the efficacy and safety of therapy with combinations of salmeterol/fluticasone propionate (SFCs) have been conducted in Chinese patients with COPD, and the benefits of combination therapy in nonsmoking patients with COPD are, to our knowledge, not known. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "STUDY OBJECTIVES: The aims were to establish the efficacy and tolerability of the therapy with SFC (salmeterol, 50 microg/fluticasone, 500 microg, twice daily) in the management of Chinese COPD patients and to investigate the effectiveness of SFC in nonsmokers with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: We compared the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 microg twice daily and the long-acting bronchodilator (tiotropium) 18 microg once daily in preventing exacerbations and related outcomes in severe and very severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The study population was a historical cohort of Texas Medicaid beneficiaries aged 40 to 64 years with COPD-related medical costs (International Classification of Diseases, Ninth Revision, Clinical Modification codes 491.xx, 492.xx, 496.xx), 24 months of continuous Medicaid enrollment (12 months before and after the index prescription), and at least 1 prescription claim (index) for a combination product containing fluticasone propionate + salmeterol, an inhaled corticosteroid, salmeterol, or ipratropium between April 1, 2001, and March 31, 2003. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The TORCH (Towards a Revolution in COPD Health) study confirmed that the effects of combined therapy with salmeterol/fluticasone propionate are greater than the monocomponents. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This review critically appraises the pharmacology of salmeterol/fluticasone propionate, the evidence for efficacy in COPD and its potential use in combination with other drugs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The TORCH study (Towards a Revolution in COPD Health) was a double-blind, randomised, placebo-controlled clinical trial, investigating the combination of salmeterol/fluticasone propionate for 3 years in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In addition to being effective, the combination salmeterol/fluticasone (50/500 microg 2x/day) is well tolerated in COPD and had a favourable benefit/risk ratio. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A study was therefore undertaken to evaluate combined salmeterol/fluticasone propionate (SFC) and fluticasone propionate (FP) alone on inflammatory cells in the airways of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All patients who were diagnosed with COPD between September 1, 2000 and August 31, 2001 and who had at least 3 months treatment with either a combined fluticasone/salmeterol inhaler (FSI, N=866), any ICS used with a LABA (ICS/LABA, N=525), ICS alone (N=742), LABA alone (N=531), or a short-acting bronchodilator alone (SABD, N=1832), were included. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The only major pharmacological advancement for the treatment of these diseases has been to increase the duration of action of bronchodilators (asthma: salmeterol; COPD: tiotropium bromide) and glucocorticosteroids (asthma: fluticasone propionate) and, increasingly, to formulate these agents in the same delivery device. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A large multicenter prospective randomized trial (Towards a Revolution in COPD Health [TORCH]) is now ongoing and will examine the effect of fluticasone propionate in combination with salmeterol on all-cause mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To determine whether combining tiotropium with salmeterol or fluticasone-salmeterol improves clinical outcomes in adults with moderate to severe COPD compared with tiotropium alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium plus fluticasone-salmeterol improved lung function (P = 0.049) and disease-specific quality of life (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [CI, 0.33 to 0.86]) and all-cause hospitalizations (incidence rate ratio, 0.67 [CI, 0.45 to 0.99]) compared with tiotropium plus placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Addition of fluticasone-salmeterol to tiotropium therapy did not statistically influence rates of COPD exacerbation but did improve lung function, quality of life, and hospitalization rates in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i.e. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: FEV1% predicted increased 2.6% (SD 8.3) in fluticasone/salmeterol- and 0.01% (SD 6.6) in fluticasone-treated patients (overall: P=0.036, asthma: P=0.025 and COPD: P=0.700). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Fluticasone/salmeterol-treated asthma patients had 1.1 more symptom-free days per week (P=0.044); no such effect was observed for COPD (P=0.769). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "the combination of salmeterol 50 microg plus fluticasone 250 microg twice daily (n=51) in patients with moderate-to-very severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Six weeks of treatment with tiotropium resulted in comparable bronchodilation compared with salmeterol plus fluticasone in patients with moderate-to-very severe COPD, despite tiotropium patients having lower lung function and fewer patients considered reversible at baseline. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the impact of combination therapy with salmeterol/fluticasone propionate compared with salmeterol alone on moderate and severe exacerbations in patients with severe COPD and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: This study demonstrates that combination therapy with salmeterol/fluticasone compared with salmeterol monotherapy significantly reduces the frequency of moderate/severe exacerbations in patients with severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Treatment with inhaled fluticasone and salmeterol significantly suppressed eosinophilic inflammation in COPD patients with sputum eosinophilia (mean 8.9% +/- 2.0% vs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In an open-label study at 38 outpatient centres, patients > or =12 years old with asthma or chronic obstructive pulmonary disease (COPD) received two actuations of fluticasone propionate/salmeterol 125/25 microg (115/21 microg ex-actuator) hydrofluoroalkane (ADVAIR) HFA) via MDI with counter twice a day until all 120 actuations were completed. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " STUDY OBJECTIVE: To examine the effect of fluticasone propionate, 250 microg/salmeterol, 50 microg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of exercise performance in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Several short-term follow-up trials have also suggested a reduction in mortality with a combination of long-acting beta(2)-agonist and inhaled corticosteroids, and a large, long-term study that is currently ongoing (the Toward a Revolution in COPD Health [TORCH] study) will provide data on the effects of fluticasone propionate and salmeterol in combination on all-cause mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The aim of this pilot study was to explore the relative efficacy in terms of improvement in symptoms and lung function of combining fluticasone propionate/salmeterol combination (FSC) and tiotropium in patients with severe-to-very severe stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Confirmation or refutation of this result may be achieved once the Towards a Revolution in COPD Health (TORCH) study reports, a large randomized controlled trial powered to detect mortality changes associated with the use of FP alone, or in combination with salmeterol, which is also collecting resource use and utility data suitable for estimating cost-effectiveness. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, the aim of this study was to investigate the effects of the low molecular weight heparin, enoxaparin (ENX), as an add-on therapy for a period of 12 weeks, to inhaled salmeterol/fluticasone propionate (SLM/FP) combination in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the ex-smokers with COPD, the albuterol responsiveness measurement was repeated after 4 weeks of treatment with fluticasone/salmeterol and after a drug washout period of 4 or 8 weeks. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "While fluticasone/salmeterol did not change Qaw significantly, it restored albuterol responsiveness (67.6 +/- 11.1% predicted; p < 0.05) in the ex-smokers with COPD; this effect was no longer seen after the drug washout period. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol/fluticasone improves FEV1% in mild and moderate more than in severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To develop a Markov model that allows the cost effectiveness of interventions in patients with chronic obstructive pulmonary disease (COPD) to be estimated, and to apply the model to investigate the cost effectiveness of an inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist (beta(2)-agonist) combination (salmeterol/fluticasone propionate) versus usual care. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Efficacy data for the combination of inhaled salmeterol/fluticasone propionate 50/500microg twice daily in poorly reversible COPD patients with a history of exacerbations were obtained from the 1-year TRISTAN (TRial of Inhaled STeroids ANd long-acting beta-agonists) study and applied to the model, based on patient profiles representative of COPD clinical trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Initial evidence suggests that for patients with poorly reversible COPD and a documented history of frequent COPD exacerbations, the addition of salmeterol (a long-acting beta(2)-agonist) to fluticasone propionate (an inhaled corticosteroid) is potentially cost effective from the Canadian healthcare payer's perspective. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 microg FP + 50 microg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of the present trial was to determine whether the combination of salmeterol and tiotropium improved lung function in COPD patients more than either of them alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In terms of improvement in lung function, the combination of salmeterol and tiotropium together with fluticasone is more effective in patients with moderate-to-severe COPD than either of the 2 bronchodilators administered alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The study will randomize 432 patients with moderate to severe COPD to one of three parallel treatment arms for 52 weeks: tiotropium and fluticasone/salmeterol; tiotropium and salmeterol; or tiotropium and placebo inhaler. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Previous studies have demonstrated that the LABA, salmeterol, improves lung function, symptoms and quality of life in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we have performed additional analyses of the combined data from two previous double-blind, placebo-controlled, parallel studies of salmeterol (50 microg, b.i.d) in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a sensitivity analysis, we compared 539 male and 180 female COPD patients, who were randomized to the saLmeterol/fluticasone combination 50/500mcg bid or placebo for 12 months. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The \"TOwards a Revolution in COPD Health\" (TORCH) survival study is aiming to determine the impact of salmeterol/fluticasone propionate (SFC) combination and the individual components on the survival of COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the US, twice-daily salmeterol/fluticasone propionate 50/250 microg is approved for use in adults with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and in the EU, the twice-daily 50/500 microg dosage is approved for use in patients with severe COPD, repeat exacerbations and significant symptoms despite bronchodilator therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In patients with moderate-to-severe COPD, twice-daily inhaled salmeterol/fluticasone propionate 50/250 or 50/500 microg for 24-52 weeks improves predose forced expiratory volume in 1 second (FEV1) significantly more than salmeterol monotherapy, improves postdose or postbronchodilator FEV1 significantly more than fluticasone propionate monotherapy and results in clinically significant improvements in health-related quality of life. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol/fluticasone propionate 50/500 microg significantly reduced annual COPD exacerbations, especially in severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Some corticosteroid-related adverse events were increased in recipients of fluticasone propionate with or without salmeterol versus salmeterol monotherapy or placebo; withdrawal from fluticasone propionate, including combination therapy, needs careful management to minimise COPD exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: The aim of this study was to compare the relative efficacy in terms of improvement in symptoms and lung function of salmeterol/fluticasone propionate (SLM/FP) combination administered through the Diskus inhaler versus theophylline (THEO) added to FP Diskus in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled long-acting beta(2)-agonist salmeterol (SM), when administered together in a single device (Diskus; GlaxoSmithKline, Inc; Research Triangle Park, NC), with that of placebo and the individual agents alone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV(1) and symptoms in the long-term.AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " In the present trial, we compared the broncholytic efficacy of the combination therapy with 50 microg salmeterol + 250 microg fluticasone and 12 microg formoterol + 400 microg budesonide, both in a single inhaler device, in 16 patients with moderate-to-severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Observational data may provide an insight into the expected survival in clinical trials of fluticasone propionate (FP) and salmeterol in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Three-year survival in 1,045 COPD patients treated with FP and salmeterol was compared with that in 3,620 COPD patients who regularly used other bronchodilators but not inhaled corticosteroids or long-acting beta2-agonists. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol has been shown to be an effective first-line bronchodilator in COPD and fluticasone has been shown to reduce the frequency and or severity of exacerbations in COPD patients in two key trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The LANTERN study evaluated the efficacy of IND/GLY compared with inhaled long-acting \u03b22-agonist (LABA)/inhaled corticosteroid (ICS) or salmeterol/fluticasone (SFC) in patients with moderate-to-severe COPD with a history of \u22641 exacerbation in the previous year. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A post hoc analysis of a previous prospective randomized study was performed for COPD patients using higher dose (HD: Fluticasone 1,000 \u03bcg/day) or medium dose (MD: Fluticasone 500 \u03bcg/day) of ICS combined with Salmeterol (100 \u03bcg/day). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: The objective of this study was to compare persistence to salmeterol/fluticasone propionate combination treatment as AirFluSal Forspiro with persistence to Seretide Diskus in patients with asthma or COPD aged 12 years and above. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The WISDOM study (NCT00975195) reported a change in lung function following withdrawal of fluticasone propionate in patients with severe to very severe COPD treated with tiotropium and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who had a history of one or no exacerbations in the previous year, in Canada, France, Italy, and Portugal. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "While both treatments were well tolerated, pneumonia occurred less frequently with aclidinium/formoterol than salmeterol/fluticasone.In stable COPD, aclidinium/formoterol significantly improved bronchodilation versus salmeterol/fluticasone, with equivalent benefits in symptom control and reduction in exacerbation risk. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study was thus designed to compare the efficacy and tolerability of salmeterol/fluticasone combination with tiotropium in patients with moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: From the GlaxoSmithKline trial registry, we selected randomised, double-blind, clinical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in duration. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae)) over 1\u00a0year in Spain, Sweden and the United Kingdom (UK). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: The direct cost burden of managing asthma and COPD for people using budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae) in 2015 was estimated at \u20ac813 million, \u20ac560 million, and \u20ac774 million for Spain, Sweden and the UK, respectively. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 \u03bcg) plus the LAMA glycopyrronium (50 \u03bcg) once daily or the LABA salmeterol (50 \u03bcg) plus the inhaled glucocorticoid fluticasone (500 \u03bcg) twice daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exacerbations; the rate was 11% lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The effect of indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was independent of the baseline blood eosinophil count. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Based on these data, a therapeutic interchange was implemented in the Kaiser Permanente Mid-Atlantic States region to convert patients with a COPD diagnosis from fluticasone/salmeterol to mometasone/formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate the impact of a therapeutic interchange from fluticasone/salmeterol to mometasone/formoterol on health outcomes in patients with COPD in a large ambulatory and managed care setting. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The investigators retrospectively reviewed the electronic medical records of patients with a COPD diagnosis who had a prescription for fluticasone/salmeterol converted to mometasone/formoterol between March 6, 2011, to March 6, 2013. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The primary endpoint was the determination of the difference in the occurrence of COPD exacerbations 6 months pre- and postconversion from fluticasone/salmeterol to mometasone/formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: Within our patient population, 34.2% (n = 178) of patients experienced at least 1 COPD exacerbation while prescribed fluticasone/salmeterol compared with 28.6% (n = 149) of patients while prescribed mometasone/formoterol (P = 0.030). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A later subgroup analysis of the primary outcome revealed that factors associated with a statistically significant decrease in the occurrence of COPD exacerbations were male sex (P = 0.023), comorbid asthma (P = 0.026), and conversion from fluticasone/salmeterol to a more potent dose of mometasone/formoterol (P = 0.014). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: There was a statistically significant decrease in the proportion of patients who experienced COPD exacerbations postconversion from fluticasone/salmeterol to mometasone/formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Biopsy samples were taken from patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 wk). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Of these, the WISDOM (Withdrawal of Inhaled Steroids During Optimized Bronchodilator Management) trial was the largest and first to examine stepwise withdrawal of ICS in patients with COPD receiving maintenance therapy of long-acting bronchodilators (ie, tiotropium and salmeterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Triple therapy using salmeterol/fluticasone propionate (FP) and tiotropium bromide is commonly used to treat chronic obstructive pulmonary disease (COPD), but sparse efficacy data exist in COPD patients with fewer symptoms and with a lower dose of inhaled corticosteroid in Japanese patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVES: To investigate the relationship between ABCB1 single-nucleotide polymorphisms and the efficacy of salmeterol/fluticasone combination (SFC) inhalation therapy for stable chronic obstructive pulmonary disease (COPD) in a Chinese Han population. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Authors: Rossi A, van der Molen T, Ricardo del Olmo, et al. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study was designed to evaluate the clinical and economic consequences of salmeterol/fluticasone (SF), formoterol/budesonide (FB), and formoterol/fluticasone (FF) in severe and very severe chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: Compared with salmeterol, tiotropium significantly increased time to first COPD exacerbation (hazard ratio 0.84; 95% confidence interval [CI] 0.76-0.92; p\u00a0=\u00a00.0002) and reduced the number of COPD exacerbations (rate ratio 0.90; 95% CI 0.81-0.99; p\u00a0=\u00a00.0383) in patients at high exacerbation risk. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "For low-risk patients, time to first COPD exacerbation and number of COPD exacerbations were numerically lower with tiotropium versus salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "DISCUSSION: This analysis confirms the higher efficacy of tiotropium versus salmeterol in prolonging time to first COPD exacerbation and reducing number of exacerbations in patients both at low and high exacerbation risk. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA) are approved maintenance therapies for chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Our meta-analysis indicated that QVA149 is superior to the salmeterol-fluticasone combination to treat COPD in respect of the frequency of adverse effects, exacerbation, pneumonia, and improvement of trough forced expiratory volume in 1 second (FEV1). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50 mcg and fluticasone propionate 250 mcg (SFC 250) in Japanese patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "AREAS COVERED: We performed an analysis of a recent study evaluating the efficacy and safety of inhaled indacaterol versus inhaled salmeterol/fluticasone in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50\u2005\u00b5g, once-daily tiotropium (TIO) 18\u2005\u00b5g or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500\u2005\u00b5g twice daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Maintenance therapy with tiotropium plus salmeterol as TSHH or as the jointly administered reference products is superior to either agent alone, safe, and well tolerated in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a phase 2b trial, batefenterol produced statistical and clinically significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 weeks of dosing in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "One retrospective cohort study suggested a greater efficacy for the budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of COPD exacerbations with budesonide/formoterol than with fluticasom/salmeterol combination. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Among the potential side effects of chronic ICS treatment in patients with COPD, recently the use of fluticasone or fluticasone/salmeterol combination has been associated with a higher prevalence of pneumonia in the major long-term studies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This review focuses on the clinical evidence for the benefit of LABA/LAMA FDCs compared with monocomponent treatments, and also compared with active comparators that are widely used for the treatment of COPD, namely tiotropium and salmeterol-fluticasone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The Indacaterol: Switching Non-exacerbating Patients with Moderate COPD From Salmeterol/Fluticasone to Indacaterol (INSTEAD) study investigated the effect of switching patients at low risk of chronic obstructive pulmonary disease (COPD) exacerbations from salmeterol/fluticasone (SFC; inhaled corticosteroid (ICS) regimen) to indacaterol monotherapy (non-ICS regimen). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To determine the economic benefits of IND/GLY compared with the free combination of indacaterol and glycopyrronium (IND\u00a0+\u00a0GLY), and with the fixed-dose combination of salmeterol/fluticasone (SFC), in a moderate-to-severe COPD population with low-exacerbation risk. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The study population consisted of long-acting bronchodilator naive COPD patients, initiating inhalation therapy with mono-LABAs (formoterol, indacaterol or salmeterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study compared the rate of COPD exacerbations over the 26 weeks after an initial exacerbation in patients receiving the combination of fluticasone propionate and salmeterol (FP/SAL) or SAL alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 \u03bcg once daily), salmeterol (50 \u03bcg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 \u03bcg twice daily) during a 6-week run-in period. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we applied IOS and spirometry to evaluate the effectiveness of fluticasone propionate and salmeterol (SFC) combined with tiotropium (TIO) in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "COPD subjects were randomized to twice daily MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, MF 400\u00a0\u03bcg, F 10\u00a0\u03bcg, and placebo; asthma subjects were randomized to MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, fluticasone propionate/salmeterol (FP/S) 250/50\u00a0\u03bcg, and FP/S 500/50\u00a0\u03bcg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide/formoterol and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of \u20ac499.90 (\u20ac195.10 for drugs, \u20ac193.10 for COPD hospitalizations, and \u20ac111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Compared with single therapy with other long-acting bronchodilators (indacaterol, glycopyrronium, and tiotropium) and fixed-combination long-acting \u03b22-agonist/inhaled corticosteroid (salmeterol/fluticasone twice daily), once-daily fixed-dose indacaterol/glycopyrronium has clinically important effects on symptoms, including dyspnea score, health status, level of lung function, and rate of moderate or severe exacerbations in patients with moderate-to-very severe COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] spirometric criteria). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Minimal data are available on the use of the fluticasone propionate/salmeterol xinafoate combination (FSC) in the real-life COPD setting and prescription compliance with the licensed specifications. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We aimed to establish whether ADRB2 polymorphisms differentially affected COPD exacerbation outcomes in response to tiotropium versus salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We did a prespecified analysis of the ADRB2 polymorphisms Arg16Gly and Gln27Glu within the 1 year randomised, double-blind, double-dummy, parallel-group Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) trial, comparing the effects of treatment with tiotropium or salmeterol on exacerbations in 7376 patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We aimed to compare the efficacy, safety, and tolerability of QVA149 versus salmeterol-fluticasone (SFC) over 26 weeks in patients with moderate-to-severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The objective of this study is to evaluate the comparative efficacy of indacaterol 75/150/300\u00a0\u03bcg once daily (OD), glycopyrronium bromide 50\u00a0\u03bcg OD, tiotropium bromide 18\u00a0\u03bcg/5\u00a0\u03bcg OD, salmeterol 50\u00a0\u03bcg twice daily (BID), formoterol 12\u00a0\u03bcg BID, and placebo for moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Twenty-eight stable COPD patients had their ILPs and FEV1 measured both before and 2\u00a0h after the use of a single dose of 18\u00a0mcg bronchodilator tiotropium and 50\u00a0mcg salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "For the combined asthma and COPD subjects, the plasma AUC and Cmax for FP and salmeterol were higher for Rotahaler:Rotahaler/Diskus geometric mean ratios (90% confidence intervals) for FP AUC0-\u03c4 of 1.52 (1.37-1.67) and Cmax of 1.94 (1.75-2.10) and salmeterol AUC0-\u03c4 of 1.15 (1.09-1.21) and Cmax of 1.56 (1.42-1.67). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 \u03bcg, FP 500 \u03bcg, salmeterol xinafoate (SLM) 50 \u03bcg, and combination FP 100 \u03bcg + SLM 50 \u03bcg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In long-term clinical studies (12 weeks to 1 year) in patients with moderate to severe COPD, OD indacaterol 150 or 300 \u03bcg improved lung function (primary endpoint) significantly more than placebo, and improvements were significantly greater than twice-daily formoterol 12 \u03bcg or salmeterol 50 \u03bcg, and noninferior to OD tiotropium bromide 18 \u03bcg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Long-acting \u03b22-agonists (LABAs) have long been used for symptomatic management of COPD, with salmeterol and formoterol being the commonly used twice-daily treatments. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Long-acting muscarinic antagonists such as glycopyrronium and tiotropium, along with long-acting beta-2 agonists such as indacaterol, formoterol and salmeterol are the pillars of pharmacological therapy for the long-term management of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The recent Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study suggested that particular phenotypes of COPD benefit from fluticasone\u00b1salmeterol by reducing the rate of FEV1 decline, yet the underlying mechanisms are unknown. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone\u00b1salmeterol and placebo treatment in GLUCOLD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Thirty-three COPD patients on stable bronchial therapy (salmeterol/fluticasone propionate 50/500 mg b.i.d. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: The aim of the study was to assess the effects of Tio, salmeterol (SM), SFC and Tio plus SFC on airway dimensions in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: At peak effect (2\u2009hr), volume responses were greater with arfomoterol via nebulizer compared with dry powder salmeterol in patients with COPD who had a PIFRresist of <60 L/min. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PARTICIPANTS: Patients with COPD diagnosed by a physician and prescriptions of either budesonide/formoterol or fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "GOLD guidelines recommend combining long-acting bronchodilators with differing mechanisms of action if the control of COPD is insufficient with monotherapy, and recent years have seen growing interest in the additional benefits that combination of long-acting muscarinic antagonists (LAMAs), typified by tiotropium, with long-acting \u03b2(2)-agonists (LABAs), such as formoterol and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study is to establish, from the UK National Health Service (NHS) perspective, the cost-effectiveness profile of indacaterol, the first once-daily long-acting beta2-agonist (LABA), compared with tiotropium and salmeterol, in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The exacerbation rates were 0.80 and 1.09 per patient-year in the budesonide/formoterol and fluticasone/salmeterol groups, respectively (difference of 26.6%; P\u00a0<\u00a00.0001); yearly rates for COPD-related hospitalizations were 0.15 and 0.21, respectively (difference of 29.1%; P\u00a0<\u00a00.0001). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Long-term treatment with fixed combination budesonide/formoterol was associated with fewer healthcare utilization-defined exacerbations than fluticasone/salmeterol in patients with moderate and severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The long-acting beta(2)-agonists (LABAs), including salmeterol and formoterol, have 12-hour duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Both the twice-daily long-acting \u03b2(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We searched PubMed for placebo-controlled studies evaluating long-term (\u226524 weeks) use of formoterol, salmeterol, or indacaterol in patients with stable COPD, published between January 1990 and September 2012. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: Our aim was to obtain descriptive data on exacerbation rates in patients with severe or very severe COPD (GOLD Stages III and IV as per GOLD 2009 classification) receiving salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC) or via separate inhalers (Sal/FP) in addition to individual existing therapy in order to investigate the potential benefit of a fixed combination device as compared with two separate devices due to potentially improved patients' compliance. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We tried a critical combination therapy for management of COPD.METHODS: Current or past smoker (passive or active) COPD patients with moderate to severe COPD who did not respond to primitive therapy (i.e., oral prednisolone (50 mg in the morning) for 5 days; with Beclomethasone Fort (3 puff q12h, totally 1500 micrograms/day), Salmeterol (2 puffs q12h, 50 micrograms/puff) and ipratropium bromide (4 puffs q8h) for two months, enrolled to study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Several recent trials in chronic obstructive pulmonary disease (COPD) have assessed the effectiveness of the fluticasone-salmeterol combination inhaler in preventing COPD exacerbations, while finding an increased risk of pneumonia. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We describe the proper methods to calculate the NNT and, using data from published trials, apply them to evaluate the relative impact of fluticasone-salmeterol treatment on exacerbations and pneumonias in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: We show that a 1-year trial of the fluticasone-salmeterol combination versus salmeterol used the incorrect event-based approach to calculate the NNT as two patients that need to be treated for 1 year to prevent one COPD exacerbation, when the proper calculation results in a NNT of 14. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The objective of this study was to investigate the effect of tiotropium compared with salmeterol on exacerbations in patients with moderate (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) chronic obstructive pulmonary disease (COPD) and those na\u00efve to maintenance respiratory therapy in the 1-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD(\u00ae)) trial (NCT00563381). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The objective of this work was to characterize the dose-response relationship between two inhaled long-acting beta agonists (PF-00610355 and salmeterol) and the forced expiratory volume in one second (FEV1) in order to inform dosing recommendations for future clinical trials in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The aim of this study was to compare the effect of inhaled budesonide/formoterol with inhaled fluticasone/salmeterol in severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 \u03bcg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A total of 44 treatment-na\u00efve, elderly Japanese patients with moderate-to-severe COPD were treated with a transdermal tulobuterol patch (TP; 2 mg, once a day) or inhaled salmeterol (50 \u00b5g, twice a day) in a randomized crossover manner. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We performed a randomized, crossover clinical trial of two\u00a0\u00d7\u00a08 weeks comparing tiotropium (18\u00a0\u03bcg once daily)\u00a0+\u00a0salmeterol (50\u00a0\u03bcg twice daily) (T\u00a0+\u00a0S) to salmeterol\u00a0+\u00a0fluticasone (50/500\u00a0\u03bcg twice daily) (S\u00a0+\u00a0F) in COPD (forced expiratory volume in 1\u00a0s (FEV(1)) \u226465% predicted, and thoracic gas volume (TGV) \u2265120% predicted). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The objective of this study was to evaluate the comparative efficacy of indacaterol 75 \u03bcg once daily (OD), tiotropium 18 \u03bcg OD, salmeterol 50 \u03bcg twice daily (BID), formoterol 12 \u03bcg BID, and placebo for the treatment of chronic obstructive pulmonary disease (COPD) based on individual patient data (IPD) from randomized controlled trials (RCTs) from the indacaterol trial program and aggregate data (AD) identified from a systematic review of RCTs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The within-trial CEA, including 7,250 patients with moderate to very severe chronic obstructive pulmonary disease (COPD), was performed alongside the 1-yr international randomised controlled Prevention of Exacerbations with Tiotropium (POET)-COPD trial comparing tiotropium with salmeterol regarding the effect on exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Then, CBF was re-measured after 30 min perfusion with pharmacologic agents that modulate mediators implicated in COPD (salmeterol xinafoate, tiotropium bromide, licofelone, luteolin, YM976, Defensin HNP-1) and again after 30 min washout. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Bronchodilators - long-acting b2-adrenergic agonists (formoterol and salmeterol) and a long-acting antimuscarinic drug (tiotropium), are the main drugs applied in symptomatic treatment of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Beclomethasone/formoterol - 400/24 mcg/die, in comparison with fluticasone/salmeterol - 500/100 mcg/die significantly reduced air-trapping and dyspnea in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Treatment-na\u00efve patients with COPD (n = 36) were prospectively treated with two kinds of LABA--inhaled salmeterol and transdermal tulobuterol patch--for 12 weeks in crossover study, and changes in pulmonary function data and 6-minute walk distance (6 MWD) were compared between groups stratified by the CysGlyGln. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Our hypothesis was tested in 114 COPD patients (median age 62.9 years, smoking exposure 45.9 pack-yrs) participating in the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) study, which previously showed an improvement in BHR with fluticasone and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study was performed to see if the addition of GSK233705 to salmeterol would provide greater bronchodilation than salmeterol or tiotropium alone in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: The addition of GSK233705 to salmeterol in partially reversible COPD patients resulted in greater bronchodilation than salmeterol or tiotropium alone and was well tolerated. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In large, longer-term clinical studies (12 weeks to 1 year) in patients with moderate to severe COPD, once-daily indacaterol 150 or 300\u2009\u03bcg improved lung function (primary endpoint) significantly more than placebo, and improvements were significantly greater than twice-daily formoterol 12\u2009\u03bcg or salmeterol 50\u2009\u03bcg, and noninferior to once-daily tiotropium bromide 18\u2009\u03bcg (all agents were administered via inhalation). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "more effective with lower total costs) to once-daily tiotropium bromide 18\u2009\u03bcg and twice-daily salmeterol 50\u2009\u03bcg in the treatment of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: This retrospective cohort study compared the risks of exacerbations and COPD-related healthcare costs between patients with chronic obstructive pulmonary disease (COPD) initiating tiotropium (TIO) alone and patients initiating triple therapy with fluticasone-salmeterol combination (FSC) added to TIO. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Clinical trials have confirmed that tiotropium is superior to salmeterol in preventing COPD exacerbations in patients with moderate to very severe COPD with history of exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Both FM (10(-9) \u2003M) and salmeterol (SM, 10(-8) \u2003M) reversed Dex insensitivity in severe asthma, but only FM restored Dex sensitivity in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Ten COPD and 10 healthy subjects were treated with salmeterol or placebo 4\u00a0h before the patient's mechanical and diffusive lung properties were measured during four non consecutive days, just before and after a rapid saline infusion, or during a similar period without an infusion.RESULTS: In both COPD and healthy subjects, rapid saline infusion with placebo or salmeterol premedication lead to a significant decrease in diffusion capacity for carbon monoxide (DLCO) and forced expiratory volume in 1\u00a0s (FEV1). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol appears to provide a protective effect, not related to bronchodilation, against an acute alveolar fluid clearance challenge secondary to lung fluid overload in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: This study aimed to evaluate the onset of effect of single-dose formoterol 9\u2009\u03bcg versus single-dose salmeterol 50\u2009\u03bcg in patients with moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In this multicentre, double-blind, double-dummy, placebo-controlled, three-way single-dose crossover study, patients \u226540 years of age with moderate COPD were randomized to single-dose formoterol 9\u2009\u03bcg via Turbuhaler\u00ae plus placebo via Diskus\u00ae, single-dose salmeterol 50\u2009\u03bcg via Diskus\u00ae plus placebo via Turbuhaler\u00ae or placebo via Turbuhaler\u00ae and Diskus\u00ae (washout period 2-7 days). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: In COPD patients, formoterol 9\u2009\u03bcg has an onset of bronchodilatory effect that is more rapid than salmeterol 50\u2009\u03bcg based on FEV\u2081 at 5 minutes post-dose. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium bromide prevented exacerbations in patients with COPD, with a significantly lower exacerbation rate and a significantly longer time to first exacerbation seen with tiotropium bromide than with placebo or salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Although the addition of salmeterol/fluticasone propionate to tiotropium bromide did not reduce the COPD exacerbation rate, it did improve lung function and HR-QOL. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We examined the short-term additive bronchodilator effects of tiotropium in patients with stable COPD already treated with salmeterol twice daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "MATERIALS AND METHODS: In a double-blind, double-dummy randomized study we evaluated the acute bronchodilator efficacy of a single 18 \u00b5g dose of tiotropium in patients with COPD under chronic treatment with a long acting beta-adrenergic (salmeterol 50\u00b5g twice a day). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 \u00b5g/500 \u00b5g combination (SFC), or placebo in a 12-week, randomized, double-blind, double-dummy study (MKI102428/NCT00642148). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical symptoms in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Data were pooled from clinical studies of 3-12 months' duration in patients with moderate-to-severe COPD receiving double-blind indacaterol 75 \u03bcg (n = 449), 150 \u03bcg (n = 2611), 300 \u03bcg (n = 1157), or 600 \u03bcg once daily (n = 547); formoterol 12 \u03bcg twice daily (n = 556); salmeterol 50 \u03bcg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 \u03bcg once daily, given open label or blinded (n = 1214). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of tiotropium and fluticasone propionate/salmeterol (FSC) is commonly used to treat chronic obstructive pulmonary disease (COPD), but no study had evaluated the effectiveness of tiotropium plus FSC with 250\u00a0\u03bcg of fluticasone propionate. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To compare, in commercially-insured individuals 240 years old, the risk of chronic obstructive pulmonary disease (COPD) exacerbations and COPD-related health care utilization and costs in patients initiating maintenance treatment with fluticasone propionate/salmeterol xinafoate 250 microg/50 microg (FSC) with those in patients initiating treatment with tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PURPOSE: To compare adherence between patients with COPD initiating therapy on tiotropium or fluticasone/salmeterol and examine the association between adherence and respiratory-related costs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Patients with COPD initiating long-acting bronchodilator therapy were more likely to be adherent to tiotropium than to fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The evidence reviewed comprises four placebo-controlled clinical studies of indacaterol treatment, three of which included treatment arms with one of the other long-acting inhaled bronchodilators (once-daily tiotropium or twice-daily salmeterol or formoterol), in 4,833 patients with moderate-to-severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol significantly reduced COPD exacerbations with both study arms exposed or not exposed to inhaled corticosteroids (ICS). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Seventy-two patients with stable COPD treated with tiotropium (n = 41) or salmeterol (n = 31) were evaluated for pulmonary function, dynamic hyperinflation following metronome-paced incremental hyperventilation, six-minute walking distance, and St George's Respiratory Questionnaire (SGRQ) before and 2-3 months following treatment with tiotropium or salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVES: To quantify healthcare use and costs associated with chronic obstructive pulmonary disease (COPD) among patients discharged from a COPD-related hospitalization or emergency department (ED) visit on a regimen of fluticasone propionate-salmeterol combination versus other inhaled maintenance therapies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The adjusted rate of COPD-related hospitalizations or ED visits was 35% lower in the fluticasone propionate-salmeterol cohort (P <.05). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Adjusted COPD-related total (medical plus pharmacy) costs were lower in the fluticasone propionate-salmeterol cohort ($240 vs $279 per patient per month, P <.05), mostly because of lower medical costs ($113 vs $160 per patient per month, P <.05). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Initiation of fluticasone propionate-salmeterol after discharge from a COPD-related hospitalization or ED visit significantly reduced the risk of a recurrent event during the ensuing months and decreased COPD-related medical costs, without an increase in COPD-related pharmacy costs, in a real-world setting. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We investigated whether the anticholinergic drug tiotropium is superior to the \u03b2(2)-agonist salmeterol in preventing exacerbations of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 \u03bcg of tiotropium once daily with that of 50 \u03bcg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study was to identify the predictors of pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Wheezing history, pre-bronchodilator pulmonary function, bronchodilator responsiveness, and emphysema extent may be used for predicting the pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Relative costs and utilization-related outcomes of a fluticasone propionate 250 \u03bcg + salmeterol 50 \u03bcg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "COPD patients \u2265 35 years with at least one LABD claim between July 1, 2004 and June 30, 2006 were classified into five cohorts based on index LABD: monotherapy with tiotropium, salmeterol/fluticasone propionate, formoterol fumarate, or salmeterol or combination therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients treated with salmeterol/fluticasone propionate (p < 0.001), formoterol fumarate (p = 0.032), salmeterol (p = 0.004), or with combination therapy (p < 0.001) had higher COPD-related costs and a greater risk of inpatient admission (p < 0.01 for all) versus tiotropium. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a large population-based study in the United Kingdom, we estimated the association between fluticasone propionate/salmeterol fixed-dose combination (FSC) and other ICS use and nonvertebral fracture incidence among patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Inhaled long-acting \u03b22-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND AND OBJECTIVE: Although salmeterol/fluticasone propionate combination (SFC) therapy has been widely used for the treatment of COPD, the relationship between airway dimensions and improvement in pulmonary function remains unknown. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We examined the effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on the management of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Use of salmeterol in symptomatic moderate COPD cases has increased FEV(1) and slowed down annual functional progression. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium is US Food and Drug Administration (FDA) approved to treat bronchospasm and reduce exacerbations in patients with COPD; salmeterol/fluticasone is FDA approved to treat airflow obstruction in COPD and reduce exacerbations in patients with a history of exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Other maintenance long-acting bronchodilators-salmeterol, formoterol, and budesonide/formoterol-are FDA approved to treat airway obstruction in COPD but lack an approved indication against exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: this study compared the onset of action of single doses of indacaterol 150 and 300 \u03bcg with salbutamol 200 \u03bcg, salmeterol-fluticasone 50/500 \u03bcg, and placebo in moderate-to-severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A total of 1,481 women and 4,631 men with COPD were enrolled in TORCH, a trial comparing salmeterol, 50 \u03bcg, plus fluticasone propionate, 500 \u03bcg, twice a day and each component individually. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients with COPD (n = 1074) enrolled in a regional managed care system in the US were identified using administrative data and divided by their medication use into three groups (salbutamol, ipratropium and salmeterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To estimate the cost-effectiveness of fluticasone propionate-salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We performed an economic analysis of pooled data from two randomized clinical trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 microg twice daily) or salmeterol (50 microg twice daily) on exacerbation rates in patients with severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Total adjusted annual COPD related exacerbation and therapeutic costs were $4,842 (95% CI; $4,731-$4,952) in the FSC group and $5,066 (95% CI; $4,937-$5,195) in the salmeterol group. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: FSC combination therapy is associated with reduced risk of any exacerbation and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs compared to treatment with salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We investigated predictive factors for response to fluticasone propionate/salmeterol (FSC) in severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients with moderate-to-severe COPD were randomised to 6 months double-blind treatment with indacaterol (150 \u03bcg once daily), salmeterol (50 \u03bcg twice daily) or placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "It also improved lung function and reduced exacerbations in patients with moderately severe COPD treated with salmeterol or tiotropium. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this post hoc analysis, data from the TOwards a Revolution in COPD Health (TORCH) study were used to investigate whether use of the long-acting beta(2) agonist salmeterol over 3 years increased the risk of cardiovascular adverse events in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Post hoc analysis of the 3-year TORCH dataset showed that salmeterol alone or in combination (SFC) did not increase the risk of cardiovascular events in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium, a long-acting anticholinergic, and salmeterol/fluticasone, a long-acting \u03b2-agonist/inhaled corticosteroid combination, are Food and Drug Administration-approved maintenance therapies to reduce exacerbations of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Here we compared the 24-h spirometry profile of once daily indacaterol 300 \u03bcg with that of placebo and twice daily salmeterol 50 \u03bcg in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients (male/female \u2265 40 years) with moderate-to-severe COPD were randomized to receive double-blind indacaterol 300 \u03bcg or placebo once daily, or open-label salmeterol 50 \u03bcg twice daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In chronic respiratory diseases in general, and chronic obstructive pulmonary disease (COPD) in particular, adherence to inhaled therapy can potentially influence disease prognosis, as demonstrated in the analyses discussed in this article and a 3-year study assessing the effects of inhaled salmeterol, inhaled fluticasone and an inhaled combination over placebo in patients with moderate-to-severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A fixed-dose dry powder combination inhaler, Seretide/Advair, containing salmeterol and fluticasone, is licensed in the European Community for the treatment of moderate to severe COPD in the strength of 50/500 microg twice daily (BID). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To assess the cost-effectiveness of 3 treatments (tiotropium, salmeterol, and no treatment) in patients with moderate chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, in patients with moderate COPD, tiotropium is more cost-effective than salmeterol and no treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered via combination inhalers with the respective long-acting beta2-agonists, formoterol and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Following a run-in period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of budesonide/formoterol (400/12 microg) and salmeterol/fluticasone (50/500 microg), separated by a 4-14-day washout period. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The study aims to compare healthcare resource utilization associated with hospitalization or emergency department (ED) visits between FDA-approved inhaled corticosteroid/long-acting beta-agonist combinations [fluticasone propionate 250 microg/salmeterol 50 microg combination (FSC)] and anticholinergic treatments (ATC) in managed-care Medicare beneficiaries with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a randomised, double-blind, multicentre, cross-over study, 442 patients with COPD aged >or=40 years (pre-bronchodilator FEV(1) <or=50%; FEV(1)/vital capacity <70%) received budesonide/formoterol (320/9 microg, one inhalation twice daily) dry powder inhaler (DPI) or salmeterol/fluticasone (50/500 microg, one inhalation twice daily) DPI daily, for 1 week each, separated by a 1- to 2-week washout. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with budesonide/formoterol DPI or salmeterol/fluticasone DPI was effective in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 microg or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "INTERPRETATION: Roflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In a randomized, double-blind, placebo-controlled, crossover study of moderate/severe stable COPD patients, we compared the effects of 4 weeks of treatment with salmeterol 50 microg b.d. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Compared with control (placebo or salmeterol), tiotropium did not significantly increase the risk of adverse major cardiovascular events among COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 microg, fluticasone propionate (FP) 500 microg, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "STUDY DESIGN: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The safety of arformoterol (50 microg QD), and salmeterol (42 microg BID), was assessed over 12 months in subjects with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Subjects with COPD (mean FEV1 1.2 L, ~41% predicted) were enrolled in the study and randomized to receive nebulized arformoterol 50 microg QD (n = 528) or salmeterol 42 microg BID (MDI; n = 265) in a prospective, multicenter, open-label, 12-month trial. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The frequency of COPD exacerbations did not increase over 12 months for arformoterol and salmeterol (weeks 0-13: 15.7% and 11.7%, respectively; weeks 39-52: 10.0% and 9.4%, respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: In this trial, both arformoterol 50 microg QD and salmeterol 42 microg BID were well tolerated in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To observe the efficacy of combination therapy with inhaled salmeterol/fluticasone and tiotropium in reducing the frequency of acute episodes of symptom exacerbation and improving lung function and health status in chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: One hundred and twenty-six patients (M/F: 92/34) with COPD were treated in a randomised, parallel-group, controlled study with salmeterol/fluticasone (50/250 microg) twice daily and tiotropium 18 microg once daily (n = 33, M/F: 23/10); salmeterol/fluticasone (50/250 microg) twice daily (n = 32, M/F: 24/8); or tiotropium 18 microg once daily (n = 32, M/F: 23/9) for 12 months. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Combination therapy with salmeterol/fluticasone and tiotropium leads to better control of symptoms and improved lung function, with no greater risk of side-effects, as compared to salmeterol/fluticasone or tiotropium alone in the treatment of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Bronchodilators are the foundation of treatment for COPD, and the long-acting beta2-agonists formoterol and salmeterol are both indicated for regular use by patients with stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The purpose of this study was to examine the duration of bronchodilation induced by the long-acting beta2-agonist salmeterol administered with an MDI and a spacer in a group of mechanically ventilated patients with exacerbation of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Ten mechanically ventilated patients with acute exacerbation of COPD received four puffs of salmeterol (25 microg/puff). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: It is concluded that four puffs of salmeterol delivered with an MDI and a spacer device induces significant bronchodilation in mechanically ventilated patients with COPD exacerbation, the duration of which is highly variable, precluding definite conclusions in regard to optimum dosing schedules. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Searches used the following terms: COPD, long-acting beta(2)-agonists, long-acting anticholinergics, combination therapy, pharmacoeconomics, safety, tiotropium, salmeterol, and formoterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The objectives of this retrospective study were to compare the effects of fluticasone propionate 500 microg/salmeterol 50 microg (FSC 500/50) with those of ipratropium (IPR) in older adult patients with COPD on the following factors: (1) the risk of all-cause and COPD-related hospitalization and emergency department (ED) visits; and (2) all-cause and COPD-related treatment costs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study determined the cost effectiveness of adding salmeterol (S) or fluticasone/salmeterol (FS) to tiotropium (T) for COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effects of initial maintenance therapy with fluticasone 250 microgram plus salmeterol 50 microgram in a single inhaler versus other inhaled medications on exacerbation risks and treatment costs among chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients age 40 years or older with a primary diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification code 490, 491, 492, or 496), at least 18 months of continuous eligibility, and an index prescription for fluticasone/salmeterol combination, salmeterol alone, inhaled corticosteroid alone, ipratropium/albuterol combination, or ipratropium alone (reference) were identified. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "An increased risk of pneumonia with inhaled corticosteroids was first reported from the Toward Revolution in COPD Health (TORCH) study, a large randomized clinical trial comparing fluticasone, salmeterol, or a combination of the two medications with placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Within the different studies, questionnaires including the George's Respiratory Questionnaire (SGRQ) the Chronic Respiratory Disease Questionnaire (CRDQ) and the Clinical COPD Questionnaire (CCQ) were used and differing results in quality of life were obtained when combination therapies such as fluticasone/salmeterol or fluticasone/salmeterol were compared with monotherapies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but there are few data on their effectiveness when used together. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To review the pharmacoeconomic impact of the fixed-dose combination of inhaled fluticasone and salmeterol in asthma and COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "For COPD, a clear reduction in exacerbation rates and improvement in quality of life has been demonstrated with salmeterol/fluticasone along with a likely improvement in survival rates. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: The data currently available suggest that the cost effectiveness of combination therapy with fluticasone and salmeterol is favourable for asthma and COPD in a variety of clinical settings. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of the present study was to evaluate, in patients with COPD, the responsiveness of the ESWT in detecting improvement in walking performance after a single dose of salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a randomised, double-blind, placebo-controlled crossover trial, 20 patients with COPD performed two ESWT at 80% of peak capacity 2.5 h after inhaling either a placebo or 50 microg of salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Relevant publications were identified through a search of MEDLINE (1995-May 2007) using the terms COPD, guidelines, treatment, maintenance therapy, bronchodilator, ipratropium, tiotropium, beta-agonist, salmeterol, and inhaled corticosteroid. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The overall efficacy of formoterol in improving lung function and controlling symptoms of chronic obstructive pulmonary disease (COPD) is comparable to that of salmeterol and potentially superior to that of ipratropium or theophylline. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Results of the INSPIRE trial suggest that salmeterol/fluticasone propionate is associated with a significantly lower mortality rate than tiotropium bromide monotherapy in patients with COPD; the two treatments had similar effects in terms of exacerbation rates and lung function. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: We compared the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 microg twice daily and the long-acting bronchodilator (tiotropium) 18 microg once daily in preventing exacerbations and related outcomes in severe and very severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we let patients with COPD hyperventilate to evoke hyperinflation, and evaluated the effects of tiotropium alone or in combination with salmeterol on hyperventilation-evoked hyperinflation. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The study population was a historical cohort of Texas Medicaid beneficiaries aged 40 to 64 years with COPD-related medical costs (International Classification of Diseases, Ninth Revision, Clinical Modification codes 491.xx, 492.xx, 496.xx), 24 months of continuous Medicaid enrollment (12 months before and after the index prescription), and at least 1 prescription claim (index) for a combination product containing fluticasone propionate + salmeterol, an inhaled corticosteroid, salmeterol, or ipratropium between April 1, 2001, and March 31, 2003. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The TORCH (Towards a Revolution in COPD Health) study confirmed that the effects of combined therapy with salmeterol/fluticasone propionate are greater than the monocomponents. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This review critically appraises the pharmacology of salmeterol/fluticasone propionate, the evidence for efficacy in COPD and its potential use in combination with other drugs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A study was therefore undertaken to evaluate combined salmeterol/fluticasone propionate (SFC) and fluticasone propionate (FP) alone on inflammatory cells in the airways of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All patients who were diagnosed with COPD between September 1, 2000 and August 31, 2001 and who had at least 3 months treatment with either a combined fluticasone/salmeterol inhaler (FSI, N=866), any ICS used with a LABA (ICS/LABA, N=525), ICS alone (N=742), LABA alone (N=531), or a short-acting bronchodilator alone (SABD, N=1832), were included. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Male and female patients aged >or=35 years with physician-diagnosed COPD received arformoterol (15 microg BID, 25 microg BID, or 50 microg QD via nebulizer), salmeterol (42 microg BID via metered dose inhaler), or placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The only major pharmacological advancement for the treatment of these diseases has been to increase the duration of action of bronchodilators (asthma: salmeterol; COPD: tiotropium bromide) and glucocorticosteroids (asthma: fluticasone propionate) and, increasingly, to formulate these agents in the same delivery device. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " In a three-way crossover pilot study, the acute effects of tiotropium 18 microg inhalation on the respiratory function and arterial blood gas tensions of 30 patients with stable chronic obstructive pulmonary disease (COPD) were compared with those of salmeterol 50 microg and formoterol 12 microg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Our objective was to assess the 5-year cost effectiveness of bronchodilator therapy with tiotropium, salmeterol or ipratropium for chronic obstructive pulmonary disease (COPD) from the perspective of the Spanish National Health System (NHS). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A large multicenter prospective randomized trial (Towards a Revolution in COPD Health [TORCH]) is now ongoing and will examine the effect of fluticasone propionate in combination with salmeterol on all-cause mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To determine whether combining tiotropium with salmeterol or fluticasone-salmeterol improves clinical outcomes in adults with moderate to severe COPD compared with tiotropium alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium plus fluticasone-salmeterol improved lung function (P = 0.049) and disease-specific quality of life (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [CI, 0.33 to 0.86]) and all-cause hospitalizations (incidence rate ratio, 0.67 [CI, 0.45 to 0.99]) compared with tiotropium plus placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Addition of fluticasone-salmeterol to tiotropium therapy did not statistically influence rates of COPD exacerbation but did improve lung function, quality of life, and hospitalization rates in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i.e. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: FEV1% predicted increased 2.6% (SD 8.3) in fluticasone/salmeterol- and 0.01% (SD 6.6) in fluticasone-treated patients (overall: P=0.036, asthma: P=0.025 and COPD: P=0.700). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Fluticasone/salmeterol-treated asthma patients had 1.1 more symptom-free days per week (P=0.044); no such effect was observed for COPD (P=0.769). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Several studies have demonstrated that long-acting beta2-agonists such as salmeterol are beneficial in chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A meta-analysis was therefore conducted to review studies in COPD to provide pooled estimates of the effect of salmeterol 50 mcg taken twice daily in addition to usual therapy on several clinically relevant endpoints, when compared with placebo/usual therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: An extensive search of literature and clinical trial databases was conducted using the terms salmeterol, COPD, chronic, obstructive, bronchitis and emphysema. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Nine randomized, double-blind, parallel-group, placebo-controlled trials of > or =12 week duration with salmeterol 50 mcg bid treatment in COPD were included (>3500 patients), with a further 14 trials excluded due to study design or reporting timelines. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "the combination of salmeterol 50 microg plus fluticasone 250 microg twice daily (n=51) in patients with moderate-to-very severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Six weeks of treatment with tiotropium resulted in comparable bronchodilation compared with salmeterol plus fluticasone in patients with moderate-to-very severe COPD, despite tiotropium patients having lower lung function and fewer patients considered reversible at baseline. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the impact of combination therapy with salmeterol/fluticasone propionate compared with salmeterol alone on moderate and severe exacerbations in patients with severe COPD and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: This study demonstrates that combination therapy with salmeterol/fluticasone compared with salmeterol monotherapy significantly reduces the frequency of moderate/severe exacerbations in patients with severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Treatment with inhaled fluticasone and salmeterol significantly suppressed eosinophilic inflammation in COPD patients with sputum eosinophilia (mean 8.9% +/- 2.0% vs. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In an open-label study at 38 outpatient centres, patients > or =12 years old with asthma or chronic obstructive pulmonary disease (COPD) received two actuations of fluticasone propionate/salmeterol 125/25 microg (115/21 microg ex-actuator) hydrofluoroalkane (ADVAIR) HFA) via MDI with counter twice a day until all 120 actuations were completed. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Several short-term follow-up trials have also suggested a reduction in mortality with a combination of long-acting beta(2)-agonist and inhaled corticosteroids, and a large, long-term study that is currently ongoing (the Toward a Revolution in COPD Health [TORCH] study) will provide data on the effects of fluticasone propionate and salmeterol in combination on all-cause mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Confirmation or refutation of this result may be achieved once the Towards a Revolution in COPD Health (TORCH) study reports, a large randomized controlled trial powered to detect mortality changes associated with the use of FP alone, or in combination with salmeterol, which is also collecting resource use and utility data suitable for estimating cost-effectiveness. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "AUTHORS' CONCLUSIONS: The available data from the trials suggest that there is little difference between regular long term use of IpB alone and salmeterol if the aim is to improve COPD symptoms and exercise tolerance. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "SELECTION CRITERIA: All RCTs comparing inhaled LABAs (salmeterol or formoterol) with placebo in the treatment of patients with stable, poorly reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "AUTHORS' CONCLUSIONS: This review shows that the treatment of patients with COPD with salmeterol 50 mcg produces modest increases in lung function. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, the aim of this study was to investigate the effects of the low molecular weight heparin, enoxaparin (ENX), as an add-on therapy for a period of 12 weeks, to inhaled salmeterol/fluticasone propionate (SLM/FP) combination in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium produces superior bronchodilation, improvements in dyspnea, health related quality of life compared to ipratropium and salmeterol in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We have investigated the acute effects of salmeterol and formoterol on echocardiographic systolic pulmonary artery pressure (sPAP) in 20 patients with COPD and a sPAP greater than 20mmHg at rest. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study demonstrated that salmeterol and formoterol were equally beneficial for pulmonary haemodynamics in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: This study investigated the addition of salmeterol to existing treatment for exacerbations in patients with poorly reversible chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: 634 patients aged >40 years with a history of COPD exacerbations (including at least two in the previous year) and poor reversibility of airflow obstruction (< or =10% predicted forced expiratory volume in 1 second) received either salmeterol 50 mug or placebo twice daily from a Diskus inhaler for 12 months. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Salmeterol has a positive effect on symptoms and health status of patients with COPD when added to usual treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The results show a drop in COPD exacerbations in comparison to Ipratropium, Salmeterol and standard care (without use of anticholinergics and beta-adrenergics). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The possibility that individual chronic obstructive pulmonary disease (COPD) patients respond better to either tiotropium or salmeterol has been suggested and an acute bronchodilator test might help to guide the choice of therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: We explored the responses to tiotropium and salmeterol within the first 3 h using the recommended dosages (18 microg for tiotropium and 50 microg for salmeterol) in order to verify whether there are differences in the short-term bronchodilator effects between these two long-acting bronchodilators in patients with stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: These data clearly show that the bronchodilator effects of tiotropium and salmeterol within the first hours after their acute administration are similar in patients with stable COPD when they are evaluated as mean changes from baseline in FEV1. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Randomized, double-blind, double-dummy, parallel-group study, comparing daytime bronchodilator efficacy of tiotropium 18 mcg once daily with salmeterol 50 mcg twice daily in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol/fluticasone improves FEV1% in mild and moderate more than in severe COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To develop a Markov model that allows the cost effectiveness of interventions in patients with chronic obstructive pulmonary disease (COPD) to be estimated, and to apply the model to investigate the cost effectiveness of an inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist (beta(2)-agonist) combination (salmeterol/fluticasone propionate) versus usual care. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Efficacy data for the combination of inhaled salmeterol/fluticasone propionate 50/500microg twice daily in poorly reversible COPD patients with a history of exacerbations were obtained from the 1-year TRISTAN (TRial of Inhaled STeroids ANd long-acting beta-agonists) study and applied to the model, based on patient profiles representative of COPD clinical trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Initial evidence suggests that for patients with poorly reversible COPD and a documented history of frequent COPD exacerbations, the addition of salmeterol (a long-acting beta(2)-agonist) to fluticasone propionate (an inhaled corticosteroid) is potentially cost effective from the Canadian healthcare payer's perspective. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 microg FP + 50 microg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: For COPD patients, treatment with tiotropium leads to a greater reduction in exacerbations (37% compared to ipratropium and 25% compared to salmeterol 25%), and a reduction in the number of days in hospital (33% compared to ipratropium and 14% compared to salmeterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Eligible patients were aged 40 to 65 years, had a primary or secondary diagnosis of COPD, and had >/=1 prescription for ipratropium (IPR), inhaled corticosteroids (ICS), or salmeterol (SAL) between January 1, 1998, and August 31, 2000. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVES: The development of a probabilistic Markov model with a time horizon of 1 year to compare the cost-effectiveness of three bronchodilators: 1) the new long-acting anticholinergic tiotropium; 2) the short-acting anticholinergic ipratropium; and 3) the long-acting beta 2-agonist salmeterol, for the treatment of patients with chronic obstructive pulmonary disease (COPD) in different countries. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of the present trial was to determine whether the combination of salmeterol and tiotropium improved lung function in COPD patients more than either of them alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In terms of improvement in lung function, the combination of salmeterol and tiotropium together with fluticasone is more effective in patients with moderate-to-severe COPD than either of the 2 bronchodilators administered alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RECENT FINDINGS: Results of recent clinical trials suggest that a long-acting inhaled bronchodilator, either once-daily tiotropium or twice-daily salmeterol or formoterol, has advantages over a regularly-scheduled short-acting anticholinergic inhaled bronchodilator (ipratropium) as initial maintenance therapy in patients with at least moderate, stable, symptomatic COPD (forced expired volume in 1 second </= 60-70% predicted; mean, approximately 37-45% predicted). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study was to assess the short term efficacy and safety of 50 and 100 microg bid inhaled salmeterol, compared with placebo and orally dose titrated slow-release theophylline in patients with stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: Inhaled salmeterol at both tested doses was better than placebo in improving lung function (FEV1, FVC, and morning PEF) of stable patients with moderate COPD over a period of 2 weeks. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled salmeterol improves lung function in stable patients with moderate-to-severe and poorly reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "It is concluded that salmeterol is an effective and well tolerated therapy, potentially preferable to theophylline, at least in the short-term management of stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The aim of this study was to compare the effects of 6 months therapy with salmeterol or ipratropium bromide on lung function (resting and dynamic parameters), exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The study will randomize 432 patients with moderate to severe COPD to one of three parallel treatment arms for 52 weeks: tiotropium and fluticasone/salmeterol; tiotropium and salmeterol; or tiotropium and placebo inhaler. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Previous studies have demonstrated that the LABA, salmeterol, improves lung function, symptoms and quality of life in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we have performed additional analyses of the combined data from two previous double-blind, placebo-controlled, parallel studies of salmeterol (50 microg, b.i.d) in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a sensitivity analysis, we compared 539 male and 180 female COPD patients, who were randomized to the saLmeterol/fluticasone combination 50/500mcg bid or placebo for 12 months. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In patients with COPD, both salmeterol and formoterol offer improved lung function and reduced COPD symptoms compared with placebo, and quality of life has been improved in some studies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol 50 microg twice daily and formoterol 12 microg twice daily are effective and safe in treating patients with asthma and COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The long acting beta2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: In terms of clinical outcomes and safety, we could not find convincing evidence that salmeterol and formoterol have demonstrated advantages to ipratropium, a less expensive drug, for patients with stable COPD and poor reversibility. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The \"TOwards a Revolution in COPD Health\" (TORCH) survival study is aiming to determine the impact of salmeterol/fluticasone propionate (SFC) combination and the individual components on the survival of COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the US, twice-daily salmeterol/fluticasone propionate 50/250 microg is approved for use in adults with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and in the EU, the twice-daily 50/500 microg dosage is approved for use in patients with severe COPD, repeat exacerbations and significant symptoms despite bronchodilator therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In patients with moderate-to-severe COPD, twice-daily inhaled salmeterol/fluticasone propionate 50/250 or 50/500 microg for 24-52 weeks improves predose forced expiratory volume in 1 second (FEV1) significantly more than salmeterol monotherapy, improves postdose or postbronchodilator FEV1 significantly more than fluticasone propionate monotherapy and results in clinically significant improvements in health-related quality of life. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol/fluticasone propionate 50/500 microg significantly reduced annual COPD exacerbations, especially in severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Some corticosteroid-related adverse events were increased in recipients of fluticasone propionate with or without salmeterol versus salmeterol monotherapy or placebo; withdrawal from fluticasone propionate, including combination therapy, needs careful management to minimise COPD exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a randomised double-blind crossover study, 23 patients with COPD (mean +/- SEM forced expiratory volume in one second 42 +/- 3% of the predicted value) inhaled salmeterol 50 microg or placebo twice daily for 2 weeks each. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Sixteen patients with \"irreversible\" COPD (<10% improvement in FEV(1) following a bronchodilator challenge; mean FEV(1) 31.1% predicted) were recruited into a randomised, double blind, placebo controlled, crossover study of salmeterol (50 micro g twice a day). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study we compared the effect of formoterol (Foradil, Aerolizer) and salmeterol (Serevent, Diskus) in terms of IC in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Both formoterol and salmeterol increase IC in patients with COPD, with formoterol 12 microg showing a significantly greater increase in IC over the first hour post-dose than salmeterol 50 microg, consistent with a more rapid onset of action. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: The aim of this study was to compare the relative efficacy in terms of improvement in symptoms and lung function of salmeterol/fluticasone propionate (SLM/FP) combination administered through the Diskus inhaler versus theophylline (THEO) added to FP Diskus in patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "There have been no direct clinical outcome studies comparing formoterol and salmeterol, but both have shown some benefits over ipratropium and theophylline in improving the symptoms, spirometric indices, exacerbations, and quality of life of patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV(1) and symptoms in the long-term.AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, formoterol and salmeterol, may be effective in acute exacerbations of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a retrospective analysis of a cohort of 997 COPD patients who received tiotropium, salmeterol or placebo, in addition to usual care, the validity and pattern of response of the BDI and TDI were examined. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a recent large scale comparative study over 6 months, tiotropium has been shown to cause superior bronchodilation and symptomatic improvement when compared to twice daily salmeterol in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Formoterol, salmeterol and oxitropium have been recommended for maintenance therapy in COPD patients, but their effect on DH has only been assessed for salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of the present study was to compare the acute effect of four inhaled bronchodilators (salbutamol, formoterol, salmeterol and oxitropium) and placebo on forced expiratory volume in one second, inspiratory capacity, forced vital capacity and dyspnoea in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients with smoking-related COPD were required to complete a 2-week baseline period before being randomized to one of three treatment groups; sibenadet (500 microg three times daily) plus placebo (twice daily); salmeterol (50 microg twice daily) plus placebo (three times daily); placebo (twice daily) plus a second placebo (three times daily). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Total healthcare costs were increased in the salmeterol group, but hospital and GP visit costs and concurrent COPD medication costs were lower. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Addition of salmeterol to COPD patients' current therapy improved lung function, health status at the expense of a modest increase in costs compared with usual therapy. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study, we compared the acute effects of higher than customary doses of salmeterol and salbutamol in 20 patients with acute exacerbation of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "These data indicate that salmeterol is effective and safe in the treatment of acute exacerbation of COPD and support its use in this clinical condition. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Observational data may provide an insight into the expected survival in clinical trials of fluticasone propionate (FP) and salmeterol in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Three-year survival in 1,045 COPD patients treated with FP and salmeterol was compared with that in 3,620 COPD patients who regularly used other bronchodilators but not inhaled corticosteroids or long-acting beta2-agonists. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: Salmeterol has been shown a useful drug for the treatment of chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "SELECTION CRITERIA: All RCTs over four weeks in duration comparing treatment with long-acting beta-2 adrenoceptor agonists (salmeterol or formoterol) with placebo in patients with stable poorly-reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All eight assessed the efficacy of salmeterol in COPD compared to placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In this study we have explored the effects on respiratory function of an additive dose of salmeterol Diskus in 15 chronic obstructive pulmonary disease (COPD) patients in regular treatment with a conventional dose of 50 microg salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: To compare the effect of adding salmeterol (50 microg bid) or placebo to concurrent anticholinergic therapy on symptom scores, quality of life, prebronchodilator lung function and exacerbations in patients with moderately severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the salmeterol group, fewer patients had exacerbations of COPD, and there was a trend toward an improved quality of life. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol has a beneficial effect when added to existing anticholinergic therapy in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In patients with chronic obstructive pulmonary disease (COPD), tiotropium 18microg once daily significantly improved lung function compared with placebo and ipratropium 40microg four times daily in 1-year trials or salmeterol 50microg twice daily in a 6-month study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Formoterol is associated with a faster onset of bronchodilation than salmeterol in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol has been shown to be an effective first-line bronchodilator in COPD and fluticasone has been shown to reduce the frequency and or severity of exacerbations in COPD patients in two key trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Sixteen patients with moderate to severe chronic obstructive pulmonary disease (COPD) and 10 non-smoker asthmatic patients received 40 mg of oral zafirlukast, 50 microg of inhaled salmeterol, 50 microg of inhaled salmeterol plus 40 mg of oral zafirlukast of placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: In both asthmatic and COPD patients, the overall effect of salmeterol and zafirlukast on the forced expiratory volume in 1 s (FEV1) was considered extremely significant (p < 0.0001), with a maximum bronchodilation above baseline after 180 min (20.7 and 11.0%, respectively) in asthmatics and after 2 h (21.7 and 11.2%, respectively) in COPD subjects. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Zafirlukast did not produce any further significant acute bronchodilation in addition to that achieved with salmeterol alone in either asthmatic or COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Nevertheless, 7 out of 16 COPD patients and 7 out of 10 asthmatic patients had a further improvement after the combination of salmeterol and zafirlukast. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The mean difference in pre- and post-salbutamol FEV1 values in both asthmatic and COPD patients after zafirlukast was significant (p < 0.05), but that after salmeterol and the combination of the two drugs was not significant (p > 0.05). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Both salmeterol and zafirlukast induced a significant increase in FEV1, although salmeterol elicited a greater improvement in both asthmatic and COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Apparently, zafirlukast at the clinically recommended dose did not produce any further significant acute bronchodilation in addition to that achieved with salmeterol alone, either in asthma or COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The hypothesis of the study was that salmeterol and ipratropium would have similar dyspnoea ratings during steady-state cycle ergometry at 1 h, but that salmeterol would reduce dyspnoea at 6 h after administration in patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The time to first COPD exacerbation was significantly longer during 12 weeks of treatment with inhaled salmeterol 50 microg twice daily than ipratropium bromide 40 microg 4 times daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Compared with placebo, inhaled salmeterol 50 microg twice daily alone, or concurrent with ipratropium bromide 40 microg 4 times daily improved lung function and reduced symptoms in patients with stable COPD in a 12-week, randomised, double-blind study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Inhaled salmeterol 50 microg twice daily plus oral theophylline had additive effects on lung function, increased the proportion of symptom-free days and decreased requirements for as-needed salbutamol compared with either agent alone according to a pooled analysis of 2 multicentre, randomised, double-blind studies.CONCLUSION: When used at the optimal dosage, 50 microg twice daily, salmeterol provides symptomatic relief and improves lung function and health-related quality of life in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those \"unresponsive\" to albuterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "formoterol, salmeterol) are a new interesting therapeutic option for patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the short term, both salmeterol and formoterol appear to be more effective than short-acting beta2 agonists, and in patients with stable COPD they are more effective than anticholinergic agents and theophylline. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "However, adverse cardiac events might occur in patients with COPD with pre-existing cardiac arrhythmias and hypoxaemia if they use long-acting 12 agonists, although the recommended single dose of salmeterol 50 microg or formoterol 12 microg ensures a relatively higher safety margin than formoterol 24 microg. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Moreover, pre-treatment with a conventional dose of formoterol or salmeterol does not preclude the possibility of inducing further bronchodilation with salbutamol in patients with partially reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A prospective, open, multi-centre study was performed to evaluate the efficacy and safety of inhaled salmeterol (50 micrograms BID) over a mean treatment period of 29 months (range: 4-1145 days) in 634 patients (54% male, age 45 +/- 15 years) with mild to moderate asthma or chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "SELECTION CRITERIA: All randomised controlled trials over four weeks in duration comparing treatment with long-acting beta2-adrenoceptor agonists (salmeterol and formoterol) with placebo in patients with stable non-reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All four RCTs assessed the efficacy of salmeterol in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Neither dose of salmeterol influenced the incidence of COPD exacerbations, (50 mcg: Peto Odds Ratio = 0.74, 95% CI: 0.47, 1.15) and (100 mcg: Peto Odds Ratio = 0.98, 95% CI: 0.64, 1.52). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "No clear answer exists about whether new, long-acting beta-agonists, such as salmeterol, should supplant anticholinergic agents as \"first-line\" therapy in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Thirty patients of stable chronic obstructive pulmonary disease (COPD) were studied for evaluation of effectiveness of inhaled salmeterol in a double blind, randomised, placebo controlled trial for seven days. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The study concluded that salmeterol 50 micrograms twice a day is effective in improving lung functions in patients with stable COPD and can be recommended as maintenance therapy for stable COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: An earlier study documented that, in patients with chronic obstructive pulmonary disease (COPD), addition of ipratropium bromide at the clinically recommended dose (40 microg) does not produce any further bronchodilation than that achieved with salmeterol 50 microg alone. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "A study was undertaken to examine the possible acute effects of higher than conventional doses of an anticholinergic agent on the single dose salmeterol induced bronchodilation in patients with stable and partially reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " A 1-yr multicentre two-tailed randomized open study was conducted in 15 centres in Italy, with the aim of comparing the clinical efficacy (over 3 months) and tolerability (over 1 yr) of salmeterol with those of oral theophylline in patients with reversible chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients with reversible COPD (forced expiratory volume in one second (FEV1) 50-80%, FEV1 after bronchodilator > 12%, n = 138) were randomized to receive salmeterol powder (50 micrograms b.i.d. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: One hundred and forty four patients with moderate or severe COPD were randomly assigned to receive three months of treatment with either salmeterol, salmeterol + ipratropium bromide, or placebo. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: In this study, we aimed to compare the onset and the duration of action of a single inhalation of formoterol and salmeterol in COPD patients having partially reversible airway obstruction. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3+/-5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV(1)) 19.3+/-3.1%] were evaluated after inhalation of 12 microg formoterol and 50 microg salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: In conclusion, this study revealed that a single dose of 12 microg formoterol and 50 microg salmeterol provided comparable bronchodilation within 12 h and had tolerable side effects in patients with mild to severe COPD having partially reversible airway obstruction. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: There is now good evidence that inhaled salmeterol is an effective agent in chronic obstructive pulmonary disease (COPD),but, at the present time, data on the effects of bambuterol, which is an oral tarbutaline pro-drug, in patients with COPD are scarce. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The objective of this research was, consequently, to compare the efficacy and safety of 20 mg oral bambuterol and 50 microg inhaled salmeterol in patients with partially reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: The speed and length of bronchodilation with 20 mg bambuterol and 50 microg inhaled salmeterol were compared in 16 patients with partially reversible COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Both oral bambuterol and inhaled salmeterol resulted in good bronchodilation in patients with stable COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " To compare the effects of salmeterol, an adrenergic drug, and ipratropium bromide, an anticholinergic drug, on breathlessness and gas exchange during exercise in patients with chronic obstructive lung disease (COPD), we performed a progressive treadmill exercise test on 15 patients on 3 days (24 h apart), after inhalation placebo, ipratropium bromide (120 micrograms) or salmeterol (50 micrograms) in a randomized fashion. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We conclude that the salmeterol, when given in conventional doses, produces significant improvement in the airway obstruction in the recovery of postexercise HbO2 desaturation and in dyspnoeic sensation in patients with COPD, effects which were similar to those observed after inhalation of the anticholinergic agent ipratropium bromide. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "These data suggest that inhaled salmeterol 50 microg BID was more effective and better tolerated than oral, titrated theophylline and allowed better long-term control of airways obstruction and symptoms with improved lung function in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "These findings clearly demonstrate that many patients suffering from stable COPD show early reversibility to a short-acting beta 2-agonist and patients who do not manifest early reversibility to salbutamol can still benefit from salbutamol or salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " We examined whether a pretreatment with formoterol, oxitropium bromide, or salmeterol might modify the dose-response curves to inhaled salbutamol in patients with stable and partially reversible chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Sixteen outpatients with partially reversible, stable COPD received 24 microg formoterol, 50 microg salmeterol, 200 microg oxitropium bromide, or placebo on four non-consecutive days. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the present study, the time course of inhaled oxitropium bromide bronchodilation in comparison to that of inhaled salmeterol in a group of patients with partially reversible COPD was evaluated. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The objectives of this study were to compare the efficacy and safety of salmeterol xinafoate (50 and 100 microg b.i.d.) with that of placebo, when added to existing therapy, in the treatment of patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Changes in health-related quality of life (HRQoL) were evaluated in patients with chronic obstructive pulmonary disease (COPD) following treatment with placebo, salmeterol 50 microg twice a day or 100 microg twice a day by metered-dose inhaler. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "To investigate the efficacy of salmeterol in smokers with COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 micrograms twice daily) and placebo in 63 patients with stable COPD (mean age 63 yrs); inclusion criteria: aFEV1) < 60% of predicted and FEV1 reversibility < 15% (0.4 mg salbutamol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Bronchodilator efficacy of salbutamol (200 micrograms), salmeterol (50 micrograms) and ipratropium bromide (40 micrograms) aerosols has been compared in 16 patients with stable chronic obstructive pulmonary disease (COPD) using a double-blind placebo controlled cross-over design. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: To investigate the efficacy of salmeterol in smokers with moderate to severe COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 micrograms twice daily) and placebo in 63 patients with stable COPD (mean age 65 years). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study compares the time course of inhaled salmeterol (25, 50 and 75 micrograms) and formoterol (12, 24 and 36 micrograms) at different doses in a group of 12 patients with partially reversible, but severe COPD (FEV1 of 12-32% of predicted values after beta 2-agonist drugs had been withheld for 24 h). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "These data demonstrate that salmeterol is equally effective as, but longer-acting than, formoterol at clinically recommended doses in patients suffering from COPD, with severe airway obstruction.(ABSTRACT TRUNCATED AT 250 WORDS)  There are two families of inhaled bronchodilators: beta-2-mimetics and vagolytics. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " In the present trial we investigated the time course of inhaled salmeterol and formoterol bronchodilation in comparison with that of inhaled salbutamol and placebo in 16 patients with moderate to severe chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Our results showed that salmeterol and formoterol are efficacious in reducing airflow obstruction in patients suffering from COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae)) over 1\u00a0year in Spain, Sweden and the United Kingdom (UK). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: The direct cost burden of managing asthma and COPD for people using budesonide\u2009+\u2009formoterol Turbuhaler(\u00ae) or fluticasone\u2009+\u2009salmeterol Accuhaler(\u00ae) in 2015 was estimated at \u20ac813 million, \u20ac560 million, and \u20ac774 million for Spain, Sweden and the UK, respectively. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study was designed to evaluate the clinical and economic consequences of salmeterol/fluticasone (SF), formoterol/budesonide (FB), and formoterol/fluticasone (FF) in severe and very severe chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "One retrospective cohort study suggested a greater efficacy for the budesonide/formoterol combination on hospital or emergency department admissions, oral corticosteroid courses, and addition of tiotropium, and an observational real-life study reported a greater reduction of COPD exacerbations with budesonide/formoterol than with fluticasom/salmeterol combination. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Among the potential side effects of chronic ICS treatment in patients with COPD, recently the use of fluticasone or fluticasone/salmeterol combination has been associated with a higher prevalence of pneumonia in the major long-term studies. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Effectiveness data from the PATHOS study, a population-based, retrospective, observational registry study conducted in Sweden, in terms of reduction in COPD and pneumonia-related hospitalizations, were considered, in order to estimate the differences in resource consumption between patients treated with budesonide/formoterol and fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of \u20ac499.90 (\u20ac195.10 for drugs, \u20ac193.10 for COPD hospitalizations, and \u20ac111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "PARTICIPANTS: Patients with COPD diagnosed by a physician and prescriptions of either budesonide/formoterol or fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The aim of this study was to investigate exacerbation rates in primary care patients with COPD treated with budesonide/formoterol compared with fluticasone/salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The exacerbation rates were 0.80 and 1.09 per patient-year in the budesonide/formoterol and fluticasone/salmeterol groups, respectively (difference of 26.6%; P\u00a0<\u00a00.0001); yearly rates for COPD-related hospitalizations were 0.15 and 0.21, respectively (difference of 29.1%; P\u00a0<\u00a00.0001). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Long-term treatment with fixed combination budesonide/formoterol was associated with fewer healthcare utilization-defined exacerbations than fluticasone/salmeterol in patients with moderate and severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The long-acting beta(2)-agonists (LABAs), including salmeterol and formoterol, have 12-hour duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: It is unknown whether the bronchodilation and anti-inflammatory effects of inhaled salmeterol and fluticasone (SF) are better than those of traditionally inhaled ipratropium, terbutaline and budesonide (ITB) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVES: The aim of this study was to compare the effect of inhaled budesonide/formoterol with inhaled fluticasone/salmeterol in severe COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " BACKGROUND: The purpose of this study was to update our network meta-analysis in order to compare the efficacy of indacaterol 75 \u03bcg with that of a fixed-dose combination of formoterol and budesonide (FOR/BUD) and a fixed-dose combination salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on evidence identified previously in addition to two new randomized clinical trials. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Bronchodilators - long-acting b2-adrenergic agonists (formoterol and salmeterol) and a long-acting antimuscarinic drug (tiotropium), are the main drugs applied in symptomatic treatment of COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Beclomethasone/formoterol - 400/24 mcg/die, in comparison with fluticasone/salmeterol - 500/100 mcg/die significantly reduced air-trapping and dyspnea in COPD patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Both FM (10(-9) \u2003M) and salmeterol (SM, 10(-8) \u2003M) reversed Dex insensitivity in severe asthma, but only FM restored Dex sensitivity in COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium bromide prevented exacerbations in patients with COPD, with a significantly lower exacerbation rate and a significantly longer time to first exacerbation seen with tiotropium bromide than with placebo or salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Although the addition of salmeterol/fluticasone propionate to tiotropium bromide did not reduce the COPD exacerbation rate, it did improve lung function and HR-QOL. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effectiveness of budesonide/formoterol fumarate dihydrate (BFC) and fluticasone propionate/salmeterol (FSC), two combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the US with respect to cost, therapy adherence, and related healthcare utilization. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Tiotropium is US Food and Drug Administration (FDA) approved to treat bronchospasm and reduce exacerbations in patients with COPD; salmeterol/fluticasone is FDA approved to treat airflow obstruction in COPD and reduce exacerbations in patients with a history of exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Other maintenance long-acting bronchodilators-salmeterol, formoterol, and budesonide/formoterol-are FDA approved to treat airway obstruction in COPD but lack an approved indication against exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study aimed to further investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered via combination inhalers with the respective long-acting beta2-agonists, formoterol and salmeterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Following a run-in period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of budesonide/formoterol (400/12 microg) and salmeterol/fluticasone (50/500 microg), separated by a 4-14-day washout period. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In a randomised, double-blind, multicentre, cross-over study, 442 patients with COPD aged >or=40 years (pre-bronchodilator FEV(1) <or=50%; FEV(1)/vital capacity <70%) received budesonide/formoterol (320/9 microg, one inhalation twice daily) dry powder inhaler (DPI) or salmeterol/fluticasone (50/500 microg, one inhalation twice daily) DPI daily, for 1 week each, separated by a 1- to 2-week washout. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSIONS: Short-term treatment with budesonide/formoterol DPI or salmeterol/fluticasone DPI was effective in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "All searches were performed using the terms: chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, or COAD AND either salmeterol, formoterol, long-acting beta 2-adrenoceptor agonist, fluticasone propionate, budesonide, inhaled corticosteroids, or inhaled glucocorticosteroids. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " Seretide (fluticasone + salmeterol--Allen & Hanburys) and Symbicort (budesonide + formoterol--AstraZeneca) inhalers have recently been licensed in the UK for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) and a history of repeated exacerbations. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Treatment-na\u00efve patients with COPD (n = 36) were prospectively treated with two kinds of LABA--inhaled salmeterol and transdermal tulobuterol patch--for 12 weeks in crossover study, and changes in pulmonary function data and 6-minute walk distance (6 MWD) were compared between groups stratified by the CysGlyGln. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Patients were 32,338 health plan members, age \u226540 years, with COPD initially treated with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or ipratropium (IPR) alone or in combination with albuterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: Relative costs and utilization-related outcomes of a fluticasone propionate 250 \u03bcg + salmeterol 50 \u03bcg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Eligible patients also had a prescription filled between January 1, 2003, and June 30, 2005, for one of the following COPD treatments: fluticasone propionate + salmeterol xinafoate, tiotropium bromide, ipratropium bromide, or ipratropium bromide + albuterol sulfate. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare, in elderly Medicare beneficiaries, chronic obstructive pulmonary disease (COPD)-related healthcare costs for patients initiating treatment with fluticasone propionate/salmeterol 250 \u03bcg/50 \u03bcg (FSC) with those for patients initiating treatment with ipratropium bromide/albuterol (IPA), ipratropium bromide (IPR), and tiotropium bromide (TIO). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The safety of arformoterol (50 microg QD), and salmeterol (42 microg BID), was assessed over 12 months in subjects with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: Subjects with COPD (mean FEV1 1.2 L, ~41% predicted) were enrolled in the study and randomized to receive nebulized arformoterol 50 microg QD (n = 528) or salmeterol 42 microg BID (MDI; n = 265) in a prospective, multicenter, open-label, 12-month trial. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The frequency of COPD exacerbations did not increase over 12 months for arformoterol and salmeterol (weeks 0-13: 15.7% and 11.7%, respectively; weeks 39-52: 10.0% and 9.4%, respectively). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "CONCLUSION: In this trial, both arformoterol 50 microg QD and salmeterol 42 microg BID were well tolerated in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the effects of initial maintenance therapy with fluticasone 250 microgram plus salmeterol 50 microgram in a single inhaler versus other inhaled medications on exacerbation risks and treatment costs among chronic obstructive pulmonary disease (COPD) patients. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Patients age 40 years or older with a primary diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification code 490, 491, 492, or 496), at least 18 months of continuous eligibility, and an index prescription for fluticasone/salmeterol combination, salmeterol alone, inhaled corticosteroid alone, ipratropium/albuterol combination, or ipratropium alone (reference) were identified. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "OBJECTIVE: This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "METHODS: We conducted an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group study of subjects with moderate to severe COPD to compare fluticasone propionate/salmeterol 250/50 microg BID (FSC) with ipratropium/albuterol 36/206 microg QID (IB/ALB). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "The time to first COPD exacerbation was significantly longer during 12 weeks of treatment with inhaled salmeterol 50 microg twice daily than ipratropium bromide 40 microg 4 times daily. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Compared with placebo, inhaled salmeterol 50 microg twice daily alone, or concurrent with ipratropium bromide 40 microg 4 times daily improved lung function and reduced symptoms in patients with stable COPD in a 12-week, randomised, double-blind study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Inhaled salmeterol 50 microg twice daily plus oral theophylline had additive effects on lung function, increased the proportion of symptom-free days and decreased requirements for as-needed salbutamol compared with either agent alone according to a pooled analysis of 2 multicentre, randomised, double-blind studies.CONCLUSION: When used at the optimal dosage, 50 microg twice daily, salmeterol provides symptomatic relief and improves lung function and health-related quality of life in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those \"unresponsive\" to albuterol. ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). ", "polarity": 1}, {"drug": "Salmeterol", "disease": "COPD", "orig_sen": "We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). ", "polarity": 1}]